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ABSTRACT 
Characterization of Opioid Binding Sites in Spinal Cord and other 
Tissues. 
Wood, M.S. 
, Keywords: Spinal Cord; Analgesia; Endogenous opioid peptides; 
k-Opioid receptor; k-Subtypes; Dorsal/ventral horn; 
Rostro-caudal distribution; Opioid binding sites; 
['H]Opioids. 
The binding of ['H]opioid ligands to homogenates prepared from the 
spinal cords of rat and other species has been studied. Similar numbers 
of sites were seen in all areas of the cord when mea~~red in a rostro-
caudal direction. There was found to be approximatel~~ x higher density 
of sites in the dorsal half of the cord compared with the, ventral half. 
" Binding studies suggested a similar relative distribution or,mu, delta 
and kappa sites in all areas of the 'cord. The results are discussed in 
relation to the reported,distribution of opioid peptides. 
In the above study the kappa binding site was defined as the binding of 
['H] unselective opioids in the presence of cold ligands to suppress 
binding to mu- and delta-sites. Competitive binding assays, however, 
suggested this site did not have the properties of a single homogeneous 
group. Approximately 50% of the apparent kappa binding was consistent 
v 
with a classical kappa site. Saturated binding assays afforded Bmax values 
which suggested lower 'true' kappa site numbers than previously supposed, 
values which were confirmed using the kappa peptide' ['H]Dynorphin A-(1-9), 
and the kappa selective ['H]U-69593. Heterogeneity was also seen in other 
central nervous system tissues. 
The heterogeneous nature of the kappa site may be due to different sites, 
due to interactions at a non-opioid site or may represent different 
conformations of the same site. The secorid, possibility was disca.nted since 
observed binding followed the cellular distribution of the plasma marker 
Na+/K+-ATPase,was stereoselective for levorphanol over dextrorphan, and 
fully displaceable by naloxone. The third possibility was investigated by 
'studying the role of Na+ and Mg2+ ions, which are reported to affect 
receptor conformation in binding assays employing brain tissues. None of 
the results obtained suggested that conformational changes were responsible 
for the observed effects, although the experiments were not exhaustive. 
Abbreviations used in this thesis 
Aib 
2',3'-CNP 
CNS 
GABA 
GppNHp 
HEPES 
HPLC 
MAO 
Na+,K+-ATPase 
NRM 
PAG 
Rpgl 
RVM 
sem 
Tris 
. a-Aminoisobutyr ic acid 
2',3'-Cyclic nucleotide ·3'-phosphohydrolase 
Central nervous system 
y~Aminobutyric acid 
5-Guanylylimidodiphosphate 
N-2-Hydroxyethylpiperazine-N-ethanesulphonic 
acid 
High performance liquid chromatography 
Monoamine oxidase 
Na+,K+-activated adenosine 5'-triphosphate 
phosphohydrolase 
Nucleus raphe magnus 
Periaqueductal grey 
Nucleus reticularis paragigantocellularis 
lateralis 
Rostro ventral medulla 
standard error of mean 
Tris(hydroxymethyl)aminomethane. 
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C H APT E R 1 
INTRODUCTION 
1 
Historical 
The pharmacological properties of the exudate from the unripe seed 
capsules of the opium poppy, Papaver somniferum have been recognized 
since 4000 B.C. The analgesic properties were later realized and 
morphine (Figure 1.1) the alkaloid most active in this respect, was 
isolated in the early 19th century and structurally resolved in 
1925 [1]. 
NMe Figure 1.1 Morphine 
In addition to pain relief however, morphine also produces decreased 
gastrointestinal motility, hypotension and respiratory depression, 
, ,; 
but more importantly tolerance and dependence after prolonged use. 
This prompted the search for a non-addictive analgesic without 
these unwanted side-effects. Early attempts included diacetylmorphine 
(heroin; Figure 1.2) which only led to an increase in the incidence 
of drug abuse. 
MeCO.O 
NMe Figure 1.2 Heroin 
MeCO.O·· 
MeO 
• . 
O,,/"-.... 
NMe 
Ho=SMe 
2 
Figure 1.3 Pethidine 
Figure 1.4 Methadone 
Figure 1.5 Etorphine 
Figure 1.6 Buprenorphine 
Later compounds included structural modifications of and 
diversifications from the central morphine nucleus in the search 
for the ideal analgesic. That compound has not yet been discovered 
but some of the drugs synthesized during this search have been used 
in medicine, for example pethidine (Figure 1.3) and methadone 
3 
(Figure 1.4), and have also found use in the treatment of drug 
addiction, particularly methadone. Some members of the very potent 
oripavines [2], most notably etorphine (Figure 1.5) are used in 
vetinary science to immobilize hoofed wild animals such as rhinoceros, 
elephant or zebra [3, 4] and more recently buprenorphine (Figure 1.6) 
has been introduced into clinical medicine for the relief of post-
operative pain [5] and chronic intractable pain in cancer patients 
[6]. 
Discovery of the endogenous opioids 
Arising from these observations was the fundamental question of why 
receptors should exist in the body for externally applied compounds. 
Martin [14] proposed that 
'morphine-ljke compounds might mimic 
an ongoing biochemical process' 
whilst Collier [23] postulated the existence of an 'endogenous 
neurochemical factor'. 
Experimental evidence for these hypotheses came when analgesia 
produced by electrical stimulation of the periaqueductal grey in the 
brain stem of rats was found· to be reversed by the antagonist 
naloxone (Figure 1.7) [24], antagonism by j loW" I : levels of 
naloxone, that is in the region of 1 mg.kg-', being taken as 
evidence for opioid receptor involvement. 
N~ Figure 1.7 Naloxone 
In 1975 Kosterlitz and Hughes, along with several other groups, 
isolated from brain and pituitary substances possessing opioid-
like activity [25 - 28]. The name enkephalin [29] was given to the 
endogenous substance isolated from porcine brain. This was shown to 
consist of two pentapeptides, differing only in their carboxy-
terminal amino acid residue which was either leucine (named leucine-
enkephalin) or methionine (named methionine-enkephalin)(Figure 1.8) 
[30]. These are now represented, according to accepted nomenclature 
as [LeuS]- and [MetS]enkephalin respectively. Several carboxy-
terminal extensions of the [MetS]enkephalin sequence were isolated 
over the next eight years, as shown within Tables 1.1a and b. 
One of the earliest extended [MetS]enkephalins to be isolated was 
the peptide B-endorphin. s-Lipotropin [38], a large peptide whose 
function was unkn~wn at its time of discovery, was shown to contain 
[MetS]enkephalin as amino acid residues 61 - 65 [30]. Mild trypsin 
digestion of S-lipotropin released the C-fragment, that is residues 
61 - 91 [39], which was also found to exist in porcine pituitary [40], 
and was shown to have opioid activity more than 30 times that of 
[MetS]enkephalin [41]. The S-lipotropin molecule was itself devoid 
of '~~pi6id'!, -like activity suggesting the need forclea,,~ge_at 
'. ~ -_ ... " I 
speci fic points in the molecule to produce smaller, " ',op~~i_~: '-
active units. The name s-endorphin is now generally used in place 
of "C-fragment" to describe residues 61 - 91 of s-lipotropin [42]. 
It has become apparent from the relative distributions in the central 
nervous system, as determined by i~munohistochemical methods, that 
8-endorphin is not the'main source of [MetS]enkephalin [43]. 
A further group of endogenous opioid peptides were discovered by 
Goldstein and colleagues [4~]. These compounds showed extremely high 
potency in the I guinea-pig ileum bioassay. : Initially a I r 
13-amino acid peptide was identified; named dynorphin A-(1-13), but 
soon other members of this carboxy-terminally extended 
[LeuS]enkephalin series were isolated including the large peptide 
dynorphin (1-32) [50 - 59] (Table 1.1c). 
4 
. Tyr -- Gly -- Gly -- Phe - R 
when R= 
Figure1.8 
H}-~H 
-N "--< 
Leucine 
H)-OH 
-N" 
SMe 
Methionine 
The enkephalins 
Leucine- enkephalin 
( [Leu 5]enkephalin ) 
Methionine -enkephalin 
( [Met 5]enkephalin ) 
5 
Table 1.1a Pre-proenkephalin products 
Opioid Peptide 
[Met S ]enkephalin 
[Leu S]enkephalin 
[Met']enkephalyl-Arg S 
[Met']enkephalyl-Arg6-Phe7 
[Met']enkephalYl-Arg6-Arg7 
[Met']enkephalyl-Arg6-Gly7-Leu' 
[Met S ]enkephalyl-Lys6 
[MetS ]enkephalyl-Arg6-Arg7-Val'-NH. (Metorphamide) 
Peptide I 
Peptide E 
BAM-12P 
BAM-20P 
BAM-22P 
Ser-Pro-Thr-Leu-Glu-Asp-Glu-His-Lys-Glu-
Leu-Gln-Lys-Arg-' 5 Tyr-Gly-Gly-Phe-Met-Arg-
Arg-Val-Gly-Arg-Pro-· 6Glu-Trp-Trp-Met-Asp-
Tyr-Gln-Lys-"Arg-Tyr-'6Gly-Gly-Phe-"Leu 
Peptide I (15-39) 
Peptide I (15-26) 
Peptide I (15-34) 
Peptide I . (15-36) 
Reference 
Hughes et al [30] 
Huang et al [31] 
stern et al [32] 
Lewis et al [33], Stern et al [34] 
Kilpatrick et al [35] 
Lewis et al [33], Stern et al [34] 
Weber et al [36] 
Jones et al [45] 
Kilpatrick et al [46] 
Mizuno et al [47] 
Mizuno et al [48] 
Mizuno et al [48] 
Table 1.1 b Pre-proopiomelanocortin-derived peptides 
Fragment 
C-fragment/ a-endorphin 
C'-fragment 
y-endorphin 
a-endorphin 
a-endorphin is: 
Amino Acid Residues 
of a-Lipotropin 
61-91 
61-87 
61-77 
61-76 
,.,}.: 
Reference 
Bradbury et 
Li & Chung 
Bradbury et 
Ling et al 
Ling et al 
6'Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-
Pro-Leu-Val-76 Thr-77 Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys 
Asn-Ala-87His-Lys-Lys-GlY-"Gln 
al [39] 
[42] 
al [39] 
[44] 
[44] 
~-----------------------------------------------------------------------------------------
Table 1.1c 
Opioid Peptide 
I I 
[Leu' ]enkephalin :_:, 
, ______ 1 • 
~-neo-endorphin 
a-neo-endorphin 
Dynorphin (1-32) 
,Dynorphin A- (1-17) 
Dynorphin B 
Dynorphin A-(1-8) 
Leumorphin 
Pre-prodynorphin products 
Amino Acid Sequence 
Tyr-Gly-Gly-Phe-Leu-Arg-Lys-
Tyr-Pro 
Tyr-Gly-Gly-Phe-Leu-Arg-Lys-
Tyr-Pro-Lys 
'Tyr-Gly-Gly-Phe-Leu-Arg-Arg-' Ile-
Arg-Pro-Lys-Leu-,aLys-Trp-Asp-Asn-
'7Gln-Lys-Arg-2 °Tyr-Gly-Gly-Phe-
Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-s2 Thr 
Sequence 1-17 
Sequence 20-32 
Sequence 1-8 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-
Val-Val-Thr-Arg-Ser-Gln-Glu-Asp-Pro-Asn-
Ala-Tyr-Tyr-Glu-Glu-Leu-Phe-Asp-Val 
Reference 
Lewis et al [33], Stern et al [34] 
Kangawa et al [51] 
Minamino et al [52] 
Kangawa et al [53] 
Fischli et al [54] 
Goldstein et al [49,50] 
Fischli et al [54], 
Kilpatrick et al [55,56] 
Minamino et al [57] 
Kakidani et al [58] 
Suda et al [59] 
•• ,,> 
Table 1.1d Other endogenous and exogenous peptides 
Opioid Peptide 
Kyotorphin 
Dermorphin 
Exogenous Opioids 
e-casomorphin 
Morphiceptin 
Amino Acid Sequence 
Tyr-Arg 
Tyr-D-Ala-Phe-Gly-Tyr-Pro-
Ser-NH. 
Tyr-Pro-Phe-Pro-Gly-Pro-Ile 
Tyr-Pro-Phe-Pro-NH. 
Reference 
Takagi et al [60] 
Montecucchi et al [61] 
Henschen et al [62] 
Chang et al [63] 
10 
Research into the or1g1ns of these different!opioidpeptides ~ 
showed that three large precursors, pre-proenkephalin A [64], 
pre-proopiomelanocortin[65] and pre-prodynorphin (pre-proenkephalin B) 
[64] were the :materialsfrom which the enkephalins, e-endorphin and 
the dynorphins '. __ ~~ _____ ~ __ .,' were released. After transport across 
, , 
the membranes of the endoplasmic reticulum, cleavage of a signal 
peptide yields the pro-peptide which, upon further cleavage at basic 
amino acid pairs such as Lys-Arg by processing enzymes yields the 
opioid peptides [64]. 
Other peptide __ ,~ ___,'_.~; molecules with opioid activity have 
also been isolated, although some of these are exogenous, originating 
from pepsin hydrolysates of food proteins (Table 1.ld). 
studies employing opioid peptides in both in vivo and in vitro systems 
have been hampered by the ready degradation of these compounds, 
resulting in a reversal of effect [26]. This problem has been partly 
overcome using two approaches. In the enkephalin series, substitution 
of the glycine residue at position 2 by D-alanine [73] and leucine 
or methionine at position 5 by their respective D-isomer [74] produced 
an increase in potency but no change in receptor selectivity [73, 74]. 
However, in the dynorphin series, the position 2 glycine appears to 
be important for receptor selectivity [69]. An alternative ~pproach 
is the use of specific enzyme inhibitors to reduce proteolysis. This 
has been shown to be successful with both enkephalin [75] and dynorphin 
[72] peptides. 
Opioid receptors 
Chemical manipulations of the morphine molecule produced compounds 
such as nalorphine [7] (Figure 1.9) and naloxone [8] which antagonized 
the effects of morphine [9, 10]. Nalorphine, in spite of its 
antagonist properties also produced analgesia [11] in addition to 
tolerance and dependence [12], although the abstinence syndrome 
differed from that in morphine-dependent subjects [12, 13]. 
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Martin [14] considered these effects and proposed that morphine- and 
nalorphine- like drugs were acting via different receptor systems. 
This hypothesis supported earlier suggestions by Portoghese [15] 
which were based upon the structural and stereochemical requirements 
of the opioid alkaloids for their biological activity outlined by 
Beckett and easy [16]. 
Martin and colleagues [17 - 20] later described three different 
receptor classes following work on the naive- and opioid-dependent 
chronic spinal dog preparation. Differences in i) behaviour, 
ii) sensitivity to naloxone and naltrexone antagonism (see Figure 1.10 
for the structure of naltrexone) and iii) cross-tolerance selectivity 
.. 
(as evidenced by the ability. or inability to suppress abstinence in 
dependent animals caused by the agonists morphine, ketocyclazocine 
(Figure 1.11) and SKF 10047 (Figure 1.12), were ascribed to actions 
at three receptor types termed ~ (morphine), k (ketocyclazocine) 
and a (SKF 10047). 
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Figure 1.11 Ketocyclazocine 
Figure 1.12 N-Allylnormetazocine 
[SKF 10047] 
Additional evidence for the existence of separate Il- and k-receptors 
came from in vitro work on isolated tissue preparations such as the 
guinea-pig ileum longitudinal muscle and mouse vas deferens, developed 
by Kosterlitz and colleagues. These workers found that some 
benzomorphans including ketocyclazocine, which did not substitute for 
morphine in. the morphine-dependant monkey [21] but were good analgesics 
in the rat, had only one quarter of the agonist potency in the mouse 
vas deferens preparation·as in the guinea-pig ileum longitudinal 
muscle preparation, when compared to normorphine (Figure 1.13). 
HO 
NH Figure 1.13 Normorphine 
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These benzomorphans also required between three and seven times 
more naloxone to antagonize their effects than did normorphine [22]. 
The rank order of potency for I opioid ~. agonists to inhibit the 
electrically evoked twitch in the two preparations was also different, 
indicative of different receptor types. However, the actions of 
the newly discovered opioid peptides, namely the enkephalins in the 
myenteric plexus of the guinea-pig ileum longitudinal muscle and the 
mouse vas deferens could not be explained solely by interaction at 
the putative ~-, k- or a-·receptors as defined by Martin. For 
example, [Met 5 ]enkephalin was 20 times more potent than normorphine 
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at inhibiting the electrically evoked twitch in the mouse vas deferens, 
whilst the two compounds were equipotent in the guinea-pig ileum 
preparation [30]. 
In addition it was shown that antagonism of the inhibitory action 
of the enkephalins in the mouse vas deferens required 10 times more· 
naloxone than did morphine, but in the guinea-pig ileum the amount 
of naloxone needed was the same as for morphine [66]. Kosterlitz and 
co-workers proposed two types of receptor for opioid peptides; the 
~-receptor with which morphine preferentially interacts and which 
predominates in the guinea-pig ileum and the enkephalin-preferring 
6-receptor,. found to predominate in the mouse vas deferens. Also 
present in the guinea-pig ileum is the k-receptor for which the 
benzomorphan drugs show selectivity [66, 67]. Further studies have 
shown the mouse vas deferens to contain ~-, 6- and k-receptors [137]. 
Extension of the above experimental rationale and the use of the 
rabbit vas deferens, a tissue containing exclusively functional 
k-receptors [6B], demonstrated the ': activity of some opioid peptides, 
especially those derived from prody~orphiri;!-;;t:the k-receptor 
[49, 50, 54, 69 - 72]. 
This work on isolated tissues was complemented by. binding studies. 
The interaction of an opioidcompound with the recognition site of a 
receptor, produces a translation into biochemical events by an 
intermediate factor, which leads ultimately to the. observed biological 
responses. Binding assays are concerned with the investigation of 
these recognition sites. 
Early work was unsuccessful in demonstrating specific binding sites 
for radiolabelled opiates mainly due to the low specific activity 
and high concentrations of radioligands I available: Goldstein and i 
colleagues"[76] showed stereospecific binding of radiolabelled 
levorphanol (Figure 1.14), but this only represented 2~, of the total 
binding to mouse brain homogenates. I Later the 'use of nanomolar I 
concentrations of opiates labelled to high specific activity afforded 
high specific binding and enabled a more detailed study of opiate 
binding sites and their properties [77 - 81]. 
HO 
NMe" Figure 1.14 Levorphanol 
Stereospecific, saturable binding was shown to be reduced by 
proteolytic enzymes and sulphydryl reagents such as N-ethylmaleimide 
(Figure 1.15) indicating the recognition site to be proteinaceous 
with important sulphydryl groups in close proximity [77]. 
Figure1.15 N· Ethy'lmaleimide 
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Temperature. and pH also influence opiate binding [78]. Subcellular 
fractionation of brain tissues showed the binding sites to be 
concentrated in the synaptosomal fraction [81, 84] suggesting that 
they are located. on nerve terminals. This binding could be displaced 
from brain and intestine homogenates by unlabelled opiates and 
opioids, with potencies which in many cases were close to those 
found in vivo for the same compounds.[77 - 80]. 
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Importantly it has been found possible to discriminate between.agonists· 
and antagonists based upon. the influence of monovalent cations' such 
as sodium [77, 78, 83,J • Agonists iareless poterltat 'displacing ~ .. _. 
1['A]antagonist binding lin the presence of 100mM sodium chloride. 
I 
This is known as the "sodium shift". However, antagonists such as 
naloxone are equipotent or more potent under these same conditions 
[83]. 
Opioid compounds with a high potency in the isolated guinea-pig ileum 
preparation were found to be better displacers of ['H]naloxone, whereas 
compounds showing higher activity in the mouse vas deferens preparation 
are better displacers of ['H][leu']enkephalin, in guinea-pig brain 
homogenates [66, 67] •. ['H]Naloxone was therefore proposed to be 
binding at ~-sites and ['H][leu']enkaphalin to 6-sites in guinea-pig 
brain. The existence of ~- and 6-sites has also been confirmed in 
rat brain [87] by studying the displacement of ['H]naloxone,' 
['H]dihydromorphine and [l25I][D,.Ala~,D-leu']enkephalin by unlabelled 
opiates and opioid peptides. 
The structural modification of the en kephalin nucleus has also been 
used to improve ~- or 6- selectivity [74, 89]. For example, the 
amidation or reduction to hydroxyl of the C-terminal carboxyl group in 
[Met']enkephalin produces an increase in p-selectivity [67, 74]. 
More extensive modifications have been made, most notably Tyr-D-Ala-
Gly-MePhe-Gly-ol which has 220 times greater activity at ~- .than at 
4-sites [90,91], the highly 6-selective bis-penicillamine derivatives, 
including [D-Pen',D-Pen']enkephalin (Figure 1.16) [92],and [D-Thr', 
l-Leu']enkephalyl-Thr','deltakephalin' (DTlET) [93]. 
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Thus, selective modifications to the enkephalin structure in 
particular, have been used to produce compounds with an increased 
resistance to proteolysis and compounds showing an increased 
. selectivity at different opioid binding sites. 
The availability of radiolabelled ethylketocyclazocine, :~! putative 
k-agonist in the behavioural studies of Martin enabled the 
demonstration of k-binding sites in the brains of guinea-pig 
[94 - 96] and rat [97, 98]. Other radiolabelled k-compounds such 
as bremazocine (Figure 1.17) [101] were shown to have a high affinity 
for this k-site, but as with ethylketocyclazocine, demonstrated a 
high degree of cross reactivity with p- and 6-sites [94 - 99]. 
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By using appropriate concentrations of unlabelled compounds, such 
as morphiceptin or [D-Ala',MePhe",Gly-olS]enkephalin with 
[D-Ala',D-LeuS]enkephalin to suppress the binding at p- and ~-sites 
respectively, more specific study of the k-site was possible. 
[96 - 98]. Endogenous peptides known to possess k-selectivity 
[69 - 72, 102 ~ 105] were used to study k-binding sites but here 
the inhibition of proteolytic enzymes was necessary [72, 104]. 
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Compounds have been synthesized in an attempt to improve k-specificity. 
l Two compounds which have. improved k-selectivity are tifluadom (Ffgure-1.18) 
1[106],1 a benzodiazepine derivative and U-50488H (trans- 3,4- dichloro-N-
I , ' , 
methyl-N-[2-(pyrrolidinyl)cyclohexyl]-benzeneacetamide; Figure 1.19) 
[107, 109]. Both are interesting since they depart from the opiate 
or enkephalin nucleus. 
Figure 1.18 Tifluadom 
Cl 
Cl Figure1.19 U-S0488H 
Some compounds which in vivo were dysphoric and psychomimetic [17] 
apparently bound to a site which was 'inaccessible' to compounds . 
such as naloxone or etorphine [110 - 112], but could be displaced· 
by (+)-SKF 10047 and non-opioids, including haloperidol (Figure 1.20) 
[111, 112]. Similarly phencyclidine (Figure 1.21) also bound to a 
naloxone inaccessible site in rat. spinal cord [112]. 
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F Figure1.20 Haloperidol 
Cl 
Figure1.21 Phencyclidine 
The above observations, combined with the low affinity of opioids 
for these 'inaccessible' sites imply that they should not be 
considered as classically opioid but may correspond to the 
recognition site of the a-:-receptor proposed by Martin [17, 113]. 
The distribution of opioid peptides and binding sites in 
the central nervous system 
i) General 
Early work showed a non-homogeneous distribution of opioid 
binding sites in the central nervous system of the rat, monkey 
and in man. High levels of binding were found in the striatum, 
lowest levels were in the cerebellum and significant amounts 
were present in the spinal cord [79, 114]. The subsequent 
development of immunology-based techniques [117] and 
autoradiography [115, 116, 136] enabled detailed distribution 
analysis of the endogenous opioid peptides and their binding 
sites. Although widely distributed throughout the central 
nervous system, both opioid peptides and opioid binding sites 
have been seen most often in association with sensory, limbic 
or neuroendocrine function. 
Focus will be on the sensory system and a proposed model for 
endogenous pain control. 
ii) The sensory system 
The brain and spinal cord may be divided into specific 
cytoarchitectural regions as shown in Figures1.22 and 1.23. 
Opioid binding sites are concentrated in three regions of the 
central nervous system associated with sensory function; 
i) the midbrain periaqueductal grey (PAG), ii) several nuclei 
of the rostral ventral medulla (RVM), specifically the midline 
nucleus raphe magnus (NRM) and in the adjacent reticular 
nuclei and iii) the dor~al horn of both the spinal cord and 
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the trigeminal (~th) nerve, particularly the marginal cells of 
lamina 1 and the substantia gelatinosa of lamina 11 [114, 115, 
119]. Small diameter primary afferents, comprising unmyelinated 
C-fibres and thinly myelinated Ao-fibres.which project to the 
cord and trigeminal nucleus also contain significant levels of 
opioid binding sites [114, 115, 119]. 
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Figure 1.22 . Brain of the rat 
KEY: 1 Rhombencephalon 
2 Cerebellum 
3 Mesencephalon 
4 Thalamus 
5 Hypothalamus 
6 Striatum 
7 Hippocampus 
8 Neocortex 
9 Olfactory peduncle 
10 Olfactory bulb 
( from Nauta & Feirtag [88] ) 
Dorsal horn 
Ventral horn 
Figure 1.23 The laminae of Rexed, 
L 7- Cat spinal cord 
(from Rexed [135]) 
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The spinal and supraspinal regions are linked by complex 
circuitry to form the major components of the endogenous 
pain control system. 
Within this system, the opioid peptides have distinct 
anatomical distributions depending upon the precursor molecule 
from which they are cleaved. For example, B-endorphin is 
concentrated in the basal hypothalamus and has axons which 
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project caudally towards the PAG [121]. Immun'oreactive 
IprOdynOrPhin...; and proenkephalin:"derived pepUdes are' found in the PAG,! 
, 
dynorphin being more ventrally distributed. In the spinal cord 
and trigeminal nucleus,enkephalins are concentrated in the 
marginal cells of lamina I and in lamina V whilst dynorphins 
are concentrated almost exclusively in the marginal layer of 
lamina I [122, 123]. 
Other proposed neuromodulators have.been identified in areas 
associated with nociceptive processing. 5-Hydroxytryptamine 
has been demonstrated within neurones of the NRM, pallidus and 
the adjacent nucleus reticularis paragigantocellularis lateralis 
(Rpgl) and the spinal cord. 
Substance P (Figure 1.24) has been demonstrated in the PAG, 
rostral medulla (where it is also co-localized with enkephalins 
[134] ) and spinal cord. The highest concentrations in the 
spinal cord are localized in lamina I!. 
Noradrenaline- containing axons are found in the rostral 
medulla and neurotensin (Figure 1.25) has been shown in axons 
which project from the PAG to the RVM [131]. 
Arg - Pro -Lys - Pro-Gln-Gln - Phe-Phe-Gly- Leu-Met-NH2 
Figure 1.24 Substance P 
pGlu - Leu - Tyr - Glu - Asn - Lys - Pro - Arg - Arg - Pro - Tyr -lie - Leu . 
Figure 1.25 Neurotensin 
The role of the spinal cord in endogenous pain control 
A potential model, based upon physiological and biochemical 
evidence, for the role of these peptides in endogenous pain 
control is shown in Figure 1.26. 
The mOdulation of nociceptive information is believed to involve 
spinal and supr~spinal regions. At the spinal level, substance P 
released from primary afferents in the dorsal horn; stimulates 
post-synaptic receptors on second-order neurones which then transmit 
the information via the spinothalamic tract to specific areas of 
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the brain. The release of enkephalins within the dorsal horn inhibits 
this substance P release [124, 125]. Although initial evidence 
suggested that this inhibition may be via a presynaptic mechanism 
[124], ultrastructural analysis has failed to show enkephalin- or 
opioid peptide- containing neurones synapsing, directly onto 
substance P - containing fibres [126]. The inhibition may be .~ a 
non-synaptic mechanism or alternatively, the action of substance P 
could be antagonized by the endogenous opioids acting at post-synaptic 
receptors. In support of this, immunoreactive enkephalinergic fibres 
have been demonstrated synapsing onto spinothalamic projecting 
neurones [127]. Additional modulation of pain transmission at the 
spinal level involves complex feedback mechanisms from supraspinal' 
centres. 
Electrical stimulation [24], in addition to microinjections of opiates 
and substance P [128, 129] has been shown to elicit naloxone -
reversible analgesia. However, substance P is reportedly excitatory 
[124] and opioids inhibitory [130] on neuronal transmission. To 
reconcile these observations it is suggested that substance P and 
opioids act at different neurones within the PAG. Since substance P 
does not bind at opiate receptors [129] it has been proposed to 
stimulate an opioidergic neurone which then inhibits an inhibitory 
(possibly y~aminobutyric acid (GABA» neurone. Opiates on the other 
hand, interact with, opioid receptors to directly inhibit the 
inhibitory neurone (Figure 1.26; PAG section). Thus, both compounds 
can produce a nett stimulation of the PAG. 
• 

~igure 1.26 A ,proposed model for endogenous pain control. 
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Projection of neurotensin-containing fibres from the PAG to the RVM 
suggests that these may be involved in linking the two centres. 
Intracisternal neurotensin has been shown to produce analgesia [132] 
supporting a possible neuromodulator role for this peptide in the 
descending pain control mechanism. Activation of the PAG subsequently 
activates the RVM, a critical link in descending pain control, from 
which projections pass to the dorsal horn of the spinal cord via the 
dorsal part of the lateral funiculus. In particular, cells from the 
NRM and Rpgl, which are thought to be regulated by excitatory 
neuromodulators and inhibitory·compounds such as noradenaline [133], 
are believed to be involved in the control of this descending 
pathway. At the spinal level, 5-hydroxytryptamine inhibits both 
spinothalamic-projecting neurones and enkephalinergic neurones. 
The inhibition of the spinothalamic neurones reduces pain transmission 
to the supraspinal centres. The synapse with an inhibitory 
enkephalinergic neurone is less easy to explain, unless the 
enkephalinergic fibre in-turn synapses with a inhibitory (possibly 
GABA) neurone. Co-localisation of substance P and 5-hydroxytryptamine 
. [126] may imply a duality of descending control via excitatory and 
inhibitory pathways. 
Endogenous pain control mechanisms are not yet fully understood. 
However, it is known that the spinal level is an important site for 
the modulation of pain and that the interpretation of pain at the 
higher centres involves the limbic system. The use of synthetic 
opioids, opiates and opioid peptides at the spinal level in particular, 
has allowed the treatment of post-operative and terminal illness pain, 
often with fewer side-effects than intravenously administered drugs. 
The un?erstanding of·such pain mechanisms is therefore important 
for the development of new treatments with lower dependence liability 
and fewer side effects. 
Aims of present work 
The pharmacological profiles of opioids after their intrathecal 
administration are well characterized in a variety of species 
and in man. Opiate receptors are known to mediate the effects· 
of these compounds and some attempts have been made to relate 
receptor-type to physiological function. However, the 
characterization of the receptor binding sites by in vitro studies 
has produced much controversy. 
It is the aim of this study to characterize more fully both the 
types of binding site present and their distribution throughout 
the spinal cord. Special emphasis will be on the spinal cord of 
the rat, but other species will be employed. The possible 
heterogeneity of k-sites proposed by some authors will also be 
investigated in the cord. Brain tissue will also be studied 
for comparative purposes. 
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C H APT E R 2 
MATERIALS AND METHODS 
1. Animals 
Male animals were used for experiments described in Chapters 
4 to 7. 
MF1 mice (25 - 30g) and Wistar rats (200 - 250g) were supplied 
by the Animal Unit, University of Nottingham, Sutton Bonnington. 
Alderley Park Wistar rats (250 - 350g) were kindly provided by 
ICI Pharmaceuticals plc, Alderley Park, Macclesfield. The 
latter were used for all rat studies unless otherwise detailed. 
Dunkin-Hartley guinea-pigs (300 - 500g) were supplied by 
David Hall, Newchurch, Burton-upon-Trent. 
For experiments described in Chapter 8, female Swiss-Webster 
outbred mice (25 - 40g) supplied by Bantin and Kingman Ltd., 
Grimston Aldlborough, Hull were used. 
Porcine spinal cords were kindly provided by Barretts .and Baird 
(Wholesale) Ltd., West B~omwich and bovine spinal cords by 
E. Coxon and Son, Ashby-de-Ia-Zouch. 
2. Chemicals 
a) General 
Scintillation cocktails: 
Unisolve E was purchased from Koch Light, Suffolk, U.K., 
PCS (Phase Combining System) was purchased from Amersham. 
International plc, U.K., Ecoscint was purchased from 
National Diagnostics, Somerville, New Jersey, U.S.A. 
Trizma Base (Tris (hydroxymethyl)aminomethane) and HEPES 
(N-2-Hydroxyethylpiperazine-N'-ethanesulphonic acid) were 
purchased from Sigma, Poole, U.K. All other reagents 
used were of analytical grade. 
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b) Drugs and peptides 
[D-Ala',D-Leu']enkephalin and [D-Ala',MePhe',Gly-oIS] 
enkephalin were purchased from Cambridge Research 
Biochemicals, Cambridge, U.K. 
The following were kindly donated: 
Diprenorphine hydrochloride (Reckitt and Colman Ltd., 
Hull, U.K.), levorphanol and dextrorphan tartrates (Roche 
Products Ltd, Welwyn Garden City', U.K.,) tifluadom base 
(Roche Products, Switzerland), xorphanol mesylate 
(H. Parrs, New York, U.S.A.), naloxone hydrochloride 
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(Endo Laboratories, New Jersey, U.S.A.), (-)-bremazocine 
hydrochloride (Sandoz, Basel, Switzerland), MR 2266 base 
«_)~_5,9_diethyl_2_(3_furylmethyl)_2'_hydroxy_6,7_ 
benzomorphan; Boehringer lngelheim, F.R.G.), U-5048BH base 
(trans-3,4-dichloro-N-methyl-N-(2-(1-pyrrolidinyl)cyclohexyl) 
benzeneacetamide) and U-69593 base «5~,7~, Be)-(+)-N-
methyl-N-(7-(1-pyrrolidinyl)-1-oxaspiro [4,5] dec-B-yl) 
benzeneacetamide; The Upjohn Company, Kalamazoo, U.S.A.), 
dynorphin A-(1-17) (Parke-Davis, Cambridge~ U.K.), and 
ICI 174B64 (N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH) free acid 
or arginine salt (Aib = a-aminoisobutyric acid~ (ICI 
Pharmaceuticals plc, Alderley, U.K.). 
All compounds were stored as the dry powder or as 1mM 
or 10mM stock solutions in water .(or for tifluadom and 
xorphanol mesylate dimethylsulphoxide) at -20°C and 
diluted as required. 
c) Labelled Ligands 
[15,16-'H]etorphine (33.1 Ci.mmol- I ), [N-allyl-2,3-'H] 
naloxone (55 Ci.mmol- I ), [15,16-'H]diprenorphine. 
(31-46.5 Ci.mmol- I ) and [tyrosyl-3,5-'H] dynorphin A-(1-9) 
(26 Ci.mmol- I ) as ethanol solutions, [tyrosyl-3,5-'H] 
[D-Ala',D-Leu']enkephalin (32.1 - 39.5 ci.mmol- ' ) in O.05M 
acetic acid and [tyrosyl-3,5-'H][D-Ala 2 ,MePhe',Gly-ol'] 
enkephalin (60 ci.mmol~') in triethylammoniumphosphate 
buffer were purchased from Amersham International plc, 
U.K. [Phenyl-3,4-'H]U-69593 (40 Ci.mmol-') and 
[9-'H](-)-bremazocine (30-41.4 Ci.mmol-') as ethanol 
solutions were purchased from NEN Research Biochemicals, 
Stevenage, U.K. ['H][D-Ala 2 ,D-Leu']enkephalin and 
['H][D-Ala 2 ,MePhe',Gly-ol']enkephalin were stored at + 4°C. 
All other radiolabelled materials were stored at -20°C. 
d) Biochemicals 
i) Enzymes 
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Salt fractioned alkaline phospatase (EC 3.1.3.1) from 
Escherichia coli, type 111-5 in 2.5M ammonium 
sulphate, 10.5 units. mg protein-' was purchased 
from Sigma, Poole, U.K. 
ii) Enzyme inhibitors 
Captopril was kindly donated by Squibb, U.S.A. 
Bestatin was purchased from Cambridge Research 
Biochemicals, Cambridge, U.K. 
iii) Nucleotides 
Adenosine 5'-triphosphate as the tris (hydroxymethyl) 
aminomethane salt, adenosine 2',3'-cyclic monophosphate 
as the sodium salt and 5-guanylylimidodiphosphate 
as the sodium salt were purchased from Sigma, Poole, 
U.K. 
All were stored desiccated at -20°C. 
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3. Procedures 
a. Preparation of homogenates for 'binding assays 
i) Tissues 
Spinal Cord 
Mice and rats were stunned and then decapitated. 
Guinea-pigs were decapitated after cervical dislocation. 
The whole spinal column was removed and the spinal 
cord displaced from the subarachnoid space by the 
method of Yaksh, & Harty [265]. 
For dorso-ventral studies, longitudinal transection 
was performed under a binocular microscope, using a 
razor blade. For rostro-caudal studies, the spinal 
cord was divided into cervical, thoracic and 
lumbo-sacral regions according to the method of 
Yaksh, & Harty [265]. 
Porcine and bovine spinal cords were rapidly removed, 
within 30 minutes of slaughter and frozen in liquid 
nitrogen. 
Other central nervous tissues 
Brain, minus cerebellum, ,from rat and guinea-pig and 
cerebellum from guinea-pig' were used where detailed 
in the text. 
Tissues were used immediately or stored over liquid 
nitrogen at -150DC to -1BODC. 
ii) Buffers 
Homogenizations and assays wereperfdrmed in 50mM 
Tris buffer adjusted to pH 7.4 with1M HCl, or in 
25mM HEPES buffer adjusted to pH 7.4 with 
ammonium hydroxide. Cations were added as their 
chlorides to buffer solutions when required. 
iii) Homogenization 
Central nervous tissue was homogenized using a 
Potter/Elvejham glass/teflon homogenizer (Voss 
Instruments S30/CB, setting 6) in 10 x w/v buffer 
for 20 seconds. After centrifugation (MSE 65, 
37500g) for 15 minutes at 2aC, the pellet was 
resusupended in 20 x w/v buffer and incubated at 
37°C for 30 minutes to remove endogenous ligands. 
After a repeat homogenization the pellet was 
resuspended in 50 x w/v buffer for assay. 
For some experiments concentrated homogenates 
(5 x w/v in buffer) were stored at between -150oC 
and -1BOoC in the vapour over liquid nitrogen. 
b. Binding assays 
Competitive displacement assays 
To the final homogenate, containing approximately 1mg.ml-1 
protein, were added solutions of the unlabelled competing 
ligand and labelled primary ligand to a total volume of 
1ml. Where suppression of binding to ~-, 6- or k-sites 
was required, unlabelled [D-Ala2,MePhe',Gly~o15]enkephalin 
for ~, [D-Ala2,D-Leus]enkephalin or ICI 174B64 for 6 and 
. U-504BBH for k were added as described. 
After incubation at 25°C for 45 minutes (30 minutes for 
['H]dynorphin A-(1-9)) or 37°C for 45 minutes, 4ml of 
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ice-cold Tris-HCI was added and the mixture vortexed then 
filtered through Whatman GF/C glass filters (particle 
retention 1.2~m) under vacuum using a Millipore 1225 
sampling Manifold. When ['H]dynorphin A~(1-9) or 
['H]U-69593 were used as the labelled primary ligand the 
glass filters were pre-soaked in buffer containing 0.1% 
polyethylenimine (Sigma, U.K.) to reduce non-specific 
binding. The retained material was washed twice with 
4ml of ice-cold buffer. Radioactivity retained on the 
filters was counted after addition of scintillation fluid 
in a Phillips PW4700 liquid scintillation counter. 
Chemiluminescence was minimized by incubation at 37°C for 
30 minutes prior to counting. 
Saturated binding assays 
The assay mixture comprised as above but contained varying 
concentrations of labelled primary ligand. Experiments 
were performed in the absence and presence of suppression 
as described under competitive displacement assays. 
4. Fractionation studies 
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The method of Gray and Whittaker [260] was employed (Figure 2.1). 
Sucrose solutions were made up to 10x w/v in 50mM Tris-HCI, 
pH 7.4 buffer. Fractions were finally resuspended in further 
Tris-HCI buffer. 
a) Myelin purification 
The method of Norton and Poduslo [256] was used to produce 
samples of purified myelin (Figure 2.2). The resulting 
pellets were finally re suspended to 5i( w/v in Tris-HCI 
buffer. 
The purity of the sub-cellular fractions was assessed 
using marker-enzymes. 
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b) Enzyme assays 
i) Dilutions 
All samples were diluted with Tris-HCI buffer as 
follows: 
Homogenate 1: 5 
p: 
1 fraction 1 :20 
S2 fraction 1: 5 
Myelin fraction 1: 5 
Synaptosomal fraction 1:10 
Mitochondrial fraction 1:10 
ii) (ATPase) 
external membranes 
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A method after that of Hosie [257] was used (Figure 2.3). 
The following solutions were prepared: 
A 0.4M Tris-HCl, pH 7.4 buffer 
B 0.02M EDTA in Tris-buffer 
C 0.06M Adenosine 5' -triphosphate in H20.(freshly 
prepared) 
D 0.2M MgCl2 
E 2.0M NaCl 
F 0.2M KCl 
G 22.51. Trichloracetic acid in H20 
H 5M H2 SO. 
I 10% Ammonium molybdate in H20 
J Butan-1-ol: Petroleum ether (100 - 1200 C) 
4:1 v/v 
K 2.0M H2SO. in ethanol 
L 0.051. SnCl 2 in 5M H2SO. 
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Assay tubes were prepared as follows: 
Set A 
O.Bml A~ 0.1ml B, 0.1ml. C, 0.03ml D, 0.15ml·E, 
0.2ml F, H.O to 1.9ml. 
Set B 
As for set A .except 0.35ml H.O replaced E. & F. 
A phosphate standard curve (0 - 1.5 pmole) was 
prepared using KH.PO •• O.Bml solution G was added. 
Blanks were prepared in which either the enzyme or 
ATP was absent. 
Enzyme solutions and assay tubes were pre-incubated 
at 37°C for 5 minutes and then assayed as shown 
(Figure 2.3). 
The activity of the enzyme was determined from the 
difference in optical density between tubes in set A 
(Na+ and K+ present) and set B (Na+ and K+ absent). 
The specific activity of the enzyme was defined as 
pmoles phosphate produced. minute -I. mg protein-I. 
iii) 2'.3'-Cyclic nucleotide 3'-phosphohydrolase 
[EC3.1.4.16]: a marker for myelin 
A method after that of Kurihara et al [266] was 
employed. 
The following solutions we~e prepared: 
A 0.2M Tris-HCl buffer, pH 7.5 
B 1% Sodium deoxycholate 
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C 4mM 2',3'-Cyclic adenosine monophosphate in H2 0 
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• I 
0 0.05M Tris-maleate buffer, pH 6.5 
E 0.3M Tris-HCl buffer, pH 9.0 containing 21 mM 
MgCl. 
F Alkaline phosphatase 
G Butan-1-ol:Toluene 1:1 v/v 
Assay tubes were made-up containing 0.2ml C and 
0.1ml D. 
A phosphate standard curve (0-2 pmoles) was prepared 
using KH.PO.. Blanks contained a volume of 0.32M· 
sucrose equivalent to that of added enzyme. 
Solubilisation of the enzyme was achieved by adding 
0.2ml A and 0.4ml B to 0.4ml enzyme preparation, 
vortex mixing for 20 seconds and leaving on ice for 
10 minutes. 
The assay was performed as shown in Figure 2.4 and 
the inorganic phosphate liber.ated determined by the 
formation of the phosphomolybdic acid complex 
, 
according to the micro-method of Martin and Doty 
[267]. Optical density was determined at 410nM 
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(Pye Unicam SP 30) against solution G as the reference. 
The specific activity of the enzyme was defined as 
pmoles inorganic phosphate liberated. 
minute-I • mg protein-I • 
iv) Monoamine oxidase [EC 1.4.3.4]: a marker for 
mitochondria 
A modification of the method employed by McEwen, Jr 
[26B] was used. 
Assay tubes 
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Figure 2.5 MAO assay method 
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Solubilisation of the enzyme was afforded by the 
addition of Triton X-lOO (Octyl Phenoxy 
Polyethoxyethanol; 1~' by volume) Sigma U.K.), 
vortex mixing for 1 minute then centrifugation 
(Quickfit Micro Centrifuge, 13000g) for 5 minutes. 
Assay tubes contained 100pl freshly redistilled 
benzylamine in 0.2M (Na.HPO.-KH.PO.) buffer, O.lM, 
final pH 7.2. 
The assay is outlined in Figure 2.5. 
Specific activity was defined as the 
optical density at 250nm. minute-I. 
at 37°C. 
change in 
mg protein-I 
(A change of 0.001 absorbance units corresponds to 
the conversion of 0.25 nmoles benzylamine to 
benzaldehyde). 
5. Protein estimation 
Protein estimation throughout was according to Lowry [269], as 
modified by Schacterle and Pollack [270]. 
6. In vitro degradation of ['H]dynorphin A-(1-9) 
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['H]Oynorphin A-(1-9) (14nM) was incubated in the presence of rat 
spinal cord homogenates as used in binding assays at 25°C for 
30 minutes. 8estatin (30pM) and captopril (300pM) were added to 
prevent enzymic degradation by peptidases [197]. The reaction 
was terminated by addition of phosphoric acid to a final 
concentration of 50mM. 
Metabolic products were analysed by high pressure liquid 
chromatography on a CIa Altex Ultrasphere ODS reverse-phase 
column (5~m, 4.6 x 250mm) using a nonlinear gradient between 
, , 
solution A" trifluoroacetic acid (26mM)-triethylamine to 
give pH 3.0 and solution B, acetonitrile (49%)-trifluoroacetic 
acid (13mM). 
The gradient was 45 - 611, B in 15 minutes, 61 - 621, B in 
30 minutes, using a flow rate of 0.5ml., minute -I. ['H]Products 
were identified by the position of standard marker peptides, 
collected and radioactivity determined by scintillation counting 
as previously described. 
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C H APT E R 3 
ANALYSIS OF RESULTS 
A. Binding Assays 
Determination of radioligand binding constants 
The foll~wing binding equations are based on the principle of 
the Law of Mass Action, that is a simple bimolecular 
interaction between a drug (L) and its binding site (R), to 
give the complex RL. 
At equilibrium 
k, 
R + L RL eqn. 1. 
The equilibrium dissociation constant, KO' provides a measure 
of the affinity of a ligand for its binding site such that 
k. [R] [L] 
KO = = eqn. 2. 
k, [RL] 
Saturated binding studies 
The KO for a labelled ligand may be determined by saturation 
experiments in which the total concentration of radioligand [Lt] 
is increased and [RL] is determined at equilibrium. The total 
binding site population [Rt] is kept constant and [RL] is 
determined as a function of [L]. 
Therefore, since Rt = [R] + [RL] then [R] = [Rt - RL] so 
[Rt - RL] [L] 
[RL] 
= KO 
which in terms of [RL] is given by 
[RL] = [Rt] [L] 
KO + [L] 
eqn. 3. 
eqn. 4. 
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! 
It can be seen that when KD ; [L] then 
[RL] ; [Rt] 
2 
eqn. 5. 
Therefore, KD is equal to the concentration of radioligand 
occupying 5m~ of the total binding sites. 
Equation 4 describes a rectangular hyperbola (Figure3.1a) 
and is equivalent to the Langmuir 'adsorption isotherm which is 
given by 
[L] ; 
That is, r ; 
r when [LR] (KD) 
r ; 
1 [Rt] - r 
the proportion of the total potential sites 
of interaction occupied by the ligand for a 
given surface onto which adsorption can occur. 
Scat chard analysis 
The method of Scatchard [217] permits the linearization of 
equation 4 as follows: 
Since 
then 
[RL] 
-'-
[L] 
[RL] 
[L] 
([Rt] - [RL]) eqn. 6. 
[Rt] [RL] eqn. 7. 
The parameters of equations 6 and 7 are more usually expressed 
as follows: 
[RL] ; B (Bound radioligand) 
[L] ; F (Free or unbound radioligand) 
[Rt] ; Bmax- (Total number of binding sites) 
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b. 
u. 
'" 
slope. -1/KD 
01' 
ID 
Free (F) B 
B 
a) Untransformed and b) transformed data from a 
saturation analysis, according to the method 
of Scatchard [217] for a single site and 
c) two non-interacting sites. 
Thus equation 7 may be re-written 
B Bmax B 
= 
F 
A plot of ~ versus B will give a slope 
eqn. B. 
-1 
of -
KD 
intercept on the abscissa of Bmax (Figure 3.1b). 
and an 
Bound, that is specifically bound radioligand is given by: 
Total counts bound - (counts bound in the presence of 
excess inhibitor*). 
* This represents non-specific binding. 
Free, that is unbound radioligand, is given by: 
Total counts added - counts specifically bound. 
Counts may be converted to a concentration term by dividing the 
dpm by the specific activity of the radioligand (in dpm). 
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The advantage of the Scatchard plot is the ease with which KD and 
and Bmax may be obtained. However, there are disadvantages. 
These include: 
a) The bound term is present in both the ordinate and abscissa: 
Therefore, any error in the bound value will be magnified 
in two dimensions. Scatter of points is therefore 
increased particularly at either of the axes where the 
measurement of the bound radioligand is subject to the 
greatest error [161] •. 
b) The data points which are evenly spaced on a non-transformed, 
hyperbolic plot (Figure 3.1a) are compressed when 
transformed, particularly at high concentrations of free 
ligand. False Bmax values may therefore be obtained because 
of erroneous judgement that saturation has been achieved, 
when it has not. 
c) The interaction of a ligand with a single class of 
binding site should produce a linear Scat chard plot. 
Interaction with more than one site, where the affinity 
of the radioligand for the separate sites is sufficiently 
different, will yield curvilinear Scatchard plots 
(Figure 3.16) •. However, a number of methodological 
artifacts, such as metabolism of the radioligand can 
.produce non-linearity and hence, lead to incorrect 
conclusions and false heterogeneity where none exists. 
d) True heterogeneity of binding sites may not be seen if, 
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for example, the affinity of the radioligand for all sites 
is similar or if the separate populations of high and low 
affinity sites are too low. The scatter and number of 
data points used, or the concentration range of radioligand 
may also lead to erroneous interpretation of an 
heterogeneity of sites. 
e) Because of the correlated, non-uniform errors present in 
both co-ordinates of the Scatchard plot, non-weighted 
linear regression of the data is statistically invalid. 
Therefore, computer-aided analyses have been developed to 
help overcome these problems. 
Computer-assisted analysis of saturation data 
The two main computer-aided analytical systems currently in use 
are non-linear regression [218] and iterative curve-fitting 
programmes such as LIGAND [161]. Both have greater statistical 
validity than simple linear regression of the data. In 
particular, LIGAND, when used appropriately represents a powerful 
tool for the estimation of KD and Bmax values. Several 
advantages are apparent with this method of analysis: 
a) The total.binding rather than specific binding is examined. 
Thus, additional errors which may be added by subtraction 
of non-specific binding are eliminated. 
b) The data points at the extremes of the curve are not 
equally weighted. Therefore, the non-uniformity of 
variance of the dependent variable B is compensated for. 
c) Incorporated within the analysis of single or multiple 
site models are statistical methods which allow the 
validity of each model to be assessed. 
The major disadvantage with computer techniques is that because 
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of the complexity and power such methods possess, the experimenter 
may be tempted to unquestioningly accept the results produced. 
Large.errors are possible where the scatter of data points is 
great, if the maximum concentration of radioligand used is not 
sufficient to occupy 90% of the binding sites, that is 9. to 10 
times the KO value, and when too few data points are used. In 
the latter case 6 to 10 points are sufficient to describe a single 
site model but twice these should be used when multiple site 
models are being analysed [213]. The requirements for Scatchard 
analysis and the sources of error from assay or methodological 
artifacts also apply to such analyses. Thus, it is the quality 
of the initial data which determines the precision and accuracy 
of an analysis,whether that analysis is performed manually or 
with the aid of computational techniques. 
Competitive inhibition studies 
The affinity of an unlabelled competing ligand for an opioid 
binding site may be determined from competitive inhibition· 
curves. With such an experiment the binding site concentration 
[Rt] and radioligand concentration [L] are kept constant, whilst 
the concentration of an unlabelled competing ligand [I] is 
varied. Therefore, the concentration of radioligand bound [RL] 
at equilibrium is a function of [I]. Such a reaction is described 
by: 
[RL] = [L] [Rt] eqn. 9. 
KO (1 + [I]/Ki) + [L] 
where [I] = concentration of free unlabelled inhibitor. 
KO = equilibrium dissocation constant for the 
interaction of the radioligand with the 
binding site. 
Ki = equilibrium dissocation constant for the 
interaction of the inhibitor I with the. 
binding site, .·defined by Ki = [R] [I]/[RI]. 
The concentration of inhibitor which displaces 50% of the bound 
radioligand, the IC s. can be determined graphically when the ~~ 
inhibition of binding is plotted against log concentration of 
inhibitor. Interpolation to the abscissa provides log IC so 
for the competing ligand (Figure 3.2a). 
The ~~ inhibition of binding by an inhibitor may be calculated 
experimentally by: 
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It is possible to linearize the displacement curve by the Hill 
transformation [219]. 
[RL] = [Rt] [L] eqn. 4. 
KO + [L] 
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Analysis of competitive displacement data 
a) ~6 inhibition - log concentration inhibitor 
curve and b) Hill plot. Figure 3.2c shows 
Hill slopes for co-operativity of inhibitor 
binding (nH = 2), displacement from an homogeneous 
population (nH = 1) and displacement from an 
heterogeneous population (nH = 0.5) of sites. 
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[RL] is the proportion of binding sites occupied by the 
[Rt] 
radioligand and may be given the term r. Substitution and 
rearrangement of equation 9 gives 
[L] = r eqn. 11. 
1 - r 
This relationship holds if one molecule of radioligand interacts 
with a single binding site. If two molecules interact 
simultaneously with a single binding site then: 
[L]2 r .K = eqn. 12. 
1 - r 
and in general 
[L]n r 
.k = eqn. 13. 
1 - r 
where n = number of molecules of radioligand interacting with 
a single binding site. 
k = constant. 
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If log (r/ (l-r» is plotted against log [L] then a straight line 
with slope n, often designated nH (the Hill coefficient) is 
obtained. For competitive binding assays it is more usual to 
plot log (1/ (100-1» against log [inhibitor], where I represents 
r. inhibition of radioligand binding by the inhibitor. The IC •• 
for the inhibitor is calculated by interpolation from log 
(1/ (100-1» = 0 (Figure 3.2b). 
A slope of unity is given when the competing ligand displaces the 
bound radio ligand from a single class of binding site or multiple 
classes of site for which the competing ligand has equivalent 
affinity. 
Low or shallow Hill slopes, that is, less than unity may be 
obtained when multiple binding sites exist for which the 
competing ligand has different affinities. Alternatively the 
low slopes may represent interconverting forms of a given 
class of binding site [213] or negative co-operativity between 
binding sites. Hill slopes of greater than unity suggest 
co-operativity of competitor binding, (Figure 3.2c). 
Having determined the IC,., the Ki for the inhibitor may be 
determined indirectly by the Cheng and Prusoff equation [220], 
that is, 
where 
Ki = IC ... KO 
KO + [L]' 
eqn. 14. 
[L] = free radioligand concentration. 
KO = equilibrium dissociation constant for the 
radioligand. 
Ki = equilibrium dissociation constant for the 
competitor. 
IC" = 50~o inhibitory concentration for competitor, 
expressed as free concentration of ligand. 
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I 
It is important to note that the concentration used in competition 
experiment calculations are the free concentrations at 
equilibrium. 
Because it is often difficult to determine the free concentrations 
of the competitor, it may be assumed that free concentration is 
equal to the total concentration present, providing that the 
amount bound is low with respect to the equilibrium dissociation 
constant. This means that the total binding sites present [Rt] 
must be much lower than the respective KO value of the radioligand 
and Ki value of the inhibitor. If [Rt] is greater than or equal 
to the equilibrium dissociation constant, then the estimation of 
Ki from equation 14 will be too high [161]. 
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Analysis of heterogeneous binding site populations: 
a) Biphasic displacement of radioligand by an 
inhibitor with different affinities for the two 
populations of binding site and b) Resolution of 
plot (a) into two Hill plots for the determination 
of binding parameters. 
Multiple binding sites 
It is possible to study the interaction of ligands with more than 
one binding site using competitive inhibition· studies, although 
as mentioned previously, the effectiveness of such work is 
dependent upon the affinity of the competitor for .the respective 
sites. In some cases, the displacement curves may·yield low 
Hill coefficients but no apparent separation of the binding 
components (Figure 3.2c). However, where there is sufficient 
difference in the affinity of the competitor for the respective 
sites, typically 100 to 1000 fold, noticeably bi-phasic plots 
may be obtained (figure 3.3a). These displacement curves may 
be resolved into separate Hill plots and analysed for binding 
constants (Figure 3.3b). In addition, the proportions of high 
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and low affinity sites labelled at the concentration of radioligand 
used, may be estimated as shown in Figure 3.3a. 
Alternatively, heterogeneous populations of binding sites may be 
studied using different radioligands with 100 to 1000 fold 
specificity for a given class of binding site. Competitive 
inhibition studies and saturated binding analyses may then be 
performed and analysed simply. 
In the present work, the results from competitive inhibition 
studies .have ·been obtained either directly from the displacement 
curves or from Hill plots. Displacement curves are represented 
as mean ~. inhibition values with error bars eXpressing the 
standard error of mean and Hill plots are represented using 
mean results. 
Saturated binding studies were analysed according to the method 
of Scatchard, USing the non-linear regression method of 
McPherson [218]. Occasionally, where indicated the data has 
been analysed for site heterogeneity using LIGAND [161]. Single 
representative plots for Scatchard analyses are presented to 
avoid problems associated with deriving mean data, including 
averaging data from assays using different concentrations of 
radioligand and thus introducing considerable errors in both the 
bound and bound/free values. 
These are in addition to the errors discussed earlier inherent 
in Scat chard analysis. 
B. Enzyme Assays 
In the study of the sub-cellular distribution of binding the 
presence of specific enzyme-markers was used as evidence that 
the desired fraction had been obtained and to allow assessment 
of the purity of fractions. 
Each fraction was compared by determination of the amount of 
component per volume of fraction derived, which was equivalent 
to one gramme of tissue. Thus, the results obtained from the 
determinations of enzyme activity for each fraction were 
multiplied by their respective "volume equivalents" to give 
the number of units per volume equivalent to 19 of tissue. 
The concentration of protein per volume equivalent to 19 of 
material was then calculated and the percentage recovered 
activity, and percentage recovered protein were calculated using 
Recovery for fraction x x 10m~ 
Sum of recoveries from all fractions 
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where recovery is expressed as units of activity (or mg protein) 
per volume equivalent to 19 of tissue. 
The relative specific concentration, RSC, may then be calculated 
by: 
1~ Recovered Activity 
1~ Recovered Protein 
This term permits the comparison of a series of results, 
without the large errors produced by random losses due to 
volume and analytical error which would be present if absolute 
values, such as activity per mg protein were used to calculate 
specific concentrations. An RSC value greater than unity 
indicates an enrichment of the component under study in that 
fraction, relative to the parent fraction. 
C. Statistical Analysis 
Results are presented as the statistical mean and standard 
error of mean. Where comparisons have been made between 
different regions of the spinal cord, analysis of variance 
(ANOVA) [222] was initially calculated. When a statistical 
significance was observed fUrther analysis was made using 
Duncan's multiple range test [222]. This latter test adjusts 
the size of the critical difference depending upon whether two 
means are adjacent or whether one or more means fall between 
those being compared. Both of these tests are based upon the 
completely randomized design of experiments. Points to . 
consider for such design are: 
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a) For each subject in the experimental group there is 
only one score. 
b) Similar numbers of subjects should be in each experimental 
group where possible. 
c) The number of groups to be compared may be arbitary, but 
more than four or five groups are rarely ,used. 
The binding experiments performed in the following experimental 
sections were designed to conform as closely as possible with the 
randomized design criteria. Each assay produced only a single 
value for Bmax or KD. The animals were randomly chosen from a 
large population. 
In some experiments tissues from more than one animal were 
pooled to provide sufficient for assay, as with spinal cord 
preparations. In this case spinal segments for cervical, 
thoracic and lumbo~sacral regions were separated and pooled 
as individual groups. Material was then randomly selected 
from the appropriate population for single assay determination. 
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C H APT E R 4 
EXPERIMENTAL CONDITIONS 
INTRODUCTION 
An 'extensive research effort has been undertaken over the past two 
decades to determine the molecular properties and functional 
roles of opioid receptors. The development of in vitro 
methodologies, including binding assays [76, 77, 79, 81] has 
provided confirmation of the results from in vivo studies [14, 
17 - 20] and from bioassays [22,30,67], which suggests the 
existence of multiple opioid receptors [66, 67]., 
The direct analysis of opioid binding site interactions by ligand 
binding techniques is relatively simple experimentally. However, 
because of the sensitivity of opioid binding to modifying influences 
such as temperature [201], pH [79], ions and nucleotides [77, 78] 
and incubation times [210], it is necessary to define the assay 
conditions. 
In the work described a selection of ['H]opioids and central nervous 
system tissues have been used and binding studied under a variety 
of conditions. 
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MATERIALS & METHODS 
Homogenates were prepared and binding studies performed as 
detailed in Chapter 2 at 37°C for 45 minutes except in experiments 
where these parameters were being studied. Mouse and rat brain 
in addition. to bovine and porcine spinal cords were used. 
[SH]Etorphine, ['H] (-)-bremazocine, ['H]diprenorphine, 
[SH][D-Ala2,D-Leu~enkephalin and ['H][D-Ala2,MePhe',Gly-ol'] 
enkephalin were the labelled ligands. 1~M unlabelled diprenorphine 
was used to define non-specific binding except when different 
unlabelled ligands were under study. The chemical formulae of 
the compounds are as given in Chapter 2. 
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RESULTS 60 
Non-specific binding 
The definition of non-specific binding of ['H]diprenorphine in 
rat brain homogenates was determined using a selection of unlabelled 
opioid compounds (Table 4.1). At this level of ['H]diprenorphine (0.2nM) 
specific binding represented 95~~ of the bound total. ligands 
displaying selectivity for individual classes of binding site 
namely U-50488H and to a lesser extent, tifluadom required much 
\ 
higher concentrations to achieve the displacement obtained with 
non-selective ligands • 
. Equilibrium binding . 
Equilibrium binding was achieved for the four ['H]opioids studied 
in different central nervous system tissues from a variety of 
animal species (Figures 4.1 - 4). The results are summarized in 
Table 4.2. Equilibrium was achieved more rapidly at the higher 
temperatures, being reached within 45 minutes for all the ligands 
studied at 37°e. In comparison ['H]etorphine required greater 
than 90 minutes at 25°e and 60 minutes at 30 0 e compared with 
45 minutes at 37°e (Figure 4.1). ['H](-)-Bremazocine reached 
equilibrium very rapidly at 37°e, within 15 minutes in porcine 
lumbo-sacral spinal cord. At 25°e it was more difficult to 
determine the time required from the temperature-time curves in 
either porcine lumbo-sacral cord (Figure 4.2a) or rat brain 
(Figure 4.3c) homogenates. 
Table 4.1 The ability of unlabelled opioids at high 
concentrations to displace ['H]diprenorphine 
(0.2nM) in rat brain homogenates at 37°C. 
Unlabelled ligand Concentration (~M) 1. Displacement* 
MR 2266 1 95.33 ± 0.29 
10 95.30 ± 0.20 
Diprenorphine 1 96.42 ± 0.39 
(-)-Bremazocine 1 94.97 ± 0.51 
10 94.59 ± 0.41 
Naloxone 10 94.58 ± 0.31 
Tifluadom 1 79.58 ± 0.83 
10 93.43 ± 0.40 
U-50488H 10 49.18 ± 2.22 
200 90.10 ± 0.23 
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Values represent means ± sem, of 4 separate experiments in duplicate. 
* 1. Displacement represents displacement of total, that is, specific 
plus non-specific ['H]diprenorphine binding by unlabelled ligand. 
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The influence of temperature on specific ['H]etorphine 
binding against time in mouse brain homogenates 
(concentration of radioligand used = 1.93nM). See 
Table 4.2 for equilibrium times. 
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equilibrium times. 
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Specific binding against time for a) ['H][D-Ala2 , 
MePhe' ,Gly-ol 5 ]enkephalin (0.30nM) ( ... ) and b) 
['H](-)-bremazocine (0.42nM)(o) at 37°C in rat brain 
homogenates. See Table 4.2 for equilibrium times. 
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Table 4.2 Equilibrium times for ['H]opioids at different temperatures in a selection of CNS tissue 
homogenates (Figures 4.1 - 4.4). 
Temperature Time to reach 
Labelled Ligand Tissue (OC) equilibrium (min.) 
['H]Etorphine Mouse Brain 25 >90 
30 70 
37 40 
- -
['H) (-)-Bremazocine Porcine lumbo-sacral 25 i 30, .. 
spinal cord 
l. __ . 
37 <15 
Rat Brain 25 \30-: 
37 130-~ 
_I 
['H][D-Ala 2 ,D-Leu S ]enkephalin Rat Brain 25 
r---. 
I ?5.i 
['H][D-Ala',MePhe',Gly-ol']enkephalin Rat Brain 25 [45] 
37 45 
Results are observations from n separate experiments in duplicate (or * triplicate). 
n 
2 
2 
2 
1* 
1* 
2 
2 
2 
2 
2 
'" 
'" 
Protein concentration 
When 1nM ['H]etorphine was used, the amount specifically bound, 
as fmoles increased linearly with protein concentrations of up 
to 1mg.ml-1 in mouse brain homogenates and up to 1.5mg.ml- ' in 
bovine lumbo-sacral spinal cord homogenates, reaching a plateau 
of 3mg.ml-
' 
in bovine cord (Figure 4.5). Concentrations of greater 
than 2mg.ml-
' 
protein were not tested with the mouse brain 
preparation. The ligand specifically bound, when expressed as the 
1~ of total activity added did not exceed "',1~ at protein 
concentrations up to approximately 6mg.ml- 1 in bovine lumbo-sacral 
spinal cord, but was greater than 10r. for protein concentrations 
of approximately 1mg'.ml-
' 
or greater in mouse brain homogenates, 
(Table 4.3). 
Post-filtration washing 
The percentage of ['HJ( - )-bremazocine specifically bound in rat 
brain homogenates reached a maximum plateau aft(,'lr three 4ml 
washings with ice-cold buffer and up to three extra washings with 
4ml aliquots of ice-cold buffer did not affect the specifically 
bound ['H](-)-bremazocine (Figure 4.6). A radioligand concentration 
of O.52nM was used for the binding assays. 
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Influence of protein concentration on specifically bound ['H]etorphine in homogenates of mouse brain 
(.) and bovine lumbo-sacral spinal cord (0). An incubation time of 45 minutes at 37"C was used. 
Concentration of radioligand was 1.0nM. See Table 4.3 for data. 
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ex> 
Table 4.3 
Species & 
Tissue' 
Mouse Brain 
Bovine lumbo-
sacral spinal 
'cord 
Binding characteristics of ['H]etorphine (1.0nM) 
at different protein concentrations. 
, 
Protein Conc. % Total Added Activity 
(mg.ml- I ) Specifically Bound 
0.16 2.43, 4.69 
, 0.25 3.68, 4.16 
0.34 5.37, 6.13 
0.49 7.09, 8.93 
0.58 9.17, 8.90 
0.99 10.17, 12.72 
1.98 14.93, 22.51 
0.49 2.10, 1.92 
0.98 3.11, 2.98 
1.49 3.93, 3.96 
2.93 5.40, 5.18 
5.87 5.38, 5.25 
Results expressed as individual values from 2 separate experiments 
in duplicate. 
~. Added activity totally bound, that is specific plus non-specific, 
represented 25~' in mouse brain and 6~' in bovine spinal cord at the 
highest protein concentration studied in each species. 
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OISCUSSION 
All of the unlabelled opioids tested displaced greater than 90% 
of the total bound ['H]diprenorphine, when the ,concentration of 
radioligand used was close to the reported KO values in gUinea-pig 
lumbo-sacral spinal cord [152] and rat brain [98]. However, 
U-50488H and tifluadom required higher concentrations to displace 
the specifically bound ['H]diprenorphine, indicative of their 
selectivity for k-sites [106, 109] and hence, reduced affinities 
at other opioid binding sites. Previous reports [97, 211] have' 
proposed that the inhibitor which is used to define non-specific 
binding should have a high affinity for the radioligand binding 
site and have a chemical structure which differs from that of the 
radioligand. This competing ligand should also be used at a 
concentration sufficient to occupy all specific binding sites but 
not high enough to displace non-specific binding. Were the latter 
to occur, the saturation isotherm'may yield biphasic Scatchard 
plots which could be mistakenly interpreted as heterogeneity of 
binding sites [211]. A concentration of approximately 100 times 
the KO concentration of the inhibitor is commonly used [212]. 
The incubation temperature used for binding assays has been shown 
to be an important variable. The results in this present study 
show that the time to reach equilibrium by a selection of ['H]opioids 
decreases as the temperature increases. Stability of the ligands 
is not a problem when using compounds ,this stable, but early 
experiments with the enkephalins [89] were performed at 0-4DC to 
reduce enzymatic breakdown of the peptides. However, because of 
the reduction in the radio ligand-binding site association rate at 
these lower temperatures, much longer assay times were required to 
allow equilibrium binding to be achieved [211]. Furthermore the 
pharmacological characteristics of opioid binding sites at these low 
temperatures were, reported in an early study [201] to change to 
a state favouring antagonist binding, and the number of binding sites 
is reported to decrease at low temperatures. For example, the Bmax 
for ['H](-)-bremazocine in guinea-pig brain increases by'1.5'times 
, 
when the assay is performed at 25DC rather than ODC [197]. 
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Other ligands also show an increase over the same temperature 
range, although the differences are not as great as with 
['H](-)-bremazocine [89]. The use of more physiologically relevant 
temperatures such as 37DC allow more direct comparisons to be made 
between the results from binding studies and those gained from 
bioassays. However; some opioid peptides such as the naturally 
occurring enkephalins and the smaller dynorphin fragments are 
uns~able at these higher temperatures [74, 197]. Therefore, the 
use of these peptides whether radiolabelled or unlabelled is not 
possible unless the temperatures are reduced and/or enzyme 
inhibitors are used [197]. It is for such reasons that many workers 
" perform their experiments at 22DC or 25DC [74, 152] under conditions 
which allow a more direct comparison between peptide and non-peptide 
radiolabelled opioids to be made. 
A further factor to be considered is that prolonged incubation at 
37DC or the .use of temperatures in excess of 40DC may reduce the 
amount of radioligand bound, possibly due to denaturation of the 
protein in the binding site [78]. However, in the present work 
changes in Bmax at different temperatures were not evident. For 
example, in the thoracic spinal cord of the rat ['H](-)-bremazocine 
afforded Bmax values of 70.3 and 68.3 fmol.mg-' at 25DC and 72.3 and 
70.1 fmol.mg-' at 37DC, both after 45 minutes incubation. 
Specifically bound ['H]etorphine increased linearly up"to 1mg~ml-' 
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in mouse brain and 1.5mg.ml-1 in bovine lumbo-sacral spinal cord 
homogenates, when 1nM radioligand was used. After this the relationship 
between specifically bound ['H]etorphine and protein concentration 
deviated from linearity. It is unlikely that this was the result 
of the available ['H]etorphine being totally bound to specific or 
non-specific sites since even at high levels of protein the total 
bound, that is specific plus non-specific binding represents only a 
relatively low ~. of the added radioligand. The concentration of 
opioid binding sites present represents only a small fraction of. 
the total protein. The free ligand concentration in an assay system 
" is directly proportional to the concentration of opioid binding 
sites present. At low opioid binding site concentrations, that is. 
. . 
when concentrations are low compared to the KD of· the radioligand 
being used, opioid binding has little effect on the free ligand 
concentrations. Therefore, the calculation of pharmacological 
constants is straightforward. However, when the binding site 
concentration is less than 10 times lower than the true affinity 
constant, the apparent KO obtained from direct concentration binding 
curves will increase as a linear function of binding site 
concentration [213]. Therefore, when high levels of binding sites 
are present in the assay mixture, the free ligand concentrations 
may be so reduced that saturability becomes difficult to demonstrate. 
The specific activity of the ligands being used must be taken into 
account when assessing protein concentrations. If only low specific 
activity ligands are used then the specific to non-specific ratio 
. will be low, particularly at the higher protein concentrations. 
However, by using high affinity ligands that is, those with a KO of 
less than 10nM, a high specific to non-specific ratio will be obtained 
and the lower will be the level of detection for the amount of 
radioligand specifically bound. In future experiments the protein 
levels used were such that the bound radioligand did not exceed 10% 
of the total added activity. 
Post-filtration washing of the homogenates retained on the filter 
is another experimental step where close control of conditions is 
necessary. The major consideration for this procedure is the rate 
of dissociation of the. ligand from the opioid binding sites. If the 
rate is slow then more extensive washing to remove excess, un bound 
radioligand is possible without disturbing the equilibrium 
established during assay. For many opioid compounds the dissociation 
rate is high from non-specific sites [212], but because it is 
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generally found that the rate of dissociation is inversely proportional 
to the KO, those ligands with higher affinity for the binding sites will 
dissociate more slowly from specific sites [212]. Therefore, 
extensive washing will greatly increase the ratio of specific to 
non-specific binding (Table 4.4). Two approaches have been used for 
filtration of the assay mixture at the end of incubation. The first 
is to cool the mixture on ice to 4°C, decreasing the dissociation 
rate from the binding site, and then filtering. This method has 
Table 4.4 
KO (M) 
10-" 
10-" 
10-" 
10-' 
10-8 
10-7 
10-· 
Relationship between steady-state dissociation 
constant (KO) and allowable separation time. 
Allowable Separation Time 
(0.15 t~)a 
1.2 days 
2.9 hours 
17 minutes 
1.7 minutes 
10 seconds 
0.10 seconds 
0.01 seconds 
a Calculations of t~ (half-life for dissociation) assume an 
association rate constant of 10· M-' S-· • 
(From Yamamura, H.!. et 81 [212]). 
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the inherent disadvantage. that the conformation .of the ... 
binding sites may be changed at these lower temperatures. 
Alternatively, the assay mixture is passed directly through the 
filters and then washed with ice-cold buffer. This latter method 
has been adopted in the present work. The levels of specific 
binding in terms of the amount bound and the percentage bound was 
high and appeared to be unaffected by washing with up to six. 
aliquots of 4ml ice-cold buffer, confirming the low dissociation 
of ['H](-)-bremazocine •. It should be remembered that the 
filtration technique does lead to a loss of material which passes 
straight through the filter, and that non-specific binding of the 
['H]opioid may occur·to the filter material [86]. This is seen 
particularly with the peptides [197] and with compounds such as 
U-69593 [198]. During assay of these materials use was made of . 
the anti-adsorbant polyethyleneimine at a concentration of 0.1%. 
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Although the factors discussed are the major influences on the results 
obtained from binding studies, other potential sources of error 
should be considered. 
The radiochemical purity of ligands is essential to ensure accurate 
results. Although many radiochemicals are prepared free of 
radioactive contaminants they may undergo decomposition upon storage. 
These contaminants may then interfere with calculations concerning 
the bound and unbound ligand concentrations or even compete for the 
binding sites,leading to errors in the estimation of binding 
parameters. Such errors may lead to unnecessarily complicated 
Scatchard plots from saturation studies, suggesting apparent 
heterogeneity [213]. The purification of radiolabelled ligands by 
chromatographic techniques prior to use is necessary. 
~letabolism of the radioligand in the assay system to inactive 
fragments, a problem especially with peptides, will lead to non-
equilibrium binding conditions in addition to an over estimation of 
the concentration of free ligand. The use of specific enzyme 
inhibitors has been shown to reduce these effects [75, 197] but care 
must be taken when using such agents since they may have additional 
actions on the tissue which alter the binding site properties [214]. 
Additionally such compounds may be adsorbed onto either contaminating 
cellular components in the assay system or vessel walls in which 
the assay mi~ture is contained [197]. This will lower the free 
ligand concentration at the binding site surface and may go 
undetected because of rapid dissociation from these non-specific 
sites upon filtration. Such adsorptive effects may lead to the 
underestimation of the absolute potency and the potency relative to 
other ligands where such losses are less prevalent [215,216]. 
A major difference between binding assay systems'and bioassay or 
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in vivo systems is the medium in. which the binding site or receptor 
preparation is bathed. Although it would be desirable to study 
binding under physiological conditions so that more direct comparisons 
may be made between binding and intact tissue systems, problems arise 
which prevent such studies. For example, in the presence of 
physiological buffers containing high levels of sodium ions opioid 
binding sites undergo conformational changes such that antagonist 
binding is promoted [78]. Since many of the radiolabelled opioids 
available are agonists, then binding under physiological conditions 
is very low [78]. It is for reasons such as this that low ionic 
strength buffers are employed. However, an advantage of these 
'buffers is that they do allow close monitoring of parameters such as 
pH and the concentrations of ions and nucleotides. Thus, pH which 
is known to be an important factor affecting opioid binding [77, 78] 
can be maintained constant throughout the duration of the 
experiment. Finally, binding studies performed using homogenates 
expose both the inner and outer surfaces of the membrane to the 
same conditions. An alternative to these techniques is the study 
of intact cells, although receptor and ligand internalization would 
disrupt equilibrium binding ,and therefore complicate interpretation 
of the data. If these problems were overcome, the method would 
have the inherent advantage of studying the intact'cell system and 
the characteristics of the opioid receptor within that environment. 
, 
In conclusion, the experimental conditions for binding assays 
must be accurately defined. Many factors can influence the results 
obtained using such studies, ·an understanding of which is 
important when interpreting results. 
From these preliminary investigations experimental conditions were 
chosen such that assays were performed at 37°C for 45 minutes using 
less than 1mg.ml~1 protein. Following the separation of bound and 
free ligand by filtration, the retained material was washed three 
times with 4ml aliquots of ice-cold buffer. Non-specific binding 
was defined using an unlabelled non-selective opioid with 
dissimilar chemical structure to that of the radioligand at 100 x KO. 
Any modification of these conditions, for example, when using labile 
peptides is detailed in the relevant methods section. 
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C H APT E R 5 
DISTRIBUTION OF OPIOID BINDING SITES 
IN THE SPINAL CORD 
INTRODUCTION 
The dorsal horn of the spinal cord is an important site of action 
for narcotic analgesics [138]. The intrathecal administration of 
morphine-like compounds [139] or opioid peptides [140-2] 
produces a profound dose-dependent, naloxone-reversible analgesia 
which implies the involvement of opioid receptors at this level. 
Autoradiographic studies using a variety of ['H]opioid ligands 
have shown opioid binding sites to be concentrated in the marginal 
zone of lamina I and the substantia gelatinosa of lamina 11 
[115, 119, 143, 147]. Lamina II cells which respond to painful 
stimuli via dendritic processes extending into the substantia 
gelatinosa [144] contain lower numbers of binding sites [119, 145, 
146]. In addition immunohistochemical analysis shows prodynorphin-
and proenkephalin A-derived peptides to be concentrated in these 
areas [134]. 
Opioid peptides [147, 149-51] and binding sites [119, 146, 152] are 
also found in lower concentrations within the ventral horn of the 
spinal cord, an area associated mainly with motor function [153]. 
Studies along the r.ostro-caudal axis show inconsistencies. 
Proenkephalin A and prodynorphin products vary by up to six-fold 
between cervical, thoracic and lumbo-sacral regions,· depending 
upon the peptide and species [149-51]. Binding studies are not 
. . 
consistent and sites are reported to be homogeneously [146, 154] 
or heterogeneously [155] distributed throughout these same regions. 
Therefore, work was performed in which the dorso-ventral and rostro-
caudal distributions of opioid binding sites were studied, both in 
terms of the total number and types of sites present. The results 
have been compared to the reported distributions of endogenous 
opioid peptides. 
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MATERIALS & METHODS 
Whole spinal cords were removed as detailed in Chapter 2 and then 
sectioned into cervical, thoracic and lumbo-sacral regions. 
Further divisions into dorsal and ventral halves were then made. 
Homogenates were prepared and binding assays performed as detailed 
in Chapter 2. 
['H](-)-Bremazocine, ['H]etorphine, ['H][D-Ala2 ,D-Leu S ]enkephalin 
and ['H][D-Ala2 ,MePhe',Gly-015]enkephalin were the radioligands 
used to define opioid binding sites. 1~M unlabelled diprenorphine 
was used to define non-specific binding. 
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RESULTS 
a) Rostro-caudal distribution of opioid binding sites 
High affinity, saturable binding was demonstrated for the 
unselective opioids ['H]etorphine. [96] in bovine cord and 
for ['H](-)-bremazocine [96] in the cords from the rat, 
guinea-pig and farmyard pig (Figures 5.1-4; Tables5.1 '" 5.2). 
['H]Etorphine bound to specific ~ites in the cervical, 
thoracic and lumbo-sacral regions of bovine cord. The 
affinity in the cervical region was significantly higher 
(p < 0.05). ['H](-)-Bremazo~ine bound with a similar 
affinity to specific sites in each of these three anatomical 
regions of rat spinal cord. 
By using 1nM each of ['H][D-Ala 2 ,MePhe',Gly-ol5]enkephalin 
to define p-sites, ['H][D-Ala 2 ,D-Leu5]enkephalin in the 
presence of 25nM [D-Ala2 ,MePhe',Gly-olS]enkephalin, to define 
B-sites and ['H](-)-bremazocine in the presence of 200nM 
each of [D-Ala 2 ,MePhe' ,Gly-ol' ]enkephalin and [D-Ala 2 ,D-Leu5] 
enkephalin to define k-sites, p-, B- and k-binding sites were 
shown to be present in cervical, thoracic and lumbo-sacral 
spinal cord of the rat (Figure 5.5; Table 5.3). K-Binding 
was predominant in all three regions. The percentages of 
each site were equivalent along the rostro-caudal axis. The 
cervical: thoracic: lumbo-sacral ratios were, for p 
0.68: 0.72: 1, for B 0.89: 1.03: 1 and for k 0.89: 0.69: 1 
respectively. 
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Table 5.1 Saturated binding analysis for ['H]etorphine in bovine spinal cord and ['H](-)-bremazocine 
in rat, guinea-pig and porcine spinal cord homogenates at 37°C (Figures 5.1 - 5.4). 
Species Region Bmax (fmol.mg- I ) KO (nM) r 
Cow Cervical 25.40 ± 6.97 0.77 ± O.OB* 0.B37 - 0.967 
Thoracic 29.64 ± 4.77 1.56 ± 0.45 O.BOO - 0.901 
Lumbo-sacral 32.24 ± 2.55 2.20 ± 0.43 0.7B9 - 0.930 
Rat Cervical 75.9B ± 1 B.48 . 1.19 ± 0.15 0.B23·- 0.B90 
Thoracic 76.27 ± 1 B. 73 1.39 ± 0.01 0.B61 - 0.944 
Lumbo-sacral 95.91 ± 6.34 1.44 ± 0.28 0.862 - 0.892 
Guinea-Pig Lumbo-sacral 65.62 ± 10.44 O.BB ± 0.16 0.950 - 0.981 
Pig Lumbo-sacral 20.63 ± 1.56 0.64 ± 0.07 O.B96 - 0.946 
Results expressed as means ± sem of n separate experiments in duplicate (triplicate for the pig). 
r = Correlation coefficient from non-linear regression. 
* KO Significantly different from thoracic and lumbo-sacral regions(P<0.05). 
No significant difference between Bmax or KO values for different regions except where indicated. 
Non-specific binding defined using 1pM unlabelled diprenorphine. 
n 
5 
4 
7 
3 
3 
3 
3 
3 
co 
'" 
Table 5.2 Specific: non-specific binding ratios for ['H]opioids in selected spinal cord regions from' 
different species. 
Species Anatomical Region 
['I1]Etorehine 
Cow Cervical 
Thoracic 
Lumbo-sacral 
['H](-)-Bremazocine 
Rat Cervical 
Thoracic 
Lumbo-sacral 
Guinea-Pig Lumbo-sacral 
Pig Lumbo-sacral 
Results e'xpressed as means ± sem. 
n = Number of separate experiments. 
All assays performed at 37DC. 
Specific: Non-Specific Ratio 
0.1nM 5nM ,~ .. , 
2.01 ± 0.44 0.60 ± 0.17 
1.31 ± 0.12 0~40 ± 0.06 
2.53 ± 0.62 0.50 ± 0.05 
7.82 ± 2.44 0.65 ± 0.23 
5.56 ± 1.33 0.65 ± 0.14 
8.04 ± 2.29 0.83 ± 0.10 
6.36 ± 0.93 1.05 ± 0.09 
3.97 ± 0.77 0.46 ± 0.10 
"Non-specific" defined as binding in presence of 1\lM unlabelled diprenorphine. 
n 
5 
4 
7 
3 
3 
3 
3 
3 
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Table 5.3 The rostro-caudal distribution of ~-, 0- and k-binding sites in rat spinal cord, as identified 
by 1nM ['H]-ligands at 37°C (Figure 5.5). 
Labelled Ligand 
[D-Ala2 ,MePhe',Gly-oI5]enkephalin 
(0.78 - 0.95nM) 
[D-Ala2 ,D-Leu']enkephalin * 
(0.90 - 1.01nM) 
(-)-Bremazocine ** 
(0.96 - 1.21nM) 
Specifically Bound (pmol.g-1 ) 
Cervical Thoracic 
0.15 ± 0.07 0.16 ± 0.06 
0.080 ± 0.014 0.094 ± 0.034 
0.79 ± 0.12 0.62 ± 0.12 
Results are expressed as means ± sem for 5 separate experiments in duplicate. 
Lumbo-sacral 
0.22 ± 0.09 
0.091 ± 0.033 
0.89 ± 0.06 
* ['H][D-Ala2 ,D-Leu']Enkephalin was suppressed with 25nM unlabelled [D-Ala2 ,MePhe',Gly-oI5]enkephalin to 
1.0nM labelled ligand to inhibit ~-site binding. 
** ['H](-)-Bremazocine was suppressed with unlabelled [D-Ala2 ,D-Leu5]enkephalin and [D-Ala2 ,MePhe',Gly-oI5] 
enkephalin each in the ratio 100nM to 0.5nM labelled ligand, to inhibit ~- and 0- site binding. 
Non-specific binding defined using 1~M unlabelled diprenorphine. 
<Cl 
N 
~------------------------------------------------------------------------------- \ 
b) Oorso-ventral distribution of opioid binding sites 
High affinity, .saturable binding was demonstrated for 
['H]etorphine and ['H](-)-bremazocine in the dorsal.and 
ventral halves of bovine lumbo-sacral spinal cord 
(Figure 5.6). The dorsal: ventral. ratio of Bmax values 
was approximately 2:1 for both ligands (Table 5.4). The 
specific binding for ['H]etorphine was similar in both 
halves but for ['H](-)-bremazocine was higher in the dorsal 
half (Table 5~6). Single experiments using ['H](-)-
bremazocine in cervical and thoracic regions of bovine cord 
afforded similar Bmax and KO values to those seen in the 
lumbo-sacral region (Table 5.5). 
['H](-)-Bremazocine labelled specific sites in a saturable 
manner in the dorsal and ventral halves of lumbo-sacral 
spinal cords from two strains of rat (Figure 5.7) •. The 
dorsal: ventral ratio of Bmax values was approximately 2:1 
and generally higher specific.binding was seen in rat cord 
when compared with bovine cord (Table 5.6). 
p_, 5- and k-Sites were all shown to be present in the dorsal 
and ventral halves of lumbo-sacral spinal cord of the rat 
(Figure 5.8; Table 5.7). The dorsal: ventral ratios were 
for k 1.85:1, p 1.73:1 and 5 1.42:1 respectively. 
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data. 
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Table 5.4 Saturated binding analyses for [SH]etorphine and [SH](-)-bremazocine in the dorsal and ventral 
halves of bovine and rat lumbo-sacral spinal cord at 37°C (Figures 5.6 and 5.7). 
Species 
['H]Etorphine 
Cow 
['H] (-)-Bremazocine 
Cow 
* Wistar Rat 
Alderley Park Rat 
Anatomical Region 
Dorsal 
Ventral 
Dorsal 
Ventral 
Dorsal 
Ventral 
Dorsal 
Ventral 
* Sutton Bonnington Wistar. 
Bmax (fmol.mg-1 ) 
18.99 ± 3.34 
12.88 ± 1.73 
29.68 ± 7.23 
17.41 ± 5.46 
96.81 ± 5.60 
46.23 ± 0.48 
75.45 ± 16.82 
37.38 ± 5.63 
0.67 ± 0.27 
0.58 ± 0.13 
0.72 ± 0.11 
1.13 ± 0.56 
0.80 ± 0.09 
0.59 ± 0.05 
1.10 ± 0.08 
1.41 ± 0.34 
Results expressed as means ± sem of n separate experiments in duplicate. 
r = Correlation coefficient from non-linear regression. 
Non-specific binding defined in the presence of 1~M unlabelled diprenorphine. 
r 
0.887 - 0.937 
0.865 - 0.969 
0.916 - 0.979 
0.861 - 0.980 
0.948 - 0.980 
0.894 - 0.976 
0.846 - 0.924 
0.838 - 0.893 
n 
3 
3 
3 
3 
3 
3 
---------- --------------------------------
Table 5.5 The dorso-ventraldistribution of opioid binding sites in bovine spinal cord: saturation 
analysis for ['H](-)-bremazocine; single assays at 37°C. 
Rostra-caudal Dorso-Ventral 
Region Region Bmax (fmol.mg-
'
) 
Cervical Dorsal 29.89 
Ventral 15.01 
Thoracic Dorsal 25.96 
Ventral 10.24 
Assays performed in triplicate. 
r = Correlation coefficient from non-linear regression. , 
Concentration ranges used for ['H](-)-bremazocine were: Cervical 
Thoracic 
Non-specific binding defined using 1~M unlabelled diprenorphine. 
KD (nM) 
1.63 
0.96 
2.08 
0.62 
(0.074 - 16.57nM) 
(0.125 - 24.00nM) 
r 
0.848 
0.903 
0.942 
0.804 
'" 
'" 
lable 5.6 Specific: non-specific binding ratios for ['H]opioids in dorsal and ventral halves of lumbo-sacral 
spinal cord from different species. 
Specific: Non-Specific Ratio 
Species 
['H]Etorphine 
Cow 
['H](-)-Bremazocine 
Cow 
Wistar Rat 
Alderley Park Rat 
Anatomical Region 
Dorsal 
Ventral 
Dorsal' 
Ventral 
Dorsal 
Ventral 
Dorsal 
Ventral 
Results expressed as 'means ± sem. 
O.1nM 
1.28 ± 0.22 
1.43±0.41 
7.42 ± 1.67 
2.65 ± 0.55 
11.67 ± 2.12 
10.58 ± 1.73 
7.63 ± 0.38 
4.48 ± 0.14 
n = Number of separate experiments performed in duplicate at 37 DC. 
Non-specific binding defined in the presence of 1~M unlabelled diprenorphine. 
0.32 ±' 0.06 
0.39 ± 0.04 
0.54 ± 0.07 
0.32 ± 0.10 
1.54 ± 0.22 
0.70 ± 0.10 
1.06 ± 0.15 
0.42 ± 0.02 
n 
3 
3 
3 
3 
3 
3 
3 
3 
~ 
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enkephalin. Results shown in Table 5.7. 
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Table 5.7 The dorso-ventral distribution of p-, 
identified by 1nM ['H]ligands at 37°C 
6-
0 
and k-binding sites in rat lumbo-sacral spinal cord, as 
(Figure 5.10). 
Specifically Bound O(pmol.g- I ) 
Labelled Ligand Dorsal Horn Ventral Horn 
[D-Ala',MePhe',Gly-olS]enkephalin 0.19 ± 0.05 0.11 ±-0.03 
o [D-Ala',D-Leu 5 ]enkephalin * 0.17 ± 0.06 0.12 ± 0.04 
(-)-Bremazocine ** 0.98 ± 0.19 0.53 ± 0.14 
Results expressed as means ± sem of 4 separate experiments in duplicate. 
* ['H][D-Ala',D-LeuS]Enkephalin suppressed with 25nM unlabelled [D-Ala',MePhe',Gly-oIS]enkephalin for each 
1.0nM labelled ligand, to inhibit binding at p-sites. 
** ['H](-)-Bremazocine suppressed with unlabelled [D-Ala',D-Leu']enkephalin and [D-Ala',MePhe',Gly-ol'] 
enkephalin each in the ratio 100nM to 0.5nM labelled ligand, to inhibit binding at p- and 6- sites. 
Non-specific binding was defined using 1pM unlabelled diprenorphine. 
-o 
N 
DISCUSSION 
a) Rostro-caudal.distribution of opioid binding sites 
Higher· levels of binding were evident in the spinal cords 
from laboratory species when compared to those from 
farmyard species, findings which are in agreement with a 
previous study in brain tissues [156]. Such species 
differences may also help to explain the anomolies for the 
KO values along the rostro-caudal axis in spinal cords from 
the rat and cow. The relatively uniform distribution of 
the number of opioid binding sites along the rostro-caudal 
axis agrees with published work using ['H]etorphine in the 
rat [155] but is contrary to results in man, where 
["H]diprenorphine sites increased from rostral through to 
caudal sections [152]. However, recent work using 
quantitative autoradiography for ['H]diprenorphine binding 
in human spinal cord suggests an homogeneous rostro-caudal 
distribution [146]. 
103 
In the current work ['H]opioids displayed a lower affinity 
for spinal binding sites than has been demonstrated previously 
in the brain [97], which refutes the work of Hack and 
colleagues [193] who found no such discrepency between 
spinal cord and brain affinities in the rat. 
The lower affinity may be caused by the large amounts of 
myelin present in the cord. Entrapment of ['HJopioid within 
liposomes would reduce the .free ligand concentration at the 
level of the binding site and hence reduce the observed 
affinity. Additionally adsorption of the ['H]ligands onto 
the myelin or other subcellular contaminants [215] may also 
account for the higher levels of non-specific binding seen 
in spinal cord. binding assays especially at higher 
concentrations of labelled ligand. This problem has been 
encountered by other workers [154, 158-60]. 
I 
By using a non-linear curve-fitting programme [161] the 
data for all experiments fitted best a single site model. 
This was not unexpected in view of the similar affinities 
at P-, 6- and k-sites for etorphine and bremazocine [96]. 
All three binding site types have previously been found in 
cervical, thoracic and .lumbo-sacral regions of rat 
[158, 162] and guinea-pig [154] and in thoracic through to 
sacral regions in the human [152]. However, several 
studies by Gouarderes and co-workers failed to identify p-
or 6-binding sites in lumbo-sacral spinal cords from rat 
[155, 163, 164], guinea-pig, monkey or man [163], or 
6-sites in the thoracic region of the rat [155]. This was 
partially supported by evidence from autoradiographical 
studies in rat and guinea-pig cord [165]. 
Recent work in rat spinal cord [158] has shown'-constant', 
. ,--~'--
cervical: thoracic: lumbo'-sacral ratios for [the p -, 1:_' 
6- and k-sites, but suggested a proliferation of p-sites 
in contrast to the data presented in this chapter. The 
high level of k-binding in the present studies agrees with 
previous work from this laboratory in the rat [160, 192] 
and with results of other workers ,in the guinea-pig [154] 
and in man [152]. Note should be taken that for the data 
in Table 5.3, the concentrations of p- and 6- ligands were 
close to their KO values, Whilst the concentration of 
['H](-)-bremazocine was considerably greater than its KO 
values (as determined in rat brain [97]). Therefore, the 
proportions of p-.and 6-sites are underestimated compared to 
k-sites. 
An extensive literature has shown the presence of many 
different endogenous opioid peptides in spinal cords from 
various species. These include prodynorphin-derived [118, 
151, 166, 167] and proenkephalin A~derived [118, 150, 168, 
169] peptides but appear to exclude the pro-opiomelanocortin-
derived peptide B-endorphin [121, 151]. 
104 
However, Haynes gt al [170] demonstrated the existence of 
B-endorphin immunoreactivity in neonatal rat spinal cord up 
105 
to the 28th postnatal day, after which all immunoreactivity 
abruptly disappeared, suggesting la B -endorphine':like peptide isl l 5yhthesi.jed:iln ,th~ spinal cord' during , developme~t;; ,,~c~-,' 
The presence of high numbers of k-sites in the rat cord 
complements the presence of prodynorphin-derived peptides 
[118, 148, 166, 167], many of which have been shown to 
possess potent activity at the k-receptor [71, 72, 1711. 
However, reports concerning their rostra-caudal distribution 
are inconsistent. for example Cox gt ~ [172] found a 
relatively homogeneous distribution of immunoreactive 
dynorphin A~(1-17), whilst Zamir and co-workers [173] 
suggest~d much higher concentrations of immunoreactive 
dynorphin B in the cervical region which decreased caudally. 
I I I 
These results 'suggesfdifferential processindsirice both ' 1- __ . __ • ___ .. ____ ._ .. , ___________ ~. _,._,~._ . _______ 1 _______________ .. J 
dynorphin A-(1-17) and dynorphin B are cleaved from the same 
precursor molecule [58]. Przewlocki and co-workers [151] 
showed a six-fold increase in levels of immunoreactive 
dynorphin A-(1-17) and a three-fold increase for immuno-
reactive a-neo-endorphin in the sacral region over the 
cervical region in human spinal cord. 
Proenkephalin A-derived pep tides show similarly inconsistent 
results for their rostra-caudal distribution. [Leu' ] Enkephalin 
has been shown,to be homogeneously distributed [169] and 
[Met']enkephalin concentrations to increase caudally [150, 
151]. [Met'] Enkephalyl-Arg6-Phe7 and [Met']enkephalyl-
Arg 6-Gly7-Leu' , two extended enkephalins showing increased 
selectivity for k-receptors [103-5, 174] both increase in 
a caudal direction [149, 150]. 
The binding !lite distribution thus appears to show little 
correlation with many of the reports on the rostra-caudal 
distribution of endogenous peptides. 
b) Dorso-ventral distribution of opioid binding sites 
Results presented in this chapter for the dorso-ventral 
distribution of opioid binding sites in spinal cord 
support existing data in the rhesus monkey [145] and in 
man [152]. High dorsal cord binding has been reported 
for ['H]naloxone, ['H]dihydromorphine and ['H]buprenorphine 
in the rat [175] and for ['H]e-endorphin in the rabbit· 
[176]. Binding data is also supported by a wealth of 
autoradiographical evidence. Reports for the rat [115, 
116, 165, 177, 178], guinea-pig [165],monkey [119, 143] and 
in humans [146, 179, 180] all show a high dorsal: ventral 
ratio for ['H]opioid binding sites. A similar pattern has 
been demonstrated in the cervical, thoracic and lumbo-sacral 
regions of spinal cords from different species [115, 119, 
146, 165, 179] supporting the findings in bovine cord in 
this current work. 
The results for the dorso-ventral distribution of ~-, 5- and 
k-binding sites agree with findings in rat, guinea-pig [165] 
and in human [152] spinal cord. The dorsal:ventral ratios 
of ~-, 5- and k-sites in the lumbo-sacral region of human 
cord (Table 5.8) were similar to those seen with rat cord 
in the present work (Table 5.7). 
Results from autoradiography show a distinct localization 
for opioid binding 
dorsal horn. This 
sites in the superficial laminae of the 
area is 
modulation of responses to 
binding in the dorsal horn 
known to be important for the 
nociceptive stimuli. High 
is not therefore unexpected. 
High levels of binding in the ventral cord are less easy 
to explain. Such sites, which are not present in distinct 
bands, may be on sensory fibres [153] or may be associated 
with motor-function [169, 181]. 
The binding pattern for ['H]opioids correlates well with the 
dorso-ventral distribution of endogenous oJJtoicLpllPJicjes and 
I I 
peptides associated with pain mechanisms. [For example, [ 
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Table'5.B 
Regions 
Sacral dorsal 
Sacral ventral 
Lumbar dorsal 
Lumbar ventral 
Distribution of opioid binding sites in human spinal cord. 
(From Czlonkowski, A. ~ §1 [152]). 
Classes of binding site (pmol.g-') 
\I 
1.95 ± 0.31 
1.70 ± 0.19 
1.76 ± 0.12 
1.42 ± 0.2B 
0.47 ± 0.30 
0.35± 0.15 
0.38 ± 0.11 
0.28 ± 0.10 
Results expressed as means ± sem for 4 separate experiments. 
k 
3.49 ± 0.10 
1.42 ± 0.17 
1.58 ± 0.10 
1.56 ± 0.24 
Assays performed at 25°C for 90 minutes~.~ ____ ~ ________________________ ___ 
[\I "~6 -,and :-sit~~:~e l:~elled U~inq O.5nM [. H]diprenorphine. \I-Binding was then d~:;:~e~,-: 
. --, -,---.. ,------"--.----,---,"---.---'---'--~-~-- r '-----I ~sing_1Dp~~ -~somorp_h~n-4-a~~de,_6~bin~~r19_ wa.E'l, then displaced using 0.1 pM [D-Ala t , D-Leu' 1 enkephalin 
land k-binding represented the remaining binding.:: 
.... 
o 
-..J 
Substance P is released from primary afferents upon noxious 
stimulation and can be inhibited by opioid compounds [124]. 
The superficial laminae of the dorsal horn is believed to 
contain a large ntimber of these synapses. Immunohisto-
chemical studies have shown a close association between 
substance P-containing and enkephalinergic fibres, many 
of which are concentrated in this area [146, 169, 182-4]. 
It has been proposed that enkephalins or endogenous compounds 
are released to prevent the release or interaction of 
substance P with its receptor, thus modulating nociceptive 
information [124]. Binding studies with ['H]substance P 
in rat thoracic spinal cord [185] have shown a concentration 
of binding sites in the substantia gelatinosa of lamina 11. 
Quantification of immunoreactive peptides shows that dorsal 
horn concentrati'ons of the proenkephalin A-derived peptides' 
[Met']enkephalyl-Arg6 -Phe7 [150] and [Met'.]enkephalyl-Arg6 -
Gly7-Leu' [149] are approximately two times those found in 
the ventral horn of rat cord. 
Of the immunoreactive prodynorphin-derived peptides present 
in rat spinal cord, dynorphin B was found almost exclusively 
in the marginal. layer of lamina I in the dorsal horn [186]. 
Quantitative studies in human cord [151] show the 
prodynorphin products a-neo-endorphin and dynorphin A-(1-17) 
to be much higher in dorsal than ventral laminae 
rostro-caudally. 
The differential distribution of the proenkephalin A- and 
prodynorphin-derived peptides suggests that they may have 
different roles in spinal function, not necessarily 
associated. with pain systems. For example, substance P, 
although related to nociceptive transmission also appears 
to be involved with ventral motor function [184]. 
The current results support analgesia in intrathecal dosing 
studies with animals, using highly selective 11-, 6 - and 
k-compounds against different nociceptive stimuli [191]. 
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Additionally, the present work supports evidence for 
spinal P-, 6- and k-receptors which has come from 
clinical studies, where post-operative and intractable 
cancer pain has been treated by, amongst others, 
k-selective dynorphin A~(1-17) [187], p-selective 
morphine [18B] and relatively 6-selective [D-Ala2 , 
D-Leu 5 ]enkephalin [189]. 
In conclusion, this work demonstrates that spinal opioid 
sites are widely distributed throughout the cords of. 
different species. The distribution of opioid sites along' 
the rostra-caudal axis ~oes not correlate well with 
reported distributions of endogenous opioid peptides •. 
However, the dorso-ventral distribution of opioid sites' 
correlates well with proposed endogenous opioids and. 
neuromodulators associated with nociceptive transmission. 
Biochemical data in this chapter lends further support 
for the involvement of p-, 6- and k-receptors in spinally 
mediated analgesia. 
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C H APT E R 6 
CHARACTERIZATION OF SPINAL K-OPIOID 
BINDING SITES 
INTRODUCTION 
Opioid receptors were first classified into varying types 
following in vivo work in the spinal dog by Martin and colleagues 
[17]. On the basis of their work ~-, k- and a-types were 
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proposed of which ~- and k-types were associated with antinociception. 
The 5-receptor was later proposed by Kosterlitz and co-workers 
[66, 67] after ligand specificity in the isolated mouse vas deferens 
preparation was found to be different to that in the guinea-pig 
ileum preparation. 
The refinement of ligand binding techniques and the development of 
autoradiography showed opioid binding sites to be differentially 
distributed in the brain [116] and spinal cord [115]. During the 
search for endogenous substances which could interact with the opioid 
recept6rs, it became apparent that three main groups of opioid-
peptides existed. B-Endorphin was cleaved from proopiomelanocortin 
[64], the enkephalins were derived from the precursor proenkephalin A 
[64] and the cleavage of prodynorphin (also called proenkephalin B) 
[65] yielded .the dynorphins. The concomitant development of 
immunohistochemical techniques [117] enabled study of the location 
of endogenous opioid peptides within the central nervous. system 
and their relationship to opioid receptor distribution. 
Of particular interest to this present~work are the dynorphins 
which have been shown to disPlay! high .1. potency at the k-receptor 
I, _' 
[49, 50, 72]. These peptides were identified in regions of the 
spinal cord associated with pain transmission and where high levels 
of opioid binding sites were also found [134]. In support of a role 
for dynorphins in antinociception at the spinal level, intrathecal 
dosing studies have shown that these peptides, in addition to other 
k-selective agents are effective in selectively reducing low grade 
nociceptive stimuli [191]. They appear to have little effect on 
high threshold stimuli such as cutaneous-thermal pain [191], 
although there is some evidence to the contrary [142, 202]. 
Whilst the presence of p- and a-sites in the spinal cord is 
accepted, inconsistencies have arisen during the attempted 
classification of k-opioid sites. Analysis of the k-population 
has produced results which suggest more than a single site [195] 
and the proposal of k-subtypes has been made [196]. 
The aim of this study has been to investigate the nature of the 
spinal k-opioid sites in different species but with particular 
emphasis on the rat. 
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MATERIALS & ~lETHODS 
lumbo-sacral spinal cords were removed, homogenates prepared and 
binding assays performed as detailed in Chapter 2. The radio-
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ligands used to label opioid sites were ['H](-)-bremazocine, 
['H]diprenorphine, ['H]dynorphin A-(1-9) and ['H]U-69593. An 
incubation temperature of 25 DC for 30 minutes was used for . 
experiments involving ['H]dynorphin A-(1-9) and the proteolytic 
degradation of this ligand was inhibited by including 300pM captopril 
and 30pM bestatin in the assay mixture [197]. The chemical structures 
of competing ligands are described in Chapter 2 •. Non-specific 
binding was defined in the presence of 1pM unlabelled diprenorphine, 
or 10pM unlabelled naloxone when ['H]diprenorphine was the 
labelled primary ligand; Methods of analysis are given in Chapter 3. 
The proteolytic degradation of ['H]dynorphin A-(1-9) was monitored 
by HPlC analysis as detailed in Chapter 2. 
RESULTS 
a) Displacement studies 
After suppression of binding to p- and 5- sites using 
100nM each of [D-Ala',D-Leu5]enkephalin and [D-Ala', 
MePhe', Gly-015]enkephalin, ['H](-)-bremazocine bound 
specifically in homogenates of lumbo-sacral spinal cord 
from the rat. This binding was completely displaced by 
1pM naloxone, and levorphanol was approximately 2400 times 
more potent than dextrorphan at these sites (Figure 6.1; 
Table 6.1). Non-selective opioids displaced the bound 
material with Hill slopes of close to unity (Figure 6.4), 
but ligands showing selectivity for individual opioid 
site-types afforded slopes of less than unity (Figure 6.2). 
In particular the displacement profile for [D-Ala',D-Leu·] 
enkephalin was noticeably biphasic. Similar results obtained 
in our laboratory afforded a Ki 8945 ± 823nM and Hill 
coefficient 0.61 ± 0.07 (Figure 6.3;- J. R.-Traynor personal 
communication) which could be resolved into two Hill plots. 
The high affinity component afforded a Ki 321 ± 68nM and slope 
1.26 ± 0.35 and the lower affinity component ki 25890 ± 5140nM 
and slope 0.89 ± 0.11 in line with its reported k-affinity 
[95]. 
['H](-)-Bremazocine was displaced by the k-selective opioids 
U-50488H and U-69593 in homogenates of porcine lumbo-sacral 
spinal cord with low affinities. When p- and o-binding was 
suppressed U-50488H, but not U-69593 showed an increase in 
slope and affinity (Figure 6.5; Table 6.2). A single 
experiment in guinea-pig lumbo-sacral spinal cord homogenate 
afforded a similarly biphasic curve for U-50488H. The high 
affinity component, representing 55% of the bound ['H] 
material was displaced with an IC •• of 9.54nM and the lower 
affinity component with an IC •• of 631nM. 
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It can be seen from Figure 6.3 that 5pM [D-Ala',D-Leu·]enkephalin 
displaces all of the higher affinity component for ['H](-)-
bremazocine binding in lumbo-sacral spinal cord homogenates 
from the rat, leaving the lower affinity site (dotted line) 
which appears to be a "classical k" binding component [196]. 
·Under these conditions naloxone displaced all the remaining 
specific binding (97.5 ± 1.5%) though with a low affinity 
(lCs • = 79.46 ± 1.49nM; nH =0.88 ± 0.05; n = 3) (Figure 6.7), 
and the ~- and 6-selective peptides and U-50488H displaced 
with slopes closer to unity (Figure 6.6; Table 6.3). Similar 
results were obtained in a second strain of rat (Table 6.3). 
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-log ( . M competing ligand) 
Displacement of ['H](-)-bremazocine (O.14-0.26nM) in the 
presence of 100nM each [D-Ala 2 ,D-Leu S]enkephalin and 
[D-Ala 2 ,MePhe',Gly-ol"]enkephalin to O.5nM labelled 
ligand, by levorphanol (.), dextrorphan (<» and naloxone 
(A) in rat lumbo-sacral spinal cord homogenates. 
See Table 6.1 for data. 
9 8 7 6 5 4 
-log ( M competing ligand) 
Displacement of ['H](-)-bremazocine (O.14-0.26nM) by 
U-504BBH (.), [D-Ala 2 ,D-Leu'lenkephalin (0) and 
[D-Ala 2 ,MePhe',Gly-ol']enkephalin (.) in rat lumbo-
sacral spinal cord homogenates, under conditions described 
in Figure 6.1. See Table 6.1 for data. 
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,Displacement of ['H](-)-bremazocine (O.5nM), in the 
presence of 100nM each [D-Ala2 ,D-Leu S ]enkephalin and 
[D-Ala2 ,MePhe',Gly-oIS]enkephalin to O.5nM labelled ligand 
by [D-Ala 2 ,D-LeuS]enkephalin in rat lumbo-sacral spinal 
cord homogenates; a) displacement curve, b) resolution 
into separate Hill plots. 
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Displacement of ['H](-)-bremazocine (D.14-0.26nM), in 
the presence of 100nM each [D-Ala',D-leu']enkephalin 
and [D-Ala',MePhe",Gly-olS]enkephalin to O.5nM labelled 
ligand by (-)-bremazocine (.), diprenorphine ( ... ) and 
. tifluadom (.) in rat lumbo-sacral spinal cord 
homogenates. See Table 6.1 for data. 
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Table 6.1 Potencies of unlabelled ligands to displace ['H](-)-bremazocine (0.14 - 0.34nM), in the 
presence of unlabelled [D-Ala 2 ,D-Leu']enkephalin and [D-Ala2 ,MePhe',Gly-ol']enkephalin in 
the ratio 100nM of each to 0.5nM labelled ligand to suppr~ss ~- and 6- binding, in rat 
lumbo-sacral spinal cord homogenates at 37"C. (Figures 6.1, 6.2 and 6.4). 
Unlabelled Ligand Ki (nM) Hill Coefficient n 
. (-)-Bremazocine 0.73 ±0.11 1.07 ± 0.16 3 
Diprenorphine 1.47 ± 0.42 0.91 ± 0.13 3 
Tifluadom 16.35 ± 3.80 1.08 ± 0.05 5 
U-504BBH 145.6 ± 44.7 0.45 ± 0.05 3 
Naloxone * 13.35 ± 1.60 0.86 ± 0.07 4 
Levorphanol B .60 ± 1.73 LOB ± 0.16 3 
Dextrorphan 20424 ± 61B8 0.97 ± 0.09 5 
[D-Ala2,D-Leu']enkephalin 4511 ± 469 0.59 ± 0.05 3 
[D-Ala2,MePhe',Gly~ol']enkephalin 
** 
133B ± 309 0.B3 ± 0.04 3 
Results expressed as means ± sem; n = number of separate experiments performed in duplicate. 
Specific binding, after suppression of binding to ~- and 6- sites was greater than 60% and linear correlation 
coefficient greater than 0.961 (0.92B for U-504BBH). 
* Specific binding was completely displaced (100.6 ± 1.7%) by 1~M unlabelled naloxone. 
** J. R. Traynor; personal communication. 
11- and 6-Suppression represented 51 ± 2~. (n = 24) of the total ['HH-)-bremazocine specifically bound. 
Non-specific binding was· defined using 1~M unlabelled diprenorphine. 
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Displacement of ['H](-)-bremazocine (O.44-0.54nM), in 
the absence (open symbols) and presence (closed symbols) 
of 100nM each of [D-Ala',D-LeuS]enkephalin and 
[D_Ala',MePhe',Gly-ol']enkephalin to O.5nM labelled 
ligand, by U-50488H (0) and U-69593 (0) in porcine 
lumbo-sacral spinal cord homogenates. See Table 6.2 
for data. 
Table 6.2 Potency of unlabelled compounds to displace [SH](-)-brernazocine (0.44 - 0.54nM), in the absence 
and presence of unlabelled [D-Ala 2 ,D-Leu']enkephalin and [D-Ala2 ,MePhe',Gly-ol']enkephalin 
each in the ratio 100nM to 0.5nM labelled brernazocine in porcine lumbo-sacral spinal cord 
hornogenates at 37"C. (Figure 6.5). 
Unlabelled Ligand Ki (nM) Hill Coefficient 
U-504BBH 
U-69593 
(Unsuppressed) 
(Suppressed) 
(Unsuppressed) 
(Suppressed) 
93.93 ± 33.00 
21.05 ± 5.40 
B7.B6 ± 12.55 
95.79 ± 23.B5 
Results expressed as means ± sern for 3 separate experiments in triplicate. 
0.49 ± 0.01 
0.73 ± 0.03 
0.95 ± O.OB 
0.91 ± 0.1B 
Correlation coefficients from linear regression were greater than 0.96B for U-504BBH and U-69593 for 
all assays. 
Specific binding was greater than 50% for all assays. 
Non-specific binding was defined in the presence of 1pM unlabelled diprenorphine. 
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8 7 5 4 
-log ( . M competing ligand) 
Displacement of ['H](-)-bremazocine (O.2B-O.62nM) in 
the presence of 5~M [D-Ala2,D~Leu']enkephalin, by 
U-504BBH (.), [D-Ala',D-Leu 5 ]enkephalin (0) and 
[D-Ala' ,MePhe' ,Gly-ol" ]enkephalin (A) in rat lumbo-
sacral spinal cord homogenates. See Table 6.3 for data. 
8 7 6 5 
-log ( .M competing ligand) 
Displacement of [3H](-)-bremazocine (O.45nM) by 
naloxone in rat lumbo-sacral spinal cord homogenates, 
under conditions described in Figure 6.6. 
Table 6.3 
Strain 
Alderley Park 
Sutton Bonnington 
Wistar 
Potencies of opioid compounds·to displace ['H](-)-bremazocine in the presence of 5~M 
unlabelled [D-Ala',D-Leu']enkephalin to 0.5nM radiolabelled ligand, in lumbo-sacral 
spinal cord homogenates from two strains of rat at 37DC. (Figures 6.6 and 6.7). 
Unlabelled Ligand Ki (nM) Hill Coefficient 
[D-Ala',D-Leu']enkephalin 35394 ± 1929 0.84 ± 0.10 
[D-Ala',MePhe~,Gly-olS]enkephalin 8983 ± 1737 1.13 ± 0.09 
U-50488H 22.80 ± 3.44 0.77 ± 0.08 
[D-Ala',D-LeuS]enkephalin 24575 1.00 
[D-Ala',MePhe~,Gly-olS]enkephalin 3223, 2744 0.94, 0.77 
U-50488H 18.00 0.80 
Results expressed as means ± semi n = number of separate experiments in duplicate. 
Correlation coefficient for linear regression was greater than 0.970 for all assays. 
['H](-)-8remazocine concentrations used were: Alderley Park 0.28 - 0.62 nM 
Sutton Bonnington Wistar 0.45 - 0.48 nM 
n 
4 
4 
3 
1 
2 
1 
Specific binding was greater than 60% after suppression for all assays, and was displaced by 1~M unlabelled 
naloxone (97.5 ± 2.m~, n = 3; Figure 6.7). 
Non-specific binding was defined in the presence of 1~M unlabelled diprenorphine. 
• 
b) Saturation analysis 
['H](-)-Bremazocine bound to high affinity sites in a saturable 
manner in lumbo-sacral spinal cord homogenates from the rat 
(Figure 6.8a). In the presence of 100nM each of unlabelled 
[O-Ala',O-LeuS]enkephalin and [O-Ala',MePhe',Gly-olS]enkephalin 
to O.SnM labelled ligand, ['H](-)-bremazocine displayed 
specific, high affinity, saturable binding in lumbo-sacral 
spinal cord.homogenates from the rat, guinea-pig and farmyard 
pig (Figures 6.8b, 6.10, 6.11). The KO values were similar 
in all species (range 0.40 -·0.72nM) but the number of sites 
was lower in the farmyard pig (-9 fmol.mg-') than in the 
laboratory species (~30 fmol.mg-').(Table 6.4). For each of 
the species studied, the number of sites was reduced in the 
presence of p- and 5-suppression when, compared to the total 
binding of ['H](-)-bremazocine in the same tissue (Table 6.4). 
From these findings the percentages of apparent k-binding 
showed little variation between species. Similar results were 
obtained for whole spinal cord preparations from a second 
strain of rat (Figure 6.9; Table 6.4). 
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The non-selective opioid antagonist ['H]diprenorphine also 
displayed high affinity, saturable binding in lumbo-sacral 
spinal cord homogenates from the rat and guinea-pig (Figures 
6.12. & 6.13). High specific binding was obtained with this 
radioligand in both species (Table 6.5). In the rat, the sites 
remaining after p- and 5-suppression for which the radioligand 
showed an increased affinity, represented 28% of the total 
sites. In the guinea-pig the remaining sites represented 43% 
of the total sites (Table 6.6) but there was no apparent increase 
in the affinity of ['H]diprenorphine for these sites. 
The total binding in rat cord was approximately twice that in 
guinea-pig cord. It should be noted that more sites were 
labelled by ['H]diprenorphine in both species than were 
labelled by ['H](-)-bremazocine. 
In the presence of SpM [O-Ala 2 ,O-LeuS]enkephalin 0.5nM-' 
labelled ligand, ['H](-)-bremazocine bound to a small population, 
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Bmax = 13.60 ± 1.32 fmol.mg- ' of high affinity sites, KO = 
0.26 ± 0.07nM (n = 3, r = 0.938 - 0.969), in rat lumbo-sacral 
spinal cord homogenates. .These sites represented 15.7 ± 0.3~' 
of the total sites labelled by [3H](-)-bremazocine (Figure 6.14). 
Opioid sites in lumbo-sacral spinal cord homogenates from 
the guinea-pig and rat were labelled in a saturable manner 
by [3H]dynorphin A-(1-9) (Figures 6.15-17; Table 6.7). The 
total number of sites labelled in the guinea-pig by this 
radioligand.was similar to the levels labelled by ['H](-)~ 
bremazocine and approximately twice that seen in the rat. 
The Bmax was reduced in both species when p- and 6-suppression 
was present, indicating cross reactivity. The Bmax seen in 
the rat for [3H]dynorphin A~(1-9) under these suppressing 
conditions was similar to that obtained using [3H](_)_ 
bremazocine in the presence of 5pM [O-Ala2 ,O-Leu']enkephalin. 
The specific binding for [3H]dynorphin A-(1-9) was low (-50~') 
in the above experiments (Table 6.8) making accurate 
interpretation of the data difficult. 
The k-selective opioid [3H]U-69593 [198] afforded Bmax and 
KO values of 24.08 ± 1.87 fmol.mg- ' and 8.45 ± 1.44nM 
respectively (n = 3, r = 0.887 - 0.931; Figure 6.18) in rat 
lumbo-sacral spinal cord homogenates. Once more, the very low 
levels of specific binding (-12%) for the radioligand made 
the results subject to error (Table 6.8). 
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Table 6.4 Saturated binding anal~sis for ['H](-)-bremazocine, in the presence of 100nM each of unlabelled 
[D-Ala' , D-Leu' ]enkephalin and [D-Ala', MePhe" ,Gly-oIS ]enkephalin to each 0.5nM radiolabelled 
ligand, in lumbo-sacral spinal cord homogenates from three different species. (Figures 6.8 - 6.11). 
Species 
-Rat 
Bmax (fmol. mg-'). 
33.59 ± 3.77 
++(85.42 ± 7.94) 
KO (nM) 
0.72 ± 0.14 
(1.27 ± 0.21) 
r 
0;963 - 0.977 
(0. 820.~ __ 0. 960) 
38.7±1.3 
-'--_._---
--'---'Sutton Bonnington 
Wistar Rat ** 
Guinea-Pig 
Pig 
--
31.27 ± 1.12 
27.56 ± 3.58 
+(65.62 ± 10.44) 
8.93 ± 0.61 
+(20.63 ± 1.56) 
0.61 ± 0.06 
0.40 ± 0.05 
(0.88 ± 0.16) 
0.56 ± 0.14 
(0.64 ± 0.07) 
0.937 - 0.976 
0.937 - 0.976 46.1 ± 9.2 
0.808 - 0.944 43.3 ± 0.14 
Results expressed as means ± sem; r = correlation coefficient from non-linear regression. 
n = Number of separate experiments performed in duplicate (* triplicate for the pig). 
9~ K = 9~ K-Sites from saturation analysis. ** 
Figures in parentheses represent total binding 
Data obtained using whole 
of ['H](-)-bremazocine: 
spinal cord homogenates. 
+ See Table 5.1 
++ See Figure 6.8a 
Non-specific binding defined in the presence of 1~M unlabelled diprenorphine. 
n 
3 
3 
3 
3* 
~ 
w 
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figure 6~12 Saturation analysis for ['H]diprenorphine in rat lumbo-sacral spinal cord homogenates. A 
concentration range of 0.051 - 17.52nM radioligand was used in the absence of suppression 
(.) and 0.031 - 10.15nM radioligand was used in the presence of 100nM each [D-Ala',D-LeuS] 
enkephalin and [D-Ala',MePhe',Gly-oIS]enkephalin to 0.45nM labelled ligand (0). Representative 
plots from 3 experiments. See Table 6.6 for data. . 
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and 0.022 - 5.41nM radioligand was used in the presenoe of 100nM each [D-Ala 2 ,D-Leu S ]enkephalin 
and [D-Ala 2 ,MePhe' ,Gly-ol" ]enkephalin to 0.45nM labelled' ligand (0). Representative plots from 
3 experiments. See Table 6.6 for data. 
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Table 6.5 ['H]Diprenorphine binding to lumbo-sacral spinal cord homogenates from rat and guinea-pig, 
in the absence and presence of p- and 5-suppression, at selected low and high ligand 
concentrations at 37°C. 
Assay Approx. Counts (dpm.mg-1 ) 
Species Conditions Conc./nM Total Saturated 
Rat Unsuppressed 0.1 1248 ± 134 257 ± 40 
2.0 9461 ± 597 1237 ± 28 
*Suppressed 0.1 547 ± 10 93 ± 9 
2.0 4341 ± 255 1673 ± 137 
Guinea Pig Unsuppressed 0.1 1097 ± 186 75 ± 14 
2.0 6764 ± 768 1486 ± 543 
*Suppressed 0.1 695 ± 212 83 ± 16 
2.0 4130 ± 559 1779 ± 506 
Results expressed as means ± sem of n separate experiments in duplicate. 
Counts expressed as dpm.mg- 1 protein. 
.' ,. Specific Specific 
991 ± 153 78.7 ± 5.0 
8224 ± 610 86.8 ± 1.0 
454 ± 13 82.9±1.7 
2668 ± 147 61.5±1.5 
1022 ± 136 92.9 ± 1.5 
5278 ± 402 79.0 ± 6.4 
612 ± 213 85.6 ± 4.2 
2351 ± 231 58.3 ± 6.7 
n 
3 
3 
3 
3 
3 
3 
3 
3 
*Suppressed at 100nM [D-Ala2 ,D-Leu']enkephalin and [D-Ala 2 ,MePhe',Gly-ol']enkephalin .0.45nM-l labelled ligand. 
Non-specific binding defined in the presence of 10pM unlabelled naloxone. 
~ 
IN 
IN 
- - -----------
Table 6.6 Saturated binding analysis in rat and guinea-pig lumbo-sacral spinal cord homogenates for 
['H]diprenorphine, in the presence and absence of 100nM each of [O-Ala2 ,O-Leu']enkephalin 
and [O-Ala2 ,MePhe',Gly-ol']enkephalin to 0.45nM labelled ligand, at 37°C. (Figures 6.12 & 6.13). 
Species 
Assay Bmax KO 
Conditions (fmol.mg-1 ) (nM) r %K 
Unsuppressed . 153.3 ± 5.26 1.03±0.29 0.871 - 0.974 
Suppressed 43.41 ± 3.61 0.50 ± 0.04 0.944 - 0.962 
Unsuppressed 83.14 ± 4.48 0.40 ± 0.02 0.942 - 0.969 
Suppressed 33.64 ± 2.97 0.40 ± 0.16 0.907 - 0.940 
Results expressed as means ± sem; r = correlation coefficient from non-linear regression. 
n = Number of separate experiments performed in duplicate. 
1~ K = % K-Sites from saturation analysis. 
Non-specific binding defined in the presence of 10 ~M unlabelled naloxone. 
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Saturation analysis for ['H]dynorphin A-(1-9), in the presence of 100nM each [D-Ala2 ,D-Leu5] 
enkephalin and [D-Ala 2 ,MePhe',Gly-015]enkephalin to O.1nM labelled ligand, in rat lumbo-sacral 
spinal cord homogenates. Results shown as individual results from 2 experiments. See-Table 
6.8 for data. 
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Saturation analysis for [8H]dynorphin A-(1-9) in guinaa-pig lumbo-sacral spinal cord homogenates. A 
concentration range of 0.018 - 3.50nM radioligand was used in the absence of suppression (.) and 
0.010 - 2.17nM radioligand was used in the presence of 100nM each [D-Ala2 ,D-LeuS]enkephalin and 
[D-Ala2 ,MePhe',Gly-oIS]enkephalin to 0.1nM labelled ligand (0). Representative plots from 3 
experiments. See Table 6.8 for data. 
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See Table 6.8 for data. 
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Table 6.7 
Species 
['H]U-69593 
Rat 
Saturated binding analysis for 
guinea-pig lumbo-sacral spinal 
Assay Bmax 
Conditions (finol. mg-' ) 
Unsuppressed 24.0B ± 1.B7 
['H]D~nor~hin A-(1-9) 
I 
['H]U-69593 in rat and ['H]dynorphin A-(1-9) in rat and 
cord homogenates atI37oc"ancl250c~respeCtivelY. (Figures 6.15 
KD (nM) r ro K n 
B.45 ± 1.44 0.BB7 - 0.931 3 
- 6.18). 
I~at I Unsuppressed 34.65± 2.46 0.71 ± 0.11 0.942 - 0.979 3 
Suppressed 7.95, 11.78 0.14,.0.29 0.920, O.B96 22.7, 30.4 
Guinea-Pig Unsuppressed 75.39 ± B.52 0.B1 ± O.OB 0.BB3 - 0.900 
Suppressed 1B.60 ± 2.39 0.56 ± 0.06 0.B46 - 0.953 24.6 ± 0.7 
Results expressed as means ± .sem; r = correlation coefficient from non-linear regression. 
n = Number of separate experiments; 7,K = 7, K-sites from saturation analysis. 
Unsuppressed = Total number of sites 
2 
3 
3 
Suppressed = Binding in the presence of 100nM each of unlabelled [D-Ala2 ,D-Leu']enkephalin and [D-Ala2 ,MePhe', 
Gly-ol']enkephalin to 0.1nM labelled ligand. 
Non-specific binding defined in the presence of 1~M unlabelled diprenorphine. 
-... 
o 
--------
Table 6.8 Low levels of binding for ['H]Dynorphin A-(1-9) and ['H]U-69593 
Approx. Counts (dpm.mg-
'
) 
Radiolabelled Conc. 
Ligand Species (nM) Total Saturated Specific 
['H]dynorphin Guinea- 0.1 355 ± 73 156 ± 31 199 ± 44 
A-(1-9) Pig 
*(Suppressed) 2.0 3018 ± 432 2204 ± 362 814 ± 70 
Rat 0.1 399, 363 170, 167 229, 194 
2.0 6026, 6953 5598, 6350 428, 603 
['H]U-69593 Rat 0.2 461 ± 32 406 ± 25 55 ± 12 
15~0 19549 ± 249 18118 ± 208 1431 ± 42 
Results expressed as means ± sem; n = number of separate experiments in duplicate. 
Counts expressed as dpm.mg protein-I. 
in Spinal Cord Assays. 
.' ,. Specific n 
56.0 ± 1.9 3 
27.8 ± 2.9 3 
57.4, 54.0 2 
7.1, 9.5 2 
11.9 ± 1.8 3 
7.3 ± 0.1 3 
*Suppressed at 100nM [O-Ala2 ,D-Leu5 ]enkephalin and [D-Ala2 ,MePhe',Gly-ol']enkephalin to 0.1nM labelled ligand. 
Non-specific binding defined in the presence of 1~M unlabelled diprenorphine. 
· c) In vitro metabolism of ['H]dynorphin A-(1-9) 
[3H]Dynorphin A-(1-9) was sensitive to proteolysis when 
incubated with rat spinal cord homogenates at 2SoC for 3D 
minutes, affording products which were separated by HPLC 
using reference standards (Figure 6.19). Metabolism occurred 
even in the presence of 3DOpM captotril and 30pM bestatin. 
Under these conditions the amino-terminal fragments, that 
is tyrosine, tyrosyl-glycine andtyrosyl-glycyl-glycine 
constituted the major metabolites and only 41% of the 
nonapeptide ['H]dynorphin A~(1-9) ~emained., Two other major 
peaks corresponded to dynorphin A ,fragment.1-S '([Leu S ] 
enkephalin) and dynorphin A-(1-8). The amino terminal 
tetrapeptide tyrosyl-glycyl-glycyl-phenylalanine was not 
detected (Figure 6.20). 
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Figure 6.19 
Elution profile of authentic peptide standards using reverse-
phase HPLC on a Cl' Altex Ultrasphere ODS reverse-phase 
column. 
Solution A = 
Solution B = 
Flow rate = 
Key to abbreviations 
Inj. 
",Tyr" 
YGGF. 
[LeuS]enk 
dyn 1-6 
. dyn 1-7 
dyn 1-8 
dyn 1-9 
Dynorphin A~(1-9) is: 
Trifluoroacetic acid (26mM) -
triethylamine to give pH 3.0. 
Acetonitrile (4910 - trifluoroacetic 
acid (13mM). 
0.5 ml. minute _1. 
Sample injected onto column. 
Tyrosine fragments; Tyr, Tyr-Gly, 
Tyr-Gly-Gly. 
Tyr-Gly-GlY-Phe. 
[Leu']enkephalin. 
dynorphin A~(1-6). 
dynorphin A-(1-7) • 
dynorphin A-(1-8). 
dynorphin A-(1-9). 
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Eluted Peak 
No. Metabolic Product % Recovered Activity 
1 Tyr, Tyr-Gly, Tyr-Gly-Gly 25.9 ± 0.7 
2 Tyr-Gly-Gly-Phe N.D. 
3 Tyr-Gly-Gly-Phe-leu 16.7 ± 1.3 
4 Tyr-Gly-Gly-Phe-leu-Arg 1.44 ± 0.11 
5 Tyr-Gly-Gly-Phe-leu-Arg-Arg 0.60 ± 0.05 
6 Tyr-Gly-Gly-Phe-leu-Arg-Arg-Ile 14.3 ± 0.2 
7 Tyr-Gly-Gly-Phe-leu-Arg-Arg-Ile-Arg 40.9 ±1.6 
Total Recovery 99.84 ± 1.99 
Results expressed as means ± sem of J separate experiments. 
All products were analysed against authentic standards on a Cl. Altex 
Ultrasphere aDS reverse-phase column. 
N.D. = no product detectable. 
Figure 6.20 Metabolism of ['H]dynorphin A-(1-9) by rat 
lumbo-sacral spinal cord homogenates, in the 
presence of 30pM bestatin and 300pM captopril, 
at 25°C. 
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DISCUSSION 
Both ['H](-)-bremazocine and ['H]diprenorphine (Figure 6.21) 
labelled a high number of sites in spinal cord homogenates. 
['H]Diprenorphine afforded higher Bmax values than ['H](-)-
bremazocine which may be indicative of ligand differences.' The 
low non-specific binding and high total binding obtained using 
['H]diprenorphine, especially at higher radioligand concentrations 
, 
may make this ligand a good choice for spinal cord binding assays, 
which are made difficult by the relatively low numbers of sites 
and the low ratio of nervous tissue:lipid material. 
N~ Figure 6.21, Diprenorphine 
['H]( -)-Bremazocine, ,in the presence of 100nM each of [D-Ala 2 ,D-Leu'] 
enkephalin and [D-Ala',MePhe-,Gly-oIS]enkephalin to suppress binding 
to 5- and \1-sites, labelled a population of sites, which were , 
initially presumed'to be of the k-type in rat lumbo-sacral spinal 
cord homogenates. These, sites represented 39% of the total number 
labelled by ['H](-)-bremazocine. Similar levels were seen in 
guinea-pig (46~') and porcine (43~0) lumbo-sacral cords. These values 
are close to those previously reported for the levels of k-sites 
seen in lumbo-sacral cords of rat [152, 155, 158, 195], guinea-pig 
[152, 154], frog, pigeon and man [152]. 
In the present work, the remaining bound radioligand was completely 
, displaced by naloxone, and levorphanol was 2400 times more potent 
than dextrorphan. These results confirm the opioid nature of the 
sites and suggest that ['H](-)-bremazocine is not labelling any 
non-opioid sites such 'as the a-site reported in rat spinal cord by 
Tam [112]. 
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However, the system is not straightforward as shallow Hill plots 
obtained from displacement studies with selective opioids suggest 
that heterogeneity exists within these k-sites. Indeed the 
displacement curve for [D-Ala 2 ,D-Leu']enkephalin could be resolved 
into two Hill plots, affording a high affinity component for which 
the competing ligand displayed an affinity atypical for interaction 
with p- or 6-sites [97] and a low affinity phase, with a Ki value 
146 
in the typical range reported for interaction of the peptide with 
k-sites [95, 97]. Theoretical calculations based on the method of 
Ariens [221] for the int~raction of more than one ligand at a binding 
site confirm that p- and 6-sites are unlikely to be responsible 
for this heterogeneity since a sum total of less than 4% of these 
sites remain in the presence of 100nM each of [D-Ala2 ,D-Leu 5 ] 
enkephalin and [D-Ala2 ,MePhe',Gly-ol']enkephalin. The theoretical 
curve and data used to derive this are shown in Figure 6.22. 
It can be seen from the displacement of ['H](-)-bremazocine by 
[D-Ala2 ,D-LeuS]enkephalin (Figure 6.3) that a concentration of 
5pM - 10pM unlabelled ligand is sufficient to displace binding of 
the radioligand from the higher 'affinity sites. In the presence 
of 5pM [D-Ala2 ,D-Leu']enkephalin, the remaining binding was displaced, 
by p- and a-selective compounds with affinities in the range reported 
for interaction at k-sites [97], and slopes of approximately unity. 
The k-selective opioid U-504BBH also displaced the bound ['H]material 
with an affinity typical for interaction at k-sites [109] but the 
slope was still apparently shallow. The visually biphasic curve 
afforded a linear correlation coefficient of 0.970. 
The rema1n1ng sites in the presence of 5pM [D-Ala2 ,D-Leu']enkephalin 
represented only 16% of the total labelled by ['H](-)-bremazocine. 
These sites have the properties of k-sites but represent just 40% 
of the k~population defined by the usual criterion of binding, that 
is ['H](-)-bremazocine in the presence of 100nr4 each of [D-Ala 2 ,D-Leu'] 
enkephalin and [D-Ala2 ,MePhe',Gly-olS]enkephalin, in rat lumbo-
sacral cord. When combined, the results from the competition 
assays and'saturation binding isotherms support the existence of 
a population of sites in addition to p-, 6- and "classical k" sites 
in rat lumbo-sacral spinal cord. 
Figure 6.22 Theoretical displacement profiles for [D-Ala2,D-Leu'] 
enkephalin (0) and [D-Ala2,MePhe~,Gly-olS]enkephalin 
( .) at 6- and )I-sites respectively in rat brain, 
after the method of Ariens [221], using experimentally 
derived data [97] given in table below. 
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Binding characteristics of o~ioids 
Ligand Affinity at opioid 
)I 5 
(-)-Bremazocine 0.32 0.74 
[D-Ala2,D-Leu']enkephalin 12.6 1.78 
[D-Ala2 ,MePhe',Gly-ol']enkephalin 1.09 960 
~~ Sites Present 46 42 
Concentration ['H](-)-bremazocine - 0.2nM. 
7 
sites 
At 100nM [D-Ala 2 ,D-Leu S ]enkephalin 2.2~~ 6-sites remaining. 
(n~!) 
k 
0.067 
50000 
2030 
12 
At 100nM [D-Ala 2 ,MePhe' ,Gly-ol']enkephalin 1. 7~, )I-sites remaining. 
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Preliminary evidence also suggests an heterogeneity of the 
k-population in guinea-pig and porcine lumbo-sacral spinal cord. 
Although the results are more difficult to interpret it would appear 
that U-50488H recognizes the two binding components with more 
selectivity than U-69593 (structure given in Figure 6.23) •. The 
paucity of sites and low specific binding achieved in porcine cord 
(Chapter 5; Table 5.2) are problems with this tissue which may 
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be overcome by the use of ligands labelled to higher specific activity. 
Me 
,>'N~O 0 o Figure 6.23 U-69593 
O· 
The existence of k-heterogeneity in spinal cord tissue has previously 
been reported. Early studies by Gouarderes and co-workers [163] 
failed to identify ~- and 0- sites, but demonstrated two classes 
of site, to which ['H]ethylketocyclazocine bound, in the lumbo-
sacral spinal cords of rat, guinea-pig, monkey and man. Further 
work in the guinea-pig cord [196] which was based on the sensitivity 
of this binding to displacement by [D-Ala',D-Leu5 ]enkephalin, led to 
the proposal of K, and K. subtypes. However, since the same group 
[165] and other workers [151, 160, 193] later demonstrated the presence· 
of ~-, 0- and k-sites in spinal cords from these same species it seems 
likely that the affinities proposed to represent K. -sites, were 
actually composite affinities made· .uP of interactions at all three 
binding site types. On the other hand, other workers [195] have 
been able to demonstrate that even after the suppression of binding 
to ~- and o-sites, a population of binding sites remain which are 
heterogeneous. 
Similarly a sub-classification of k-sites in brain, based on 
displacement studies using reportedly k-selective peptides has been. 
attempted by other workers. 
When binding to p- and 6- sites was suppressed, Pfeiffer and 
colleagues [199] were. able to demonstrate two binding components 
for the displacement of ['H]diprenorphine by dynorphin A~(1-17) 
in homogenates of human amygdala. Also, Su [200] showed two 
components for the displacement of ['H]ethylketocyclazocine,in 
the presence of p-, 6- and a-suppression by dynorphin A~(1-13) in 
homogenates of guinea-pig brain. 
The observed heterogeneity of the.k-opioid receptor in the current 
work may be the result of different types of receptor, or high and 
low affinity forms of a single type of receptor. For example, the 
existence of high and low affinity forms of the p-receptor has been 
proposed by Wolozin and Pasternak [i08]. Other neuromodulators such 
as dopamine have been shown to interact with high and low affinity 
states of the dopamine receptor [209]. In such cases the high 
affinity state is generally recognized by agonists, but antagonists 
recognize both states equally well. 
Much of the literature precendent has used non-selective ['H] opioids 
in the presence of the suppression of binding to p- and 6- sites, 
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to define k-binding sites. In an attempt to improve on this approach, 
use was made of the more k-selective ligands ['H]dynorphin A~(1-9) 
and ['H]U-69593. Low numbers of sites were labelled by ['H]dynorphin 
A~(1-9) in the presence of unlabelled p- and 6-selective peptides 
as described previously, and by ['H]U-69593 in rat lumbo-sacral 
spinal cord homogenates. The low levels of specific binding seen 
particularly with ['H]U-69593 may have introduced significant error 
into the results. Indeed Lahti and colleagues [198] were unable to 
identify any specific binding for ['H]U-69593 in rat spinal cord. A 
similar number of sites were labelled by the k-selective opioids 
under the conditions described above and by ['H](-)-bremazocine in 
the presence of SpM [D-Ala',D-LeuS]enkephalin. These results add 
support to the existence of "classical k" sites in rat lumbo-sacral 
spinal cord, but at very low levels. 
The higher total sites labelled.by ['H]dynorphin A~(1-9) in the 
guinea-pig cord and the increase in the affinity of the radioligand 
for the sites remaining after the suppr·ession of binding to ,,- and 
6-sites in rat but not in guinea-pig cord, suggest differences in 
spinal receptor populations between the two species. 
However, the. difficulties of working with [SH]dynorphin A-(1-9) 
must be emphasised and taken. into account in assessing the 
significance of the results. The low affinity of [SH]dynorphin in 
the absence of suppression may reflect. cross-reactivity with p- and 
5-sites [72]. Additionally adsorption onto experimental vessels and 
subcellular contaminants [215, 216] is known to reduce the free 
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ligand concentration and hence produce.an underestimate of the absolute 
potency. The metabolism of [SH]dynorphin A~(1-9) to [SH]fragments 
with high affinities for opioid binding. sites is a very real source 
of error, especially in the unsuppressed assays where suchmetabolites 
can compete for p-, 6- and possibly k-sites. For example,.[SH][LeuS] 
enkephalin, [sH][Leus ]enkephalyl-Arg6 , [SH][LeuS]enkephalyl-Arg6 -Arg7 
and [SH]dynorphin A~(1-8) are all metabolites with activity at p- and 
6-sites. The :extended [LeuS]enkephalins,especially [SH]dynorphin 
A-(1~8) also show activity at the k-site [72, 174, 197]. 
Gillan and her colleagues [197] have demonstrated that [SH]dynorphin 
A-(1-9) in th·e presence of 30pM bestatin and 300pM captopril; was 
metabolized in gUinea-pig brain homogenates such that only 17.5% of 
the recovered radioactivity represented the nonapeptide. When 
L-leucyl-L-arginine was included, further stabilization of the 
LeuS-Arg6 bond was afforded so that the [SH]dynorphin A-(1-9) 
fraction increased to almost 50% of· the total recovered activity. 
In the current work 40% of the original nonapeptide remained when 
metabolism by rat lumbo-sacral spinal cord homogenates was inhibited 
by 30pM bestatin and 300pM captopril. 
It is noteworthy that the present studies, like the work of Gillan 
and colleagues analysed only the free metabolites and not those bound 
at the k-site •. Evidence suggests that bound peptides are less 
susceptible to metabolism than those in the biophase [214], but 
further proof of this proposal requires separation of the.bound and 
unbound peptides. [197]. The suppression of binding to p- and 5-sites 
in the current work will have reduced cross-reactivity by the 
metabolites at these sites. Since the free ligand concentration of 
[sH]dynorphin A~(1-9) was reduced the observed affinity is likely to 
have been underestimated. However the Bmax is most probably a true 
estimate since saturation equilibrium binding was achieved in nearly all 
assays, a possible exception being the guinea-pig (Figure 6.17). 
However, in addition recent results from our laboratory have 
shown that bestatin, captopril anddipeptides such as L-leucyl-
L-leucine. reduce the specific binding of both ['H]dynorphin 
A-(1-B) and ['H]dynorphin.A-(1-9) in rat brain homogenates 
(D. Dixon and J. Ii'. ,Tray nor unpublished observations). Such 
inhibition of binding could have reduced the observed Bmax in the 
present spinal cord experiments. 
The presence of spinal opioid binding sites has prompted 
investigations into their physiological relevance and in particular, 
the roles of the. corresponding receptors in the modulation. of 
nociceptive stimuli. Compounds with reported p-, &- and k-selectives 
have been tested in both animal models and clinical situations. 
Yaksh and colleagues [190, 194] demonstrated that compounds with 
reported p-selectivity. produce. a powerful suppression of responses 
to cutaneous-thermal and visceral-chemical pain in rats. &-Selective 
compounds were reported to be effective only against cutaneous-
thermal pain. Although some .of the compounds used in these studies 
are not as selective as initially proposed, the results have been 
substantiated by further work using. more selective ligands [191]. 
k-Selective compounds were proposed to selectively block visceral-
chemical pain [191]. 
Particular interest has been focussed on the k-receptor since inter-
action at this receptor produces analgesia, but fewer of the 
unwanted side-effects. such as respiratory depression, dependence 
liability and constipation. Many studies have employed the endogenous 
k-ligands, the dynorphins in addition to synthetic k-selective 
agonists. For example, Jhamandas and colleagues [202] studied 
analgesia induced by U-50488H and two dynorphin fragments, dynorphin 
A-(1-8) and dynorphin A-(1-13) using the rat tail-flick test. 
U-50488H required higher doses of naloxone for reversal than the 
dynorphins. The latter also reduced the spontaneous urine. output in 
rats but U-5048BH was without effect. These workers concluded that 
the two classes of compound appear to act via different receptors 
and that the dynorphins may interact with more than just the 
k-receptor. It should be noted that U-50488H-induced analgesia' was 
not maximal until 60 minutes post injection which may indicate 
redistribution to higher centres, rather than a local spinal effect. 
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In contrast Stevens and Yaksh [203] found that k-receptor mediated 
analgesic activity for intrathecally administered U-50488H was 
limited to visceral-chemical stimuli in the rat, whilst dynorphin 
A-(1-17) produced no antinociceptive.responses at doses below those 
which produced motor dysfunction. This is believed to be mediated 
by des-tyrosyl fragments and is a phenomenon which is not uncommon 
with high doses of dynorphin pep tides [204, 205]. The authors 
therefore proposed that the high potency of the dynorphins at the 
k-receptor in vitro was not seen in vivo. In support of this a 
recent report 'by Leighton and co-workers [276] failed to show any 
evidence for k-receptor mediated analgesia at the spinal level with 
U-50488H, U-69593 or PD117302 «±)-trans-N-methyl-N-[2-(1-
pyrrolidinyl)-cyclohexyl]benzo[b]-thiophene-4-acetamide) [277], 
using the paw pressure and tail-flick tests. These are animal 
models used for higher grade pain which require higher efficacy 
compounds than visceral-chemical stimuli. 
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Thus although some apparently conflicting evidence exists over the 
receptors'through which compounds with reported k-selectivities 
act,there is general agreement that k-receptors mediate antinociceptive 
responses to lower grade visceral pain at the spinal level. Indeed 
in spite of the controversy surrounding the opioid nature of the 
analges'ia induced by the dynorphins in animal models, these compounds 
have been shown to be clinically effective in the management of 
intractable cancer pain after intrathecal administration [187]. In 
these studies, analgesia was effected at doses which did not cause 
motor dysfunction and very few other side effects were seen. 
In conclusion, the present work has demonstrated an heterogeneity of 
the k-population in the lumbo-sacral spinal cord of the rat. Such 
heterogeneity may extend to other species. Only a small proportion 
these sites in the rat appear to be of the "classical kIf type since 
the additional sites do not appear to bind [SH]dynorphin A-(1-9), or 
the k-selective opioid [SH]U-69593. Although the remaining sites 
require further definition the results do lend support for the 
involvement of k-receptors in antinociceptive responses at the spinal 
level. 
C H APT E R 7 
CHARACTERIZATION OF BRAIN K-OPIOID BINDING SITES 
IN THE RAT AND GUINEA-PIG 
INTRODUCTION 
The existence of \1-, 6 - and k-opioid binding sites has been 
demonstrated in the spinal cord [152, 154, 192] and in brain 
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[157, 249]. Work in the spinal cord suggested an apparently, 
heterogeneous k-population [163, 196] and an absence of \1- and 
6-sites. Although the same research group later demonstrated the 
presence of \1- and 6 -sites, in spinal cord tissues [165], suggesting 
that the apparent heterogeneity actually represented \1-, 6 - and 
k-sites, other workers [195] were able to demonstrate that even 
after binding ~o \1- and 6 -sites was suppressed, the residual 
k-population was apparently heterogeneous. An heterogeneity of 
k-sites has, also been demonstrated in brain tissues [199, 200]. 
Heterogeneous binding may be real. On the other hand such binding 
characteristics maybe seen if both high and low affinity states 
of the same receptor are present [213]. When monovalent cations 
such as Na+ are used alone, or in combination with guanyl nucleotides 
[241, 245], it is possible to almost abolish agonist binding whilst 
leaving antagonist binding relatively unaffected. Alternatively 
divalent cations, for example Mg2+' may be employed to promote 
high affinity binding for some agonists [245], particularly to 
6-siteS [245, 254]. However, it is known that mono- and divalent 
cations differentially affect the binding of ['H]opioids to \1-, 6-
and k-sites [245, 254, 255]. Therefore, a careful selection of the 
levels of ligand needed to effect \1-, 6- or k- suppression is necessary 
for each experimental condition. 
Apparent heterogeneity of binding may also arise from ['H]opioid 
interaction with low affinity specific sites on lipids [95] or even 
glass fibre filters [96]. Myelin is composed of a high proportion of 
phospholipid and galactolipid [256] and may constitute a potential 
target for these interactions. Na+, K+-activated adenosine 
5'-triphosphate phosphohydrolase (Na+, K+-ATPase; EC 3.6.1.3), is an 
enzyme-marker for the external membranes of nerve terminals [257]. 
Monoamine oxidase (MAO; EC 1.4.3.4) is localised on the 'inner 
membrane of mitochondria [259] and constitutes a useful marker enzyme 
for mitochondria. 2',3'-Cyclic nucleotide 3'-phosphohydrolase 
(2',3'-CNP; EC 3.1.4.16)is a myelin-specific enzyme [256]. 
Therefore, the subcellular components may be identified after 
their separation by differential centrifugation. 
The aim· of this work· was to characterize k-binding in brain 
tissue, a relatively abundant source of opioid binding sites, 
under carefully chosen experimental conditions. 
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MATERIALS & METHODS 
Homogenates of rat or guinea-pig brain or guinea-pig cerebellum 
were prepared and binding assays were performed using a selection 
of different buffers as detailed in Chapter 2. 
Binding assays were performed at 25°C for 45 minutes (30 minutes 
for ['H]dynorphin A~(1-9». 
['H](-)-Bremazocine, ['H]dynorphin A~(1-9) and ['H]diprenorphine 
were the radiolabelled ligands used. Non-specific binding was 
defined using 1pM diprenorphine for ['H](-)-bremazocine and 
['H]dynorphin A~(1-9) or 10pM naloxone for ['H]diprenorphine. All 
other·chemicals used were as described in Chapter 2. 
All preparations and procedures for the subcellular distribution 
of opioid binding were performed as described in Chapter 2 (pp. 
32 - 41). 
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RESULTS 
Binding studies in 50mM Tris-HCl, pH 7.4 buffer 
a) Competition assays 
['H](-)-Bremazocine was displaced from rat (Figure 7.1) and 
guinea-pig (Figure 7.2) brain homogenates by ~- and 6-
selective opioid peptides. In the rat a biphasic curve was 
obtained for the ~-selective peptide [D-Ala 2 ,MePhe',Gly-ols] 
enkephalin affording a high affinity component indicative of 
binding to a ~-site [90,91] and a low affinity component. 
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The former represented 45 - 501~ of the specifically bound 
radioligand. The displacement profile for [D-Ala 2 ,D-Leu s] 
enkephalin was apparently monophasic uP.to 10~M (Figure 7.1). 
However, the Hill coefficient was low and there was a discernable 
inflexion of the displacement curve at approximately 100nM, 
indicative of interaction with more than one type of binding 
site. The o-antagonist ICI 174864 displaced 35% of the 
specifically bound ['H](-)-bremazocine with an IC,. in line 
with its reported 6-affinity[238] and a Hill slope close to 
unity (Table 7.1). 
In the guinea-pig, all three unlabelled competing ligands 
displaced ['H](-)-bremazocine in a biphasic manner (Figure 7.2), 
although the higher affinity component for each curve 
represented a much lower proportion of the bound material than 
was seen with the rat. Indeed ICI 174864 displaced only 1m~ 
of the bound radioligand. The plateaux between the binding 
components were also larger for each of the ligands used. The 
calculations of the. IC .. values and. Hill coefficients in guinea-
pig. brain may contain significant errors due to the low levels 
of displacement obtained in this tissue, but were in line with 
reported values [90, 157, 238] (Table 7.1). 
When ['H](-)-bremazocine binding to ~- and 6-sites was suppressed 
using unlabelled [D-Ala2 ,MePhe',Gly-ols]enkephalin and 
[0-Ala2 ,D-LeuS ]enkephalin each in the ratio 100nM to 0.2nM 
radioligand, different displacement profiles for the remaining 
K-population were obtained in the rat and guinea-pig. 
In the rat, [D-Ala',MePhe',Gly-ol']enkephalin displaced the 
specifically bound radioligand with low affinity and a slope 
close to unity (Figure 7.3; Table 7.2). [D-Ala',D-Leu'] 
enkephalin and U-504BBH both displaced ['H](-)-bremazocine 
with low affinities and afforded Hill coefficients of less 
than unity (Figure 7.3; Table 7.2). There was no biphasic 
nature visually apparent in either of these curves. 
In the guinea-pig, [D-Ala',MePhe',Gly-oIS]enkephalin and 
U-504BBH produced shallow Hill slopes. The affinity for 
U-50488H was markedly higher than in the rat under the same 
conditions, and close to reports for interaction of this ligand 
with K-sites [lOB, 109] (Figure 7.4; Table 7.2). 
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Displacement of ['H]( - )-bremazocine by [D-Ala' ,D-Leu' ]enkephalin (.) (0.46-0 .52nM), [D-Ala' ,MePhe' , 
Gly-ol' ]enkephalin (0) (0.51-0.52nM) and lCI 174864 (.) (0.53-0.58nM) in guinea-pig brain 
homogenates prepared in 50mM Tris-HCl buffer. Values in parentheses show concentration ranges of 
radioligand. See Table 7.1 for data. 
Table 7.1 Potencies of ~- and ~-selective opioid peptides to displace 
in rat and guinea-pig brain homogenates at 25 DC in Tris-HCl 
Tissue Competing Ligand IC,. nM 
Rat brain [D-Ala2 ,MePhe',Gly-ol']enkephalin H 15.84 ± 4.46 
L >5~M 
[D-Ala',D-Leu']enkephalin H 35.93 ± 4.01 . 
L >80~M 
ICI 174864 H 849.6 ± 120.6 
L >80~M 
Guinea-pig [D-Ala 2 ,MePhe',Gly-ol']enkephalin H 26.14 ± 5.91 
brain L >6~M 
[D-Ala2 ,D-Leu']enkephalin H 8.47 ± 1.11 
L >60~M 
lCI 174864~ H 215.4 ± 48.1 
L >100~M 
Results expressed as means ± sem of 3 separate experiments in duplicate. 
Min. r = Minimum linear correlation coefficient. 
H = High affinity binding component. 
L = Low affinity binding component. 
Non-specific binding· was defined using 1~M unlabelled diprenorphine. 
['H](-)-bremazocine (0.40 - 0.71nM) 
buffer (Figures 7.1 & 7.2). 
nH Min. r 
0.86 ± 0.04 0.990 
1.10 ± 0.10 0.993 
0.52 ± 0.04 0.934 
0.97 ± 0.06 0.987 
1.07 ± 0.13 0.932 
0.93 ± 0.08 0.993 
0.86 ± 0.20 0.841 
0.87 ± 0.18 0.830 
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Displacement of ['H](-)-bremazocine (O.20-0.2BnM), in the 
presence of 100nM each of [D-Ala',D-LeuS]enkephalin and 
[D-Ala',MePhe',Gly-ol']enkephalin to O.2nM labelled ligand, 
by [D-Ala' ,D-Leu' ]enkephalin (.), [D-Ala2 ,MePhe' , Gly-ol' ] 
enkephalin (0) and U-504BBH (.) in rat brain homogenates 
prepared in 50mM Tris-HCl buffer. See Table 7.2 for data. 
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Displacement of ['H](-)-bremazocine (O.20-0.23nM) by 
[D-Ala 2 ,D-Leu' ]enkephalin (.), [D-Ala2 ,MePhe' ,Gly-ol'] 
enkephalin (0) and U-50488H (.) in guinea-pig brain 
homogenates under the conditions described in Figure 7.3. 
See Table 7.2 for data. 
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Table 7.2 Potencies of selective opioids to displace ['H](-)-bremazocine in the presence of 100nM 
each of unlabelled [D-Ala',D-Leu']enkephalin and [D-Ala',MePhe~,Gly-ol']enkephalin to 0.2nM 
labelled ligand in brain homogenat,es at 25°C in Tris-HCl buffer (Figures 7.3 & 7.4). 
Tissue Unlabelled Ligand lC.. (nM) 
Rat Brain [D~Ala',MePhe",Gly-ol']enkephalin 2706 ± 363 
(0.20 - 0.28nM) [D-Ala',D-Leu'-lenkaphalin 16509 ± 2954 
U-50488H 178.3 ± 36.5 
Guinea-pig brain [D-Ala',MePhe",Gly-ol']enkephalin 4439 ± 397 
(0.20 - 0.23nM) [D-Ala',D-Leu']enkephalin 56287 ± 4913 
U-50488H 12.19 ± 0.90 
Results expressed as means ± sem of 3 separate experiments in duplicate. 
Min. r = Minimum linear correlation coefficient. 
Figures in parentheses represent ['H](-)-bremazocine concentration range. 
Non-specific binding defined using 1~M unlabelled diprenorphine. 
nH Min. r 
0.96 ± 0.04 0.986 
0.64 ± 0.03 0.925 
0.69 ± 0.02 0.988 
0.72 ± 0.02 0.991 
0.90 ± 0.13 0.994 
0.74 ± 0.03 0.987 
-Cl 
N 
b) Saturation analysis 
In rat brain, ['H](-)-bremazocine in the presence of 100nM 
each of [D-Ala2 ,O-Leu']enkephalin and [O-Ala 2 ,MePhe',Gly-olS] 
enkephalin to 0.2nM labelled ligand labelled approximately 
one tenth of the total site numbers. The affinity in the 
presence of suppression was higher than when no suppression 
was present (Figure 7.5; Table 7.3). Both Scatchard plots 
were linear. ['H]Oiprenorphine labelled a higher total number 
of sites (Bmax 339.6 ± 26.3 fmol.mg-'; Figure 7.11) with 
higher affinity ,(KO 0.36 ± O.04nM) than ['H](-)-bremazocine. 
,When experiments were performed in guinea-pig cerebellar 
homogenates, a tissue containing mainly K-sites [242], both 
['H](-)-bremazocine and ['H]dynorphin A-(1-9) under the ~-
and 5-suppressing conditions described above, labelled 
similar numbers of high affinity sites ,(Figures 7.6: & 7.7; 
Table 7.3). 
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cerebellar homogenates prepared in 5DmM Tris-HCI buffer. 
Representative plot from 3 experiments. See Table 7.3 for 
data. 
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Table 7.3 Saturated binding analysis for ['H](-)-bremazocine or ['H]dynorphin A-(1-9) in the presence 
of 100nM each of unlabelled [O-Ala2 ,O-Leu']enkephalin and [O-Ala2 ,MePhe',Gly-oIS]enkephalin 
to 0.2nM labelled ligand (0.1nM for ['H]dynorphin A-(1-9)) in CNS tissues from rat and 
guinea-pig in Tris-HCI buffer at 25 DC (Figures 7.5 - 7.7). 
Tissue 
Rat Brain 
Guinea-pig 
cerebellum 
Radioligand 
['H](- )-8remazocine 
(0.027 - 11.75nM) 
['H](-)-Bremazocine 
(0.025 - 10.80nM) 
['H]Oynorphin A-(1-9) 
(0.045 - 7.35nM) 
Bmax (fmol.mg- 1 ) 
*210.3 ± 22.2 
21.18 ± 1.74 
56.13 ± 1.75 
63.98 ± 12.25 
Results expressed as means ± sem of 3 experiments in duplicate. 
r = Non-linear correlation coefficient. 
Figures in parentheses represent radioligand concentration ranges used. 
* Results represent binding in the absence of suppression. 
Non-specific binding defined using 1pM unlabelled diprenorphine. 
KO (nM) r 
1.19 ± 0.12 0.975 - 0.991 
0.31 ± 0.05 0.968 - 0.989 
0.17 ± 0.01 0.969 - 0.981 
0.30 ± 0.09 0.872 - 0.988 
'" 
'" 
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Binding studies in 50mM Tris-HCl buffer containing 25mM Nael 
a) Competition assays 
The ability of unlabelled ligands to define non-specific 
binding was reassessed in, the presence of 25mM Nael (Table 7.4). 
The non-selective opioid compounds all displaced greater 
than 96% of the total" that is, specific plus non-specific 
['H]diprenorphine bound. The antagonist naloxone also 
displaced greater than 96% when used at higher concentrations. 
U-504BBH and to a,lesser extent tifluadom, are two compounds 
showing k-binding properties~ They are also both agonists. 
These latter propertie~are reflected by the low potencies 
of the compounds in the presence of 25mM NaCl. Thus, only 
when 200pM U-504BBH or 10pM tifluadom is used, does the 
displacement o~ bound ['H]diprenorphine exceed 80%.- These 
results demonstrate that the ligands used to define non-
specific binding in Tris-Hel buffer are also suitable in the 
presence of 25mM sodium ions. 
['H]Diprenorphine displacement in rat brain homogenates by 
the p-selective [D-Ala 2 ,MePhe',Gly-ols]enkephalin or 
k-selective U-504BBH afforded low Hill coefficients although 
neither curves were visually biphasic (Figure 7.8). The 
6-antagonist rcr 174B64 was able to displace only 30~~ of 
the bound material. Surprisingly, when lower concentrations 
of ['H]diprenorphine were used, rcr 174864 displaced the 
bound ligand with a lower affinity and with a shallow slope 
(Figure 7.9). Data is presented in Table 7.5. 
['H]Diprenorphine (0.23nM) binding in guinea-pig cerebellar 
homogenates was displaced by U-504B8H in an apparently 
biphasic manner (Figure 7.10). ' The higher affinity component 
represented approximately 75% of the bound radioligand and 
afforded rcs• values of 20.90nM and 22.33nM in two experiments. 
The Hill coefficients for these curves were 0.61 and 0.57 
respectively.' The IC. 0 of the lower affinity component was 
greater than 10~M. 
b) Saturation analysis 
In Tris-HCI containing 25mM NaCl, the Bmax and KD values were 
315.6 ±..14.3 fmol.mg-' and 0.28 ± 0.06nM, which were not 
significantly different from studies in Tris-buffer alone 
(Figure 7.11). There appeared to be no difference in the 
shape of the Scatchard plots obtained under both experimental 
conditions. 
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Table 7.4 
Unlabelled Ligand. 
MR 2266 
Diprenorphine 
(-)-Bremazocine 
Naloxone 
Tifluadom 
U-50488H 
The ability of unlabelled ligands at high concentrations to displace ['H]diprenorphine (0.25nM) 
binding from rat brain homogenates in Tris-HCI buffer containing 25mM NaCI, at 25 DC. 
Concentration (~M) 
1 
10 
1 
1 
10 
10 
1 
10 
10 
200 
1~ Displacement* 
96.02 ± 0.16 
96.81 ± 0.44 
96.81 ± 0.39 
96.68 ± 0.30 
96.71 ± 0.28 
96.41 ± 0.35 
68.06 ± 1.03 
89.42 ± 0.42 
37.26 ± 2.89 
82.07 ± 0.38 
Re~ults are means ± sem of 4 experiments· ·in duplicate. 
* % Displacement represents the displacement by .the unlabelled ligand of total, that is, specific plus 
non-specific ['H]diprenorphine binding, in the presence of 25mM NaCI. 
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Displacement of ['H]diprenorphine by U-504BBH (0) and 
[D-Ala',MePhe',Gly-ol']enkephalin (0) in rat brain 
homogenates prepared in 50mM Tris-HCI buffer containing 
25mM NaCI. Assays using lower concentrations (-O.2nM) 
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of radioligand are shown in open symbols, and assays using 
higher radioligand concentrations (-2nM) are shown in 
solid symbols. See Table 7.5 for data. 
.. 
i : 
8 7 6 5 
·Iog ( .M competing ligand) 
Displacement of low (A) and h~gh ("') concentrations of 
['H]diprenorphine by ICI 174B64 in homogenates of rat 
brain prepared in 50 mM Tris-HCI buffer containing 25mM 
NaCI. See Table 7.5 for data. 
Table 7.5 Potencies of selective opioid compounds to displace ['H]diprenorphine binding in rat brain 
homogenates in Tris-HCI buffer containing 25mM NaCI at 25°C (Figures 7.8. & 7.9). 
['H]Diprenorphine 
Competing Ligand Concentration (nM) IC •• (nM) nH 
[D-Ala2 ,MePhe",Gly-oIS]enkephalin 0.14 - 0.19 63.34 ± 8.71 0.45 ± 0.04 
1.98 - 2.18 732.1 ± 158.6 0.59 ± 0.07 
U-50488H 0.20 - 0.24 17657 ± 4463 0.63 ± 0.03 
2.05 - 2.31 41393 ± 4041 0.76 ± 0.01 
ICI 174864 0.20, 0.24 917.0, 357.3 0.78, 0.75 
1.82, 2.31 249.5, 232.2 0.55, 1.04 
Results expressed as means ± sem of n experiments in duplicate or as individual results. 
nH = Hill coefficient. 
Non-specific binding for ['H]diprenorphine defined using 10pM unlabelled naloxone. 
Hill slopes for ICl174864 were calculated taking the plateau to represent 100% displacement. 
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Displacement of [3H]diprenorphine (0.23nM) by U-50488H in guinea-pig cerebellar homogenates 
prepared in 50mM Tris-HCl buffer containing 25mM NaCl. Mean of 2 experiments. 
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Saturation analysis for ['H]diprenorphine in rat brain homogenates prepared in 50mM Tris-HCl buffer (0) and 
50mM Tris-HCl buffer containing 25mM NaCl (.). A concentr.ation range of 0.027 - 40.02nM labelled ligand 
was used for all experiments. Representative plots from 3 experiments. 
Binding studies in 25mM HEPES buffer containing 10mM MgCl., pH 7.4 
a) Competition assays 
['H]Diprenorphine displacement in rat brain homage nates by 
the p-selective [D-Ala2 ,MePhe',Gly-ol']enkephalin produced 
a biphasic curve (figure 7.12). The high affinity component 
afforded an IC,.value in the typical p-range [90, 91] and 
represented 40 - 45% of the labelled sites. A plateau was 
evident between 20nM and 100nM displacing ligand. 
[D-Ala',D-Leu']enkephalin, in the presence of p~suppression 
also afforded a biphasic displacement curve (figure 7.12) 
with an IC, •. \alue for the high affinity binding component, 
which represented 25 - 301. of the total labelled sites, in the 
reported range for interaction with 6-sites [97, 157]. A 
plateau was discernable between 20nM and 100nM displacing 
ligand. Results are summarized in Table 7.6. 
When U-50488H displaced the specifically bound ['H]dipre-
norphine in the presence of 100nM each of unlabelled 
[D-Ala2 ,D-Leu']enkephalin and [D-Ala',MePhe',Gly-ol'] 
enkephalin to suppress binding to 6- and p-sites respectively, 
a noticeably biphasic curve was obtained with a pronounced 
plateau (figure 7.13; Table 7.6). The high affinity component 
represented approximately 20% of the .bound material. and 
afforded an affinity in line with that reported for 
interaction with k-sites .[108, 109, 242]. It was therefore 
possible to selectively block p-, 0- and k-sites in this 
buffer system and still retain a binding component. 
This residual ['H]diprenorphine binding remaining after 
p_, .6- and k-suppression was displaced by [D-Ala2 ,D-Leu'] 
enkephalin, [D-Ala2 ,MePhe',Gly-oP]enkephalin and U-50488H 
with low affinities which were intermediary between those 
reported for p~, 0- and k-site interaction (figure 7.14; 
Table 7.7). The two peptide analogues also afforded shallow 
Hill slopes whilst the slope for·U-50488H was closer to unity. 
174 
175 
This residual binding was also displaced by 1~M naloxone, and 
levorphanol was approximately 300 times more potent than 
dextrorphan (Figure 7.15). Displacement of a second non-selective 
opioid, [SH](-)-bremazocine by [D-Ala 2 ,D-Leu"]enkephalin under 
the same experimental conditions (Figure 7.16) afforded an IC •• 
and slope similar·to those obtained using [SH]diprenorphine 
(Figure 7.14; Table 7.7). 
When t~e displacements were repeated in guinea-pig brain under 
the same conditions (Figure 7.17) similar affinities to those 
. seen with rat brain were obtained (Tables 7.7. & 7.8), but the 
slopes were close to unity. In the light of these observations 
. it was decided to investigate the guinea-pig brain binding 
sites more closely. 
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-log ( M competing ligand) 0 
Displacement of ['H]diprenorphine (O.23-0.3S0nM) by [D-Ala2• 
MePhe' ,Gly-~l' ]enkephalin (0) and [D-Ala2 ,D-Leu' ]eni<ephalin I 
1(_111) _ ° :n the presence ofl100nM[D-Ala2 ,MePhe' ,Gly-ol'] 
enkephai1n 1n rat brain homogenates prepared in 25mM HEPES 
buffer containing 10mM MgCI2 • See Table 7.6 for data. 
9 8 7 6 
-log C .M competing ligand) 
Displacement of ['H]diprenorphine (O.23-0.32nM), in the 
presence of 100nM each of [D-Ala2,D-LeuS]enkephalin and 
[D_Ala2,MePhe',Gly-oIS]enkephalin to O.2nM radioligand, 
by U~504SSH in rat brain homogena~es prepared in 25mM 
HEPES buffer containing 10mM MgCI2. See Table 7.6 for 
data. 
5 
Table 7.6 Displacement of ['H]diprenorphine in rat brain homogenates by selective opioid ligands in 25mM 
HEPES buffer containing 10mM MgCI. at 25 DC (Figures 7.12. & 7.13). 
Competing Ligand 
[D-Ala',MePhe',Gly-ol']enkephalin 
[O-Ala',D-Leu']enkephalin * 
U-50488H ** 
['H]Diprenorphine 
Concentration (nM) 
0.23 - 0.38 
0.23 - 0.38 
0.23 - 0.32 
H 
L 
H 
L 
H 
L 
lC, • nM nH 
3.75±1.36 1.05 ± 0.15 
947 ± 207 0.67 ± 0.11 
3.44 ± 0.96 1.02 ± 0.04 
>6\1M 0.71 ± 0.01 
3.27, 6.32 0.70, 1.00 
>5\1M 0.72 ± 0.07 
Results expressed as means ± sem for n separate experiments in duplicate, or as individual results. 
nH = Hill coefficient. 
* Performed· in the presence of 100nM unlabelled [D-Ala',MePhe',Gly-oIS]enkephalin to suppress \I-binding. 
n 
4 
4 
3 
3 
2 
3 
** Performed. in the presence of 100nM each of unlabelled [D-Ala',MePhe',Gly-ols]enkephalin and [D-Ala',D-LeuS] 
enkephalin to· suppress \1- and &-binding. 
H = High affinity binding site. 
L = Low affinity binding site. 
Non-specific binding defined using 10\lM unlabelled naloxone. 
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Figure 7.15 
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-log C M competing ligand) 
Displacement of ['H]diprenorphine (O.23-0.31nM), in the 
presence of 100nM each of,[D-Ala',D-LeuS]enkephalin, 
[D-Ala',MePhe',Gly-olS]enkephal{n and U-50488H to O.2nM 
labelled ligand, by [D-Ala' ,D-Leu s ]enkephalin (.), 
[D-Ala' ,MePhe' ,Gly-ol S ]enkephalin (0) and U-50488H 
( .) in rat brain homogenates prepared in 25mM HEPES 
buffer containing 10mM MgCl,.·, See Table 7.7 for data. 
8 7 6 5 
-log ( M competing ligand) 
178 
Displacement of ['H]diprenorphine (O.21-0.23nM) by naloxone 
(A ), levorphanol ( ... ) and dextrorphan (T) in rat brain 
homogenates under the conditions described in Figure 7.14. 
Mean results from 2 experiments. See Table 7.7 for data. 
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Displacement of ['H](-)-bremazocine (O.23-0.2BnM), in the presence of 100nM each [D-Ala',D-Leu'] 
enkephalin, [D-Ala',MePhe',Gly-015]enkephalin and U-504BBH to O.2nM labelled ligand by [D-Ala', 
D-Leu']enkephalin in rat brain homogenates prepared in 25mM HEPES buffer containing 10mM MgCl •• 
See Table 7.7 for data. 
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Table 7.7 The displacement of non-selective ['U]opioids in the presence of 100nM each unlabelled [D-Ala 2 ,D-Leu S ] 
enkephalin, [D-Ala 2 ,MePhe",Gly-olS]enkephalin and U-50488H to suppress 6-, ~-'and k-binding respectively, 
by selective opioids in rat brain homogenates, in 25mM HEPES buffer containing 10mM MgCl 2 at 25°C 
(figures 7.14 - 7.16). 
Radioligand 
['H]Diprenorphine 
['H] (-)-Bremazocine 
Radioligand 
Concentration (nM) 
0.23 - 0.31 
0.21 - 0.23 
0.23 - 0.28 
Unlabelled Competing 
Ligand 
[D-Ala2 ,D-Leu S ]enkephalin 
[D-Ala2 ,MePhe" ,Gly-oIS]enkephalin 
U-50488H 
Naloxone 
Dextrorphan 
Levorphanol 
[D-Ala 2 ,D-Leu S ]enkephalin 
lC .. 
(nM) 
15135 ± 3319 
3711 ± 351 
6649 ± 1461 
38.10, 47.52 
17050,17656 
48.00, 58.50 
9633 ± 1308 
Results expressed as means ± sem of n separate experiments in duplicate or as individual results. 
nH = Hill Coefficient 
Minimum linear correlation coefficient was greater than 0.977 for all assays. 
1 ~M naloxone displaced 94.n~ of the specifically bound radioligand. 
nH n 
0.66 ± 0.08 4 
0.72 ± 0.08 3 
0.88 ± 0.08 3 
1.26, 1.30 2 
1.01, 1.17 2 
1.08, 1.12 2 
0.69 ± 0.11 3 
Non-specific binding defined for ['H]diprenorphine using 10~M unlabelled naloxone and for ['H](-)-bremazocine using 1~M 
unlabelled diprenorphine. 
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Displacement of ['H]diprenorphine (O.25-0.31nM), in the presence of 100nM each of EO-Ala', 
O-Leu']enkephalin, [O-Ala',MePhe',Gly-olS]enkephalin and U-50488H to O.2nM labelled ligand, 
by [O-Ala' ,O-Leu s ]enkephalin (.), [O-Ala' ,MePhe' ,Gly-ol' ]enkephalin (0) and U-50488H (.) 
in guinea-pig brain homogenates prepared in 25mM HEPES buffer containing 10mM MgCl.. See 
Table 7.B for data. 
co 
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Table 7.8 Potencies of unlabelled selective opioids to displace ['H]diprenorphine (0.25 - 0.31nM), in the 
presence of unlabelled [D-Ala',D-Leu5]enkephalin, [D-Ala',MePhe',Gly-015]enkephalin and 
U-50488H, each in the ratio 100nM to 0.2nM labelled ligand, in guinea-pig brain homogenates in 
HEPES buffer containing 10mM MgCl. at 25°C (Figure 7.17). 
Unlabelled Ligand lC 50 (nM) 
[D-Ala',D-Leu 5]enkephalin 16851 ± 3620 
[D-Ala',MePhe',Gly-ol']enkephalin 2607 ± 334 
U-50488H 4503 ± 1125 
Results expressed as means ± sem for 3 separate experiments in duplicate. 
Minimum linear correlation coefficient was greater than 0.959 for all assays. 
Non-specific binding was defined using 10~M unlabelled naloxone. 
Hill Coefficient 
0.93 ± 0.09 
0.98 ± 0.06 
0.97 ± 0.06 
183 
['H]Diprenorphine binding in guinea-pig brain homogenates was 
displaced by [D-Ala2,MePhe',Gly~ol']enkephalin in a biphasic 
manner (Fjgure 7.18). The high affinity site, representing 
approximately 30% of the bound material had the characteristics 
of a ~-site [90, 91], but the plateau was not very pronounced. 
The displacement profile for [D-Ala 2,D-Leu s]enkephalin showed 
no biphasic nature by visual inspection although the shallow 
Hill slope was indicative of more than one type of binding 
site, nor was the IC •• for this displacement consistent with a 
6-site interaction [97, 157] (Table .7.9). 
On the other hand the selective 6-antagonist ICI 174864 
displaced approximately 33% of the specifically bound 
['H]diprenorphine with high affinity and a marked plateau 
was. observed. In an attempt to improve the ability of 
[D-Ala 2,MePhe',Gly-ol']enkephalin to separate binding 
components, displacements were reassessed in the presence 
of 1~M ICI 174864 (Figure 7.17). However, .there was no 
apparent change in the displacement profile obtained. The 
displacement of specifically bound ['H]diprenorphine in the 
presence of 6-suppression (1~M ICI 174864) and ~-suppression 
{100nM [0-Ala2,MePhe',Gly-oIS]enkephalin)by U-50488H afforded 
a clearly biphasic curve. Approximately 55~o of bound material 
could be attributed to high affinity binding (k-sites) (Figure 7.19). 
A secpnd k.,..select~vel~gand dynorphin 1,\.(1-17) [50, 71] 
displaced the residual ['H]diprenorphine binding with low 
affinity and a shallow Hill sloPEl (Figure 7.20). Re-calculation 
of the affinity, taking 65~o to represent total displacement 
gave an increase in affinity but still afforded a shallow slope 
(Table 7.10). When ['H]diprenorphine binding was additionally 
suppressed at k-sites, the affinity·of dynorphin A-{1-17) was 
reduced and the slope was less than unity. Only 50% of the 
bound radioligand was "sensitive" 
of dynorphin A~{1-17) up to 1~M. 
to displacement by concentrations 
When the plateau was chosen 
to represent 100% displacement of this component, the re-calculated 
slope was close to unity and the affinity increased, but 
remained lower than for observations in the presence of only 
~- and 6-suppression. 
U-50488H, [0-Ala2 ,D-Leu']enkephalin and [D-Ala2 ,MePhe',Gly-olS] 
enkephalin were all relatively inactive at displacing the 
remaining bound [' H]ligand (Figure 7.21; Table 7.10). 
'When ['H]diprenorphine in the presence of ~- and &-suppression, 
was displaced from guinea-pig cerebellar homogenates by 
U-50488H, a biphasic curve was obtained (Figure 7.22a). The 
high affinity site represented approximately 75% of the 
bound radioligand. This curve was resolved into two Hill plots 
(Figure 7.22b) affording a high affinity component, lC •• 
1.60 ± 0.36nM and slope 1.04 ± 0.04, typical of a k-site 
interaction [242] and a low affinity component, lC •• 
535.7 ± 70.5nM, slope 0.91 ± 0.12. 
b) Saturation analysis 
['H]Diprenorphine binding in the presence of p-, 5- and 
k-suppression was reduced to less than 101. of the total 
sites labelled in guinea-pig, brain in this buffer system 
(Figure 7.23). The affinity of the radioligand for the 
remaining sites was high (Table 7.11). 
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Displacement of ['H]diprenorphine by [D-Ala 2 ,MePhe' ,Gly-ol' ]enkephalin (0), [D-Ala 2 ,D-Leu'] 
enkephalin in the presence of 100nM [D-Ala 2 ,MePhe' ,Gly-ol']enkephalin (.), ICI 174864 (.) 
and [D-Ala 2 ,MePhe' ,Gly-ol' ]enkephalin in the presence of hIM ICI 174864 (.) in guinea":pig 
brain homogenates prepared in 25mM HEPES buffer containing 10mM MgC1 2 • See Table 7.9 for 
radioligand concentrations used and results. 
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Displacement of [3H]diprenorphine (D.22-D.25nM), in the presence of 100nM [D-Ala2,MePhe~,Gly-ol'] 
enkephalin and 1~M ICI 174864 to D.2nM radioligand, by U-50488H in guinea-pig brain homogenates 
prepared in 25mM HEPES buffer .containing 10mM MgCl.. See Table 7.9 for data. 
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Table 7.9 Affinities for p-, 5- and k-selective ligands to displace ['H]diprenorphine in guinea-pig brain 
homogenates in 25mM HEPES buffer containing 10mM MgCl 2 at 25DC (Figures.7.18. & 7.19). 
['H]Diprenorphine 
Competing Ligand Concentration (nM) IC s• (nM) 
[D-Ala 2 ,MePhe',Gly-oIS]enkephalin 0.25 .. 0.27 H 3.27 ± 0.94 
L 817.6 ± 13.7 
[D-Ala 2 ,D-Leu']enkephalin * 0.26 31.62 ± 1.05 
ICI 174864 0.28 - 0.31 H 48.56 ± 17.04 
L >10pM: 
[D-Ala2 ,MePhe",Gly-oIS]enkephalin ** 0.26 - 0.33 H 4.27 ± 1.46 
L 894.9 ± 183.9 
U-50488H *** 0.22 - 0.25 H 2.93 ± 0.24 
L 2396 ± 624 
Results expressed as means ± sem for n separate experiments in duplicate. 
nH = Hill coefficient. 
nH 
1.07±0.10 
0.74 ± 0.02 
0.46 ± 0.05 
0.87 ± 0.10 
1.16 ± 0.10 
0.80 ± 0.08 
1.06 ± 0.12 
0.82 ± 0.07 
* Suppressed using 100nM unlabelled [D-Ala',MePhe",Gly-ol']enkephalin (lI-suppression). 
** Suppressed using 111M unlabelled ICI 174864 (5-suppression). 
*** Suppressed using 100nM unlabelled [D-Ala',MePhe',Gly-oIS]enkephalin and 1pM unlabelled ICI 174864. 
H = High affinity site. 
L = Low affinity site. 
Non-specific binding defined using 10pM unlabelled naloxone. 
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Displacement of [8H]diprenorphine (0.20-0.21nM) by dynorphin A-(1-17) in guinea-pig brain homogenates 
prepared in 25mM HEPES buffer containing 10mM MgCl •• Open circles show results obtained.in the . 
presence of 100nM [D-Ala',MePhe',Gly-ol']enkephalin and 1~M ICI 174864; closed circles show results 
obtained in the presence of the above plus additional suppression by 100nM U-50488H. See Table 7.10 
for data. 
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Figure 7.21 Displacement of [SH]diprenorphine (O.19-0.21nM) in the presence of 100nM each of [D-Ala',MePhe', 
Gly-olS]enkephalin and U-50488H, and 1pM ICI 174864 to O.2nM labelled ligand by [D-Ala',D-LeuS] 
enkephalin (.), [D-Ala' ,MePhe' ,Gly-olS ]enkephalin (0) and U-50488H (.) in guinea-pig brain 
homogenates prepared in 25mM HEPES buffer containing 10mM MgCl,. See Table 7.10 for data. 
Jable 7.10. Displacement of ['H]diprenorphine by p-, 6- and k-selective opioid compounds in gUinea-pig 
brain homogenates in the presence of 1DDnM each of unlabelled U-5D488H and [D-Ala·,MePhe·, 
Gly-ol']enkephalin and 1pM unlabelled lCl 174864 (to suppress binding to k-, p- and 6-sites) 
in 25mM HEPES buffer containing 1DmM MgCI. at 25°C (Figures 7.20. & 7.21). 
Competing Ligand 
Dynorphin A-(1-17) * 
Oynorphin A-(1-17) 
[D-Ala',D-Leu']enkephalin 
[O-Ala',MePhe',Gly-ol']enkephalin 
U-5D48BH 
['H]Oiprenorphine 
Concentration (nM) 
0..20 - 0..21 
0..19 - 0..21 
lC .. (nM) 
47.0.9 ± 3.89 
+ (13.25 ± 1.54) 
753.0. ± 79.0 
+, (36.26 ± 10..11) 
+++ >1DpM 
6559 ± 519 
Results expressed as means ± sem for 3 separate experiments in duplicate. 
nH = Hill coefficient. 
Min. r = Minimum linear correlation coefficient. 
Dynorphin A-(1-17) values for whole curve, except (+) where calculated using plateau as 10m~. 
nH 
0..45 ± 0..0.3 
(D.82± 0..0.3) 
0.40 ± 0..0.6 
(0..93 ± 0..17) 
IO:31±-O-:03\ 
)---
0..92 ± 0..0.2 
++ [D-Ala',D-Leu']enkephalin displaced less than 50.% bound material in only 1 out of 3 observations at 1585nM. 
Min. r 
0..992 
O.9!l6 
0..959 
0..917 
0..962 
,+++ [D-Ala' ,MePhe' ,Gly-ol']enkephalin only displaced greater than 5D1~ bound material in 2 out of 3 observations at 1Op11. 
* Suppressed using 1pM unlabelled lCl 174064 and 1DDnM unlabelled [D-Ala' ,MePhe',Gly-ol']enkephalin (p- and,6-suppression). 
Non-specific binding defined in the presence of 1DpM unlabelled naloxone. 
a. 
b. 
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Displacement of ['H]diprenorphine (O.22nM),in the 
presence of 100nM [D-Alat,MePhe',Gly-ol']enkephalin 
and 1~M ICI 174864 to O.2nM radioligand, by U-50488H 
in guinea-pig cerebellar homogenates prepared in 25mM 
HEPES buffer containing 10mM MgCl t : a) Displacement 
profile b) Resolution into Hill plots. 
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Saturation analysis for ['H]diprenorphine in guinea-pig 
brain homogeinates prepared in 25mM HEPES buffer, 
containing 10mM MgCI.. in the' absence ( .) and, presence 
(0) of 100nM each of [O-Ala' ,MePhe~ ,Gly-oIS ]enkephalin 
and U-50488H, and 1]JM lel 174864 to O.2nM labelled 
ligand.' Representative plots from 3 experiments. See 
Table 7.11 for radioligand concentration ranges used and 
results. 
• 
Binding studies in 25mM HEPES buffer, pH 7.4 
a) Competition·assays 
The displacement of ['H]diprenorphine in rat and guinea-pig 
brain homogenates by U-504BBH was studied (Figure 7.24) using 
the \1- and 5-suppressing conditions previously determined. 
In the rat a high affinity k-component [109] (IC •• = 
5.07 ± 2.30nM; slope = 1.16 ± 0.11) represented approximately 
21% of the bound material. A low affinity component 
(lC,. = B055. ± 1B50nM; slope = 0.75 ± 0.13) was also evident 
and a plateau extended from approximately 20nM to 100nM 
unlabelled ligand. In the guinea-pig the high affinity, 
k-component (IC •• = 4.89 ± 0.56nM; slope = 1.06 ± 0.03) 
represented approximately 33% of the bound radioligand. 
The low affinity component afforded an IC •• value of 
6741 ±·247nM and a slope 0.91 ± 0.17. A plateau was.evident 
from approximately 40nM to 300nM. 
b) Saturation analysis 
The maximum number of sites labelled by ['H]diprenorphine in 
guinea-pig brain homogenates was reduced by approximately 
1.5 times in the absence of magnesium ions. However, the 
number of sites remaining after \1-, 5- and k-suppression was 
similar in both buffers (Figure 7.25; Table 7.11). 
The influence of buffer systems on ['H]diprenorphine binding 
High specific.binding was seen for ['H]diprenorphine in all the. 
buffer systems tested in this chapter (Table 7.12). A summary of 
the influences of ions and buffers on opioid binding sites in 
. different CNS tissues is presented in Table 7.13. 
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Displacement of ['H]diprenorphine by U-504BBH in rat brain (.) and guinea-pig brain (0) homogenates 
prepared in 25mM HEPES buffer. Rat brain experiments' were performed in the presence of 100nM each of 
[D-Ala2 ,D-Leu']enkephalin and [D-Ala2 ,MePhe',Gly-ol']enkephalin to 0.2nM radioligand, using a radioligand 
concentration range of 0.22 - 0.24nM. Guinea-pig brain experiments were performed in the presence of 
100nM [D-Ala2 ,MePhe',Gly-ol']enkephalin and 1pM IeI 174B64 to 0.2nM radioligand, using a radioligand 
concentration range of 0.21 - 0.23nM. 
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Saturation analysis for ['H]diprenorphine in guinea-pig 
brain homogenates prepared in 25mM HEPES buffer, in the 
absence (.) and 'presence (0) of 100nM each of 
[D-Ala ",MePhe" ,Gly-ol']enkephalin and U-50488H and 1 JlM ' 
leI 174864 to O.2nM labelled ligand. 'Representative 
plot from J, experiments. See' Table 7.11 for radioligand 
concentration ranges used and results. 
Table 7.11 Saturated binding analysis for ['H]diprenorphine in guinea-pig brain homogenates in 25mM HEPES 
buffer and 25mM HEPES buffer containing 10mM MgCl. , at 25DC (Figures 7.23 & 7.25). 
Buffer ['H]Diprenorphine Bmax 
Conditions Suppression Concentration (nM) ( fmol. mg- 1 ) KD (nM) 
HEPES None 0.027 - 10.79 117.8 ± 16.22 0.160 ± 0.004 
* 1l+6·+k 0.027 - 2.80 22.55 ± 4.44 0.079 ± 0.010 
+HEPES/Mg None 0.121 - 10.80 172.2 ± 11.32 0.201 ± 0.037 
* 1l+6+k 0.086 - 2.46 16.42 ± 1.55 0.097 ± 0.021 
Results expressed as means ± sem for 3 separate experiments in duplicate. 
r - Non-linear coefficient. 
~. Total 
Sites 
18.9±1.1 
9.22± 0.12 
r 
0.886 - 0.973 
0.854 - 0.946 
0.928 - 0.998 
0.860 - 0.975 
* Suppressed using 100nM each of unlabelled [D-Ala',MePhe 4 ,Gly-ol']enkephalin and U-50488H ( 11- & k-suppression) 
and 11lM unlabelled ICI 174864 (~-suppression). -
+ HEPES/t4g represents 25mM Hepes buffer containing 10mM MgCl •• 
Non-specific binding defined using 10llM unlabelled naloxone. 
Table 7.12 The influence of cations and buffers upon ['H]diprenorphine binding in brain homogenates from 
rat and guinea-pig, at 25 DC. 
Species & 
Tissue' 
Rat brain 
Guinea-pig 
brain 
Buffer 
System 
Tris/Na 
HEPES/Mg 
HEPES 
HEPES/Mg 
HEPES 
['H]Diprenorphine 
Concentration 
(nM) 
0.20 - 0.24 
0.23 - 0.24 
0.22 - 0.24 
0.25 - 0.26 
0.21 - 0.23 
Counts Bound (dpm) 
Total Non-specific 
6176 ± 185 276 ± 18 
5503 ± 179 334 ± 12 
4537 ± 77 282 ± 13 
5453 ± 137 352 ± 12 
3062 ± 39 231 ± 12 
Results expressed as means ± sem of n individual experiments in duplicate. 
Total = Specific plus non-specific ['H]diprenorphine binding. 
Non-specific = binding of ['H]diprenorphine in the presence of 10pM unlabelled naloxone. 
Tris/Na = 5DmM Tris-HCl buffer containing 25mM NaC!. 
HEPES/Mg • 25mM HEPES buffer containing 10mM MgCl •• 
HEPES = 25mM HEPES buffer. 
.' ,. Specific n 
95.3 ± 0.3 10 
93.9 ± 0.2 8 
93.6 ± 0.4 10 
94.2 ± 0.3 9 
92.0 ± 0.7 8 
Table 7.13 The influence of ions and buffers on the high affinity binding displaced by compounds with p-, 5- and 
k-specificity at 25°C. [D-Ala',D-LeuS]enkephalin (in the presence of p-suppression) or ICI 174864 
• 
displaced from 5-sites, [D-Ala',MePhe',Gly-ol']enkephalin displaced p-binding and U-50488H displaced 
k-binding. A summary of the results obtained in Chapter 7. 
Radioligand 
['H](-)-Bremazocine 
['H]Diprenorphine 
Concentration 
Range 
(nM) 
0.40 - 0.52 
0.54 - 0.71 
0.51 - 0.52 
0.53 - 0.58 
1.B2 - 2.31 
0.23 
0.23 - 0.38 
0.23 - 0.38 
0.23 - 0.32 
0.26 - 0.33 
0.28 - 0.31 
0.22 - 0.25 
0.22 
0.22 - 0.24 
0.21 - 0.23 
Tris-HCl = 50mM Tris-HCl buffer. 
Species '" 
Tissue' 
Rat Brain 
GP Brain 
Rat Brain' 
GP Cerebellum 
Rat Brain 
GP Brain 
GP Cerebellum 
Rat Brain 
GP Brain 
Tris/Na = 50mM Tris-HCl buffer containing 25mM NaCl. 
HEPES/Mg = 25mM HEPES buffer containing 10mM MgCl •• 
HEPES = 25mM HEPES bu ffer. 
P f · "GP" . . re ~x = gu~nea-p~g. 
Buffer 
# System 
Tris-HCl 
Tris/Na 
HEPES/Mg 
HEPES 
Approximate 
Proportion of 
Competing Ligand Sites UO) 
[D-Ala',MePhe',Gly-ol']enkephalin 50 
ICI 174864 35 
[D-Ala',MePhe',Gly-ol']enkephalin' 18 
ICI 174864 10 
ICI 174864 30 
U-50488H 75 
[D-Ala' ,MePhe' ,Gly-olS]enkephalin 41 
[D-Ala' ,D-Leu s ]enkephalin 27 
U-50488H 21 
[D-Ala' , MePhe' " Gly-olS ]enkephalin 41 
ICI 174864 33 
U-50488H 55 ' 
U-50488H 75 
U-50488H 21 
U-50488H 32 
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Subcellular distribution of opioid binding 
After the fractionation of rat brain tissues according to the method 
of Gray and Whittaker [260] (Chapter 2) the mitochondrial enzyme-
marker monoamine oxidase (MAO) was concentrated in the mitochondrial 
pellet, the myelin marker ·2',3'-cyclic nucleotide 3'-phosphohydrolase 
(2',3'-CNP).was concentrated in the crude myelin fraction, though the 
membrane marker Na+,K+-activated adenosine 5'-triphosphate 
phosphohydrolase (Na+,K+-ATPase) was distributed between the 
synaptosomal and myelin fractions (Figure 7.26; Table 7.14) suggesting 
contamination of the myelin fraction. ['H]Diprenorphine binding 
followed the membrane marker Na+,K+-ATPase. Using ['H](-)-bremazocine, 
,opioid binding was confirmed in myelin. In the presence of ~- and 
6-suppression the specifically bound radioligand was reduced by 10r. 
suggesting that most of the binding was of the k-type. Under these 
conditions this bound material was displaced by U-504BBH (Figure 7.27) 
affording an IC so value of 56.23nM, Hill slope 0.55 (means of two 
experiments in duplicate). Indeed attempts were made to purify the 
crude myelin (Figure 7.2B) but difficulty was experienced in ga~n1ng 
reproducible results, especially for Na+,K+-ATPase (Table 7.15). 
However, the activity of Na+,K+-ATPase did appear to decrease with 
myelin purification and this was closely followed by a decrease in 
['H]diprenorphine binding. The activity of the myelin marker 
2',3'-CNP increased approximately four fold during purification. 

• 
Figure 7.26 
Distribution of marker enzyme activity and ['H]diprenorphine 
binding in rat brain fractions. Data is given in Table 7.14. 
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Table 7.14 Enzyme marker activity and [SH]diprenorphine binding in the subcellular components of rat 
brain (Figure 7.26). 
Fraction 
P, 
Crude Myelin 
Synaptosomal 
Mitochondrial 
MAO 
*2.09 ± 2.09 
*2.69 ± 2.69 
*8.57 ± 8.57 
: 86.1 ± 7.5 
1. Recovered Activity 
2' ,3'-CNP + "+ Na ,K -ATPase 
11.0±7.9 **0 
62.5 ± 7.8 34.4 ± 3.6 
18.6 ± 1.7 50.2 ± 2.6 
7.88 ± 4.82 9.54 ± 4.9 
Results expressed as means ± sem of 3 separate experiments in duplicate. 
MAO = Monoamine oxidase [EC 1.4.3.4]. 
2' ,3'-CNP = 2' ,3'-Cyclic nucleotide3'-phosphohydrolase [EC 3.1.4.16]. 
[SH]Diprenorphine 
binding 
3.86 ± 3.47 
43.6 ± 10.9 
42.2 ± 9.6 
10.5 ± 3.6 
Na+,K+-ATPase = Na+,K+-Activated adenosine triphosphate phosphohydrolase [EC 3.6.1.3] •. 
* Activity detected in only one out of three experiments. 
** No activity detected in all three experiments. 
Non-specific binding for ['H]diprenorphine defined in the presence of 10pM unlabelled naloxone. 
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, 
Table 7.15 
Myelin Fraction 
Crude 
Purified 
Enzyme-marker activity and ['H]diprenorphine binding in crude and purified myelin 
(Figure 7.2B). 
Activity (Units. mg- 1 ) 
* 2',3'-CNP ** Na+,K+-ATPase *** ['H]Dip. 
3.15 ± 2.29 0~42 ± 0.05 10.0 ± 1.B 
14.1 ±1.B + 0.12 ± O.OB + 4.64 ± 1.7 
Results expressed as means ± sem of 4 separate experiments in duplicate. 
2',3'-CNP = 2',3'- Cyclic nucleotide 3'- phosphohydrolase. 
Na+ ,K+-ATPase = Na+ ,K+ - Activated adenosine 5' -,triphosphate phosphohydrolase. 
['H]Dip. = ['H]Diprenorphine. 
Units of activity: * 2',3'-CNP - 1 unit = 1 pmole phosphate liberated. minute -1. 
** Na+,K+-ATPase - 1 unit = 1 pmole phosphate liberated. minute-1 
*** ['H]Diprenorphine - 1 unit = 1 fmole specifically bound •. 
+ No activity was detectable in two out of the four assays. 
Non-specific binding for ['H]diprenorphine was defined usinq 10pM unlabelled naloxone. 
N 
o 
01'> 
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DISCUSSION 
Conditions under which 11- and 5-opioid sites could be selectively 
blocked were chosen from binding studies in rat and guinea-pig brain 
homogenates prepared in 5DmM Tris-HCI buffer. Under these 
suppressing conditions, the remaining binding displayed characteristics 
of an heterogeneous population of opioid sites in both species. In 
the rat, these sites represented approximately 10% of the total 
number labelled by ['H](-)-bremazocine in line with previous reports 
for k-sites [97, 193]. However, displacement studies using 11-' 5-
and k-selective compounds afforded binding constants which were not 
typical of interaction at k-sites. In the guinea-pig, the binding 
constants afforded were in line with those for interaction at k-sites 
but the shallow Hill plots suggested that the situation may be more 
complex. It was seen that [D-Ala2 ,MePhe'.,Gly-ols]enkephalin afforded 
shallow Hill slopes in the guinea-pig but not in the rat, whilst 
[D-Ala2 ,D-Leus ]enkephalin afforded shallow Hill plots only in the rat, 
which-may suggest a different heterogeneity in the rat compared to 
the guinea-pig. However, the Various components of binding were not 
separable. 
When 25mM sodium chloride was included in the Tris-HCl buffer, 
conditions which have been previously shown to promote the antagonist 
state of the opioid receptor [253] and confirmed by the shift to 
lower potency for agonists, it was not possible to discern more than 
one binding component for U-5D488H or [D-Ala2 ,MePhe',Gly-ol'] 
enkephalin. Further, ICI 174864 displaced ['H]diprenorphine with an 
affinity in the range for interaction with 6-SiteS [238, 239] only at 
high concentrations of radioligand (2nM), suggesting that with the 
level of [aH]diprenorphine usually used (D.2nM) few 6 -sites were being 
labelled. 
Saturation analysis of ['H]diprenorphine showed no change in Bmax or 
KO values in the presence/absence 
previous observations by Childers 
change for these parameters using 
sodium chloride, although others 
of 25mM sodium chloride supporting 
and Snyder [241], who showed no 
the antagonist ['H]naloxone in 1DDmM 
(Wood and colleagues _[248]) have 
demonstrated an increase in both the affinity and Bmax under similar 
conditions. 
Kosterlitz and colleagues [255] have shown a potentiation of 
['H]diprenorphine binding at the p-site by sodium ions and an 
apparent inhibition at the k-siteunder the same conditions. 
Therefore, the Il-:, cS- and k-binding of ['H]diprenorphine may be 
differentially affected by sodium ions ~hich may result in the nett 
effect of no change in the binding parameters observed. 
In a buffer system of 25mM HEPES containing 10mM magnesium chloride 
it was possible to discern high and low affinity binding components 
separated by a plateau for [D-Ala2 ,D-Leu S ]enkephalin, [D-Ala2 , 
MePhe',Gly-ols]enkephalin and U-50488H displacement of 
['H]diprenorphine in rat brain homogenates. The high affinity 
components of these curves corresponded to displacement from cS-, p-
206 
and k-sites respectively. When suitable con~entrations of these 
unlabelled ligands were chosen to suppress ['H]diprenorphine binding to cS-, 
p- and k-sites, a low affinity component still remained which could 
be studied. The increased potency of levorphanol over dextrorphan and 
displacement by naloxone showed that the remaining sites were opioid 
in nature. The apparently low affinities of levorphanol and naloxone 
suggest that the sites have more in common with the k-type than with 
p- or cS-types and the shallOW Hill slopessugges\:\thatheterogeneity 
may still exist within the remaining population. 
Results in guinea-pig brain homogenates show that after p- and 
cS-suppression, displacements using U-50488H and the k-selective 
peptide dynorphin A-(1-17) afforded shallow Hill slopes and lower 
affinities than previously reported for interaction atk-sites by 
these ligands[72, 242]. Indeed after suppression of the k-component 
only 501~ of the remaining ['H]diprenorphine bound was sensitive to 
displacement by dynorphin A~(1-17) suggestive of heterogeneity of 
the k-population in guinea-pig brain. 0 Consideration should be given 
to the fact that the apparently low affinities seen with dynorphin 
A~(1-17) in these studies may result froom adsorptive losses of free 
ligand onto sub-cellular contaminants and vessels containing the assay 
mixture [214-16]. The remaining sites represent only a small 
proportion «10%) of the total sites labelled by [·H]diprenorphine. 
In agreement with the findings presented in this chapter Morre and. 
colleagues [262] have shown that after ~-, ~- and a-suppression, 
['H]ethylketocyclazocine is readily displaced in guinea-pig brain· 
homogenates by non-peptidic opioids but was "resistant" to 
displacement by dynorphin A~(1-9), dynorphin A~(1-17) and by a-
and B-neo-endorphins. The "dynorphin-sensitive" site was proposed 
to correspond to the "classical k" site. Similarly Su [200] has 
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proposed an heterogeneity of k-sites in guinea-pig brain homogenates 
which are readily displaced by tifluadom, U-50488H and dynorphin 
A~(1-13), but in a biphasic manner. In this work 100nM [O-Ala', 
O-Leu']enkephalin was used to suppress both ~- and ~-sites and therefore, 
some of the apparent heterogeneity may represent interaction with 
un suppressed ~-sites. An heterogeneous k-population may also exist 
in human brain. Thus Pfeiffer and co-workers [199] have shown that 
in the presence of ~- and 6-suppression ['H]diprenorphine was 
displaced in a biphasic manner from human amygdala by dynorphin 
A-(1-17). The k-population was divided into "dynorphin A-(1-17)-
sensitive" and "-insensitive" sites. 
On the other hand Audigier and colleagues [261] were unable to show 
any specific binding for ['H]etorphine in guinea-pig striatum after 
suppression with 5~M unlabelled [O-Ala',O-Leu']enkephalin and 
deTonstrated an homogeneous population of sites at lower levels of 
~- and 6-suppression. This result may reflect regional differences 
in the distribution of opioid sites. 
Reports on heterogeneity of the k-population in rat brain are few 
presumably because of the low levels of k-sites present in this 
tissue [97, 193]. However, there is some evidence in the literature 
that an heterogeneity of k-binding does exist although it has rarely 
been fully addressed. For example, Mansour and co-workers [263] used 
[O-Ala' ,MePhe",Gly-ol' ]enkephalin and [O-Pen', O-Pen' ]enkephalin to 
suppress ['H](-)-bremazocine binding to ~- and ~-sites respectively. 
Under these conditions, U-50488H displaced the radioligand with an 
affinity in excess of 650nM. Morris and Herz [264] suppressed 
['H](-)-bremazocine binding to ~- and 6-sites using 1~M each of 
. [O-Ala',O-Leu']enkephalin and [O-Ala2 ,MePhe',Gly-ol']enkephalin. 
The remaining binding was displaced by U-50488H affording an le •• of 
approximately 30nM and a slope of less than unity. ' The higher 
. . 
affinity of U-50488H under these conditions may reflect an over-
suppression of \1- and &-sites and therefore, the removal of some 
of the low affinity component •. In both of the above reports, the 
autoradiographicaldistribution of k-sites was studied using the 
suppressing conditions described above. The distribution of k-sites, 
which is anatomically distinct from either \1- or &-sites will 
therefore include any extra unidentified binding sites. The close 
correlation of the k-site and the low affinity site distributions 
may represent indirect' evidence that the two are related,.possibly 
representing high and low affinity forms of the same receptor. 
When HEPES ,alone was the buffer system used,the displacement profile 
for U-50488H'in rat brain homogenates remained relatively unchanged 
from that seen in HEPES containing magnesium ions. In the guinea-pig 
there waS a'more.pronounced change in the displacement curve,with a 
marked decrease in the % of the high affinity component and a shift 
to decreased potency for the low affinity binding component of 
approximately three-fold, suggesting a differential effect on the 
high and low affinity U-50488H binding sites by magnesium ions. The 
proportion of sites remaining after \1-, &- and k-suppression was 
approximately 19% of the total labelled by ['H]diprenorphine. This 
higher percentage was reflected by a decrease in the Bmax for the total 
sites labelled in HEPES buffer alone, rather than an increase in the 
number of sites remaining after suppression. The higher levels of 
['H]diprenorphine binding in the presence of magnesium ions may be 
the ,result of increased &-binding [245, 254]. The apparent increase 
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in the high affinity k-component in guinea-pig brain when magnesium ions 
are included in the HEPES buffer is more difficult to explain, since 
divalent cations have been shown to reduce binding at the k-site for 
['H]dynorphin A-(1-9) [254], ['H](-)-bremazocine [254, 255] and 
['H]diprenorphine [255]. 
The lower levels of binding seen in HEPES only (Table 7.12) may help 
to explain the low levels of binding seen by Lahti and colleagues 
[198] for ['H]U-69593 in a variety of eNS tissues. 
The heterogeneity of k-sites was explored further using guinea-pig 
cerebellar homogenates. In 50mM Tris-HCI buffer containing 25mM 
sodium. chloride a biphasic curve was obtained when ['H]diprenorphine 
was displaced by U-504BBH. However, since no suppression was 
present the lower affinity component may represent ~- and 6-sites. 
, 
When the displacement was repeated in the presence of p- and 
6-suppression using homogenates prepared in 25mM HEPES buffer 
containing 10mM magnesium chlorid'e, a biphasic curve afforded lower 
IC •• values for both the high affinity component and more especially 
the lower affinity component, which was five-fold more potent in the 
cerebellum than in the guinea-pig brain. These results are 
inconsistent with the work of Robson and her colleagues [242] who 
demonstrated an homogeneous population of k-sites in the guinea-pig 
cerebellum by displacing ['H]{-)-bremazocine, in the presence of p-
and 6-suppression with U-504BBH. One possible explanation for the 
discrepancy is that these workers used 100nM [D-Ala 2 ,D-Leu 5 ]enkephalin 
to suppress 6-sites (this present work used 1pM ICI 174B64) which 
may also have suppressed some of the lower affinity component to the 
extent that it no longer affects the slope of the Hill plot. 
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The extra sites are unlikely to be interconverting high and low affinity 
forms of the k-site since shallow Hill plots have been obtained for 
the displacement of ['H]{-)-bremazocine by U-504BBH in guinea-pig 
cerebellar homogenates in a selection of different buffers, including 
more physiologically relevantHEPES-buffered Krebs [246]. 
Saturation analysis ~howed that (S H]dynorphin A-:{1-9) and [sH){-)-
bremazocine labelled similar numbers of sites in the guinea-pig 
cerebellum, after p- and 6-suppression. These results are similar to 
those seen in. the guinea-pig (but, not the,rat) spinal cord (Chapter 6). 
Binding data presented in this thesis suggests that the nature of the 
population of opioid sites remaining after p- and 6-suppression may 
differ between species and may even vary between the CNS regions of the 
same species (in the· case of the guinea-pig). Alternatively, the 
results may reflect differences in the size of the populations of the 
high affinity and lower affinity components in the tissues studied. 
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Following an early report that ['H]opioids bind stereospecifically 
to cerebrosides [85], investigations were performed using 
['H]diprenorphine to see if binding to myelin could be responsible for 
the apparent heterogeneity observed in the displacement assays. 
The distribution of ['H]diprenorphine binding followed that of the 
plasma-membrane marker Na+,K+-activated ATPase in subcellular fractions 
of rat brain, suggesting that.the extra sites are not the result of 
radioligand binding to cerebrosides or other myelin components [85]. 
These results are supported by the findings of Pert and her 
colleagues [84]. Cross-contamination between fractions was evident 
which may be a consequence of the preparative technique used, 
. especially the severity of the initial homogenisation [257]. 
Entrapment of synaptosomes within the PI' crude myelin and mitochondrial 
fractions [257] is another li~ely cause of the contamination seen with 
the present studies. The degree of myelin contamination may also be 
a function of the age of rats used since it is known that the 
myelin content of rat brain increases by 1500% between days 15 and 180 
[256]. In an attempt to study possible opioid binding to myelin, the 
myelin fraction was purified. This afforded inconsistent results and 
although the binding of ['H]diprenorphine appeared to follow 
Na+,K+-ATPase activity, further work is required to confirm the 
binding of ['H]opioids to myelin. 
In conclusion, by using carefully selected assay conditions it has been 
possible to study a population of opioid binding sites which are not 
of the ~-, 5- or k-type. Heterogeneity of the k-component was 
• 
evident in rat and guinea-pig neural tissues although the characteristics 
of these sites appeared to vary between species and CNS regions. 
The low affinity of dynorphin A-(1-17) and U-50488H, two k-selective 
ligands for the sites remaining after ~-, 5- and k-suppression implies 
that they may not be subtypes of the k-receptor and preliminary studies 
suggest that they are· not low. affinity sites on myelin. However, they 
may represent low affinity states of the ~-, 5- or k-receptor which 
. are not susceptible to the low concentrations of suppressing agonists 
used. This work provides a method by which further characterization 
may be performed.!In the light of this work,::the definition of the k-opioid 
I I 
I binding site requires modification! (see Appendix). I 
C H APT E R 8 
OPIOID BINDING STUDIES IN THE SPINAL CORD 
OF THE MOUSE, AND SOME BINDING CHARACTERISTICS 
OF XORPHANOL 
INTRODUCTION 
The mouse is a commonly used animal for testing the antinociceptive 
properties of opioid analgesics. Activity has been demonstrated 
at the spinal [224-226] and supraspinal levels [223-225] for 
compounds with different activity profiles at p-, 6- and 
k-receptors. Although the involvement of these receptors in 
different antinociceptive responses has been postulated, there 
appears to have been no attempt to verify the existence of such 
receptors in the spinal cord by binding assays. 
The opioid analgesic xorphanol (Figure 8.1) is a relatively recently 
introduced compound known to have analgesic properties in different 
species [227, 229] including the mouse [228, 229] and in man 
[230, 231]. 
HO 
N~ Figure 8.1 Xorphanol 
In vitro work using peripheral tissues known to contain opioid 
receptors from the guinea-pig [229, 232], rat and rabbit [229] 
have postulated that xorphanol possesses partial agonist 
properties at the k-receptor and antagonist properties at·the 
p-receptor [229]. This work supports .observations 'seen in whole 
animal studies [228, 229].' The apparently low dependence liability 
of the compound [232, 233] and few side effects have made xorphanol 
a useful candidate for analgesia in clinical situations [230, 231]. 
However, the current literature does not appear to contain any work 
in which the binding characteristics of xorphanol have been studied. 
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The aim of this study is to characterize the opioid binding sites 
in mouse spinal cord, using standard ligand binding techniques 
. employing P-, 6- and k-selective compounds. Secondly, xorphanol 
binding will be studied in mouse cord and then in more readily • 
available central nervous system (eNS) tissues from the guinea-
pig. 
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MATERIALS & METHODS 
Whole spinal cords from female Swiss-Webster outbred mice were . 
removed as described in Chapter 2. Homogenates of mouse cord, 
guinea-pig brain and guinea-pig cerebellum were prepared and 
binding studies at 25 DC were performed as detailed in Chapter 2, 
except for antagonist binding which was studied u·sing 
['H]naloxone or ['H]diprenorphine in the presence of 1DOmM 
sodium chloride and 50~M of the stable guanosine triphosphate 
analogue, 5-guanylylimidodiphosphate (GppNHp). 
Radiolabelled ligands used to label opioid binding sites were 
['H]diprenorphine, ['H][D-iUa 2 ,MePhe' ,Gly-ol 5 ]enkephalin, 
['H][D-Ala2 ,D-LeuS]enkephalin and ['H]naloxone. 
Non-specific binding was defined using 1~M unlabelled MR 2266 
for ['H]naloxone, 1~M unlabelled diprenorphine for ['H][D-Ala 2 , 
MePhe',Gly-oIS]enkephalin and ['H][D-Ala2 ,D-LeuS]enkephalin and 
10~M unlabelled naloxone .for ['H]diprenorphine. All compounds 
have the chemical structures described in Chapter 2. 
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RESULTS 
Studies in mouse spinal cord homogenates 
a) Saturation analysis 
The total high affinity, saturable ['H]diprenorphine 
binding in whole spinal cord homogenates from the mouse 
was reduced by 78%,when p- and 6-suppression was present 
(Figure 8.2; Table 8.1). The affinity of the radioligand 
increased upon suppression. 
['H][D-Ala2 ,D-Leu']Enkephalin, in ,the ,presence of p-suppression 
labelled a total population of high affinity sites which 
may be attributed to 6-sites representing 14% of the total 
number'labelled by ['H]diprenorphine (Figure 8.3). The 
,levels of specific binding with ['H][D~Ala·,D-LeuS] 
enkephalin,were low (Table 8.2) and may therefore contain 
considerable error. 
The p-selective peptide ['H][D-Ala2 ,MePhe',Gly-oIS] 
enkephalin bound in a saturable manner to high affinity sites 
(Figure 8.4) which may 
be attributed to p-sites [90, 91]. 
From this data the total binding of the putative P-, 6-
and k-populations represented only 82 fmol.mg-', that is 65% 
of the total sites labelled by ['H]diprenorphine in mouse 
spinal cord homogenates (125.4 fmol.mg-'). 
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Figure 8.2 Saturation analysis for ['H]diprenorphine in the absence Ce) and presence CO) of 100nM [D-Ala',D-Leu 5] 
enkephalin and [D-Ala',MePhe',Gly-oI5]enkephalin to 0;2nM labelled ligand in homogenates of mouse whole 
spinal cord. Concentration range of radioligand used was 0.098 - 10.30nM in the absence of suppression 
and 0.098 - 5.05nM for suppressed assays. Representative plots from 3 experiments. See Table 8.1 for data. N ~ 
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Figure B.} Saturation analysis for ['H][D-Ala 2 ,D-Leu S ]enkephalin, in the presence of 25nM [D-Ala',MePhe',Gly-oIS] 
en kephalin to 1nM radioligand in homogenates of mouse whole spinal cord. Concentration range of radio-
ligand used was 0.111 - 10.79nM. , Representative plot from} experiments. See Table B.1 for data. 
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Figure 8.4 Saturation analysis for ['H][D-Ala2 ,MePhe',Gly-oIS]enkephalin in homogenates of mouse whole spinal cord, 
using a radioligand concentration range of 0.063 - 9.57nM. Represent?tive plot from 3 experiments. 
See Table 8.1 for data. 
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Table 8.1 Determination of ~-, d- and k-binding sites in mouse whole spinal cord homogenates by 
saturated binding analysis at 25°C (Figures B.2 - 8.4). 
Ligand and Assay Conditions 8max (fmol.rng-1 ) KD (nM) 
['H]diprenorphine (Total) 125.4 ± 2.4 0.59 ± 0.14 
*(Suppressed) 27.71 ± 0.43 0.23 ± 0.03 
['H][D-Ala 2 ,D-Leu']enkephalin 17.32 ± 3.66 2.44 ± 0.56 
** (Suppressed) 
['H][D-Ala·,MePhe',Gly-ol']enkephalin 36.72 ± 3.02 1.22 ± 0.34 
Results expressed as means ± sern for n separate experiments in duplicate. 
r = Non-linear correlation coefficient. 
r 
0.934 - 0.989 
0.863 - 0.963 
0.937 - 0.976 
0.966 - 0.972 
n 
3 
3 
3 
3 
* Suppressed at 100nM each unlabelled [D-Ala 2 ,MePhe',Gly-ol']enkephalin and [D-Ala 2 ,D-Leu']enkephalin to 0.2nM 
['H] ligand. 
** Suppressed at 25nM [D-Ala2 ,MePhe',Gly-olS]enkephalin to each 1nM labelled ligand. 
Non-specific binding defined in the presence of 1~M unlabelled diprenorphine for ['H][D-Ala 2 ,D-Leu']enkephalin and 
['H][D-Ala2 ,MePhe' ,Gly-ol' ]enkephalin, and 1DllM unlabelled naloxone: for ['H]diprenorphine. 
N' 
CD 
,------- -----
Table 8.2 Levels of ['H][D-Ala 2 ,D-Leu S ]enkephalin binding in mouse whole spinal cord homogenates at 25 DC. 
Approximate 
Radioligand 
Concentration (nM) 
0.1 
0.2 
1.0 
3.0 
10.0 
Total 
91 ± 22 
214 ± 41 
628 ± 73 
1112, 1761 
4084 ± 967 
Results expressed as means ± sem. 
Bound dpm.mg-
' 
protein 
Non-Specific Specific 
29 ± 18 63 ± 5 
88 ± 20 127 ± 21 
288 ± 44 340 ± 36 
706, 1125 406, 636 
3604 ± 856 962 ± 210 
n = Number of separate experiments from which data were derived. 
~. Specific 
Binding 
73 ± 11 
60 ± 3 
54 ± 3 
37, 36 
25 ± 5 
NOD-=-specific binding defined in the presence of 1JlM unlabelled diorenorphine. _________ , 
I Binding studies were performed in the presence of 25nM unlabelled I [D-Ala LMePhe' ,Gly-ol 5]enkephalin 
I~~-:~Ch -;nM labelled ligand.·· . .. .... ... . ..... - .. . ... . .. .. 
n 
3 
3 
3 
2 
3 
N 
-\0 
, 
,b) Displacement studies 
Binding at putative k-sites was studied using [8H] 
diprenorphine in the presence of p- and 6-suppression 
(Figure 8.5; Table 8.3). Xorphanoldisplaced the 
remaining binding with a slope close to unity and 
(-)-bremazocine similarly displaced with a slope of 
unity, but. with a relatively higher affinity. The 
k-selective opioid U-50488H afforded a shallow Hill plot 
and a very low affinity (IC,. > 10pM).' ['H]Diprenorphine 
binding at a level ofO.2nM was reduced by 45% in the 
presence of p- and 6-suppression. 
The binding of 1nM [8H][D-Ala 2 ,D-Leu 5]enkephalin in the 
" presence of p-suppression represented 75% of the total, 
specifically bound. This binding, taken to represent 
binding at 6-sites, was readily displaced by xorphanol and 
the 6-antagonist' ICI 174864 with Hill slopes close to unity 
(Figure 8.6; Table 8.3). 
Both [D-Ala',MePhe',Gly-oI5]enkephalin and xorphanol 
displaced ['H][D-Ala',MePhe',Gly-oI5]enkephalin from p-sites 
with Hill slopes of close to unity (Figure 8.7). Comparison 
studies in guinea-pig brain afforded similar results 
(Figure 8.8; Table 8.4). 
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Displacement of ['H]diprenorphine (O.1B-O.25nM), in the presence of 100nM each of [D-Ala2 ,D-Leu S ]enkephalin 
and [D-Ala2 ,MePhe',Gly-olS]enkephalin to O.2nM radioligand, by (-)-bremazocine ( T ), xorphanol' (-) and 
U-50488H (.) in mouse whole spinal cord homogenates. See Table B.J for data. 
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Figure 8.6 . Displacement of ['H][D-Ala',D-LeuS]enkephalin (O.98-0.99nM), 
in the presence of 25nM [D-Ala',MePhe",Gly-olS]enkephalin 
to 1nM radioligand, by xorphanol (.) and lel 174864 (.) 
in mouse whole spinal cord homogenates. See Table 8.3 for 
data. 
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Displacement of ['H][D-Ala',MePhe",Gly-olS]enkephalin 
(2.24-2.38nM) by xorphanol (.) and [D-Ala' ,MePhe" ,Gly-oP] 
enkephalin in mouse whole spinal cord homogenates. See 
Table 8.3 for data. 
Table 8.3 Displacement of binding from putative ~~, 6- and k-binding sites in mouse whole spinal cord 
homogenates at 2S0 C (Figures-8.S - 8.7). 
Radioligand 
(concentration range) 
*['H]Diprenorphine 
(0.18 - 0.2SnM) 
**['H][D-Ala",D-Leu'] 
enkephalin 
(0.98 - 0.99nM) 
['H][D-Ala" ,MePhe' ,Gly-ol'] 
enkephalin· 
(2.24 - 2.38nM): 
Unlabelled 
. Competing Ligand 
{-)-Bremazocine 
U-50488H 
Xorphanol 
ICI 174864 
Xorphanol 
[D-Ala" ,MePhe', 
Gly-ol']enkephalin 
Xorphanol 
Hill 
ICSO (nM) Coefficient (nH) 
2.79 ± 0.41 0.91 ± O.OS 
>10000 0.63 ± 0.02 
4.71±0.71 1.05 ± 0.08 
440 ± 130 1.08 ± 0.10 
4.0S ± 0.48 1.00 ± 0.12 
13.79 ± 1.00 1.14 ± 0.05 
3.51 ± 0.87 1.17 ± 0.11 
Results expressed as means ± sem from n separate experiments in duplicate. 
r = Correlation coefficient from linear regression. 
Minimum 
r 
0.935 
0.978 
0.938 
0.930 
0.968 
0.981 
0.975 
* Binding to ~- and 6-sites suppressed using 100nM each of unlabelled [D-Ala",D-Leu']enkephalin and 
[D-Ala",MePhe',Gly-ol']enkephalin to each 0.2nM labelled ligand. 
n 
3 
3 
3 
3 
3 
4 
4 
** Binding to ~-sites suppressed using 25nM unlabelled [D-Ala 2 ,MePhe',Gly-ol']enkephalin to 1nM labelled ligand. 
Non-specific binding defined in the presence of 1~M unlabelled diprenorphine, except for ['H]diprenorphine where 
10~M unlabelled naloxone was used. 
Xorphanol studies 
Xorphanol showed no selectivity in mouse spinal cord 
homogenates under the experimental conditions used. The 
displacement curves all afforded Hill slopes of 
approximately unity (Table 8.3). 
Further characterization of·xorphanol was achieved using 
['H]ligands under conditions favouring agonist or antagonist 
states of the·receptor. The agonist ['H][D-Ala2 ,MePhe', 
Gly-ol']enkephalin, in addition to low concentrations 
(0.15nI4 - 0.21nM) of the antagoni·st ['H]naloxone [87] ~ere 
used to label p-sites. 80th ['H]ligands were displaced in 
guinea-pig brain homogenates by unlabelled naloxone and 
[D-Ala 2 ,MePhe',Gly-015]enkephalin with affinities indicative 
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of interaction at p-sites, and by xorphanol (Figures 8.8 - 8.11; 
Table 8.4. & 8;5). Low levels of specific ['H]naloxone binding 
under these conditions (Table 8.5) meant that only two out of 
three experimental results could be used. The slopes of the 
displacement curves were all close· to unity. \~hen ['H]naloxone 
(0.2nM) was studied in the presence of 100mM sodium chloride and 
50pM GppNHp the level of bound radioligand increased and 
non-specific binding decreased (Table 8.6). Under these 
. conditions the p-agonist [D-Ala2 ,MePhe',Gly-oI5]enkephalin 
showed a potency shift of approximately 50 times to lower affinity 
(Figure 8.9; Table 8.5), naloxone shifted by approximately 
twice to higher affinity (Figure 8.10) and xorphanol 
shifted by approximately three-fold to lower affinity 
(Figure 8.11). It was also seen that the slope of the 
displacement curves for [D-Ala 2 ,MePhe',Gly-olsJenkephalin 
and naloxone, but not xorphanol were less than unity. 
(Table 8.5). 
Xorphanol interaction with k-sites was studied using 
['H]diprenorphine in the guinea-pig cerebellum under the 
agonist/antagonist conditions used above (Table 8.5). In 
the presence of sodium ions and GppNHp the total ['H]diprenorphine 
bound at 0.2nM appeared to increase (Table 8.6). 
Under these conditions the U-50488H displacement curve 
shifted 10-fold to lower potency (Figure 8.12), the 
naloxone displacement shifted by 1.5 times to higher 
affinity (Figure 8.13) and xorphanol was equipotent 
(Figure 8.13). The Hill slope for U-50488H remained 
shallow and for xorphanol remained close to unity. 
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Displacement of ['H][D-Ala",MePhe',Gly-olS]enkephalin (Z.47-Z.54nM) by xorphanol (.), naloxone 
(A) and [D-Ala" ,MePhe., Gly-olS ]enkephalin (0) in guinea'-pig brain homqgenates.. See. Table: . 
B.4 for data. 
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Table 8.4 Displacement of ['H][D-Ala 2 ,MePhe',Gly-ol']enkephalin (2.47 - 2.54nM) in guinea-pig brain 
homogenates at 25 DC (Figure 8.8). 
Competing Ligand IC .. (nM) nH 
[D-Ala 2 ,MePhe',Gly-ol']enkephalin 11.19, 9.87 0.98, 0.79 
Naloxone 10.78, 8.36 1.00, 1.01 
Xorphanol 2.25, 3.99 1.33, 1.32 
Results expressed as individual determinations from 2 experiments in duplicate. 
nH = Hill coefficient. 
Minimum r = minimum correlation coefficient from linear regression. 
Non-specific binding defined using 1~M unlabelled diprenorphine. 
Minimum r 
0.985 
0.996 
0.980 
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Displacement of ['H]naloxone (D.1S-0.21nM) by [D-Ala2,MePhe~,Gly-ol"]enkephalin, in the absence (0) 
and presence (.) of 100mM NaCI and;' SOpM GppNHp, in homogenates of guinea-pig brain. 
See Table B.S for data. 
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Displacement of ['H]naloxone (0.15-0.21nM) by naloxone, 
in the absence (t;.) and presence (A) of 100mM NaCl and 
( 50]lM GppNHp, in guinea-pig brain homogenates. See 
Table 8.5 for,data. 
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Displacement of ['H]naloxone (0.15-0.21nM) by xorphanol, 
in the absence (c) and presence (.) of 100mM NaCl and 
I'5IJ]lM GppNHp, in guinea-pig brain homogenates. See 
Table 8.5 for data. 
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Displacement of ['H]diprenorphine (o..24-0.36nM) by U-50488H, 
in the absence (0) and presence (.) of 100mM NaCI and 
150\1M GppNHp, in guinea-pig cerebellar homogenates: 
a) Displacement curve b) Hill plot. For data see 
Table 8.5. 
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Displacement of ['H]diprenorphine (O.24-0.36nM) by. 
. xorphanol ([J) and naloxone (A), in the absence 
(open symbols)_and presence (closed symbols) of 
100mM Nael and 50 lpM GppNHp in guinea - pig cerebellar 
homogenates. 'See Table 8.5 for data. 
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Table 8.5 Displacement of ['H]naloxone in guinea-pig brain homogenates.and r'H]diprenorphine in guinea-pig cerebellar 
homogenates at 25°C, in the absence and presence of 100mM NaCl and 50pM GppNHp (Figures 8.9 - 13). 
Control + 100mM NaCl . & 50pM GppNHp 
Species & Radioligand 
Competing Ligand 
['H]Naloxone (0.15 - 0.21nM) 
Guinea-ei!l brain 
[D-Ala" ,MePhe'.,Gly-ol'] 
enkephalin 
Naloxone 
Xorphanol 
1C50 (nM) 
13.20, 16.29 
5.45, 10.41 
0.46, 0.67 
['H]Diprenorphine (0.24 - O. 36nM) 
Guinea-ei!l cerebellum 
U-50488H 20.03 ± 2.00 
Naloxone 21.06 ± 1.68 
Xorphanol 1.09 ± 0.90 
nH 
0.77, 1.10 
0.88, O~93 
1.06, 0.89 
0.73 ± 0.07 
0.91 ± 0.11 
1.09 ± 0.10 
min. r n 1C50 (nM) nH 
0.991, 0.975 2 792 ± 75 0.63 ± 0.03 
0.978, 0.935 2 4.50 ± 0.86 0.78 ± 0.04 
0.983, 0.932 2 1.38 ± 0.10 1.03±0.04 
0.953 3 213.7 ± 28.5 0.40 ± 0.05 
0.980 3 15.07 ± 1.29 0.78 ± 0.05 
0.%0 3 1.34 ± 0.16 1.01 ± 0.07 
Results expressed as means ± sem or as individual results for n separate experiments in duplicate. 
min. r = minimum correlation coefficient from linear regression. 
nH = Hill coefficient. 
min. r 
0.977 
0.955 
0.949 
0.959 
0.9% 
0.994 
n 
3 
3 
3 
3 
3 
3 
Non-specific binding for ['H]naloxone defined using 1pM unlabelled MR 2266. For ['H]diprenorphine 10pM unlabelled naloxone 
was used. 
------------------------------, 
Table 8.6 Sped fic binding of [S H]opioids in the absence and presence of 1,1 OOmM NaCI and 50)lM GppNHp I __ 
in guinea-pig CNS tissue homogenates at 25 DC. 
Bound (cpm) 
Non-
Tissue & Radioligand Conditions Total Specific Specific 
Guinea-pig brain 
[8H]Naloxone 
(0.15 - D.21nM) 
Guinea-pig cerebellum 
['H]Diprenorphine 
(0.24 - 0.36nM) 
Control 
NaCl + GppNHp 
Control 
NaCl + GppNHp 
Results expressed as means ± sem. 
n = Number of assays from which data was derived. 
452 ± 78 
625 ± 64 
1289 ± 22 
1890 ± 140 
172 ± 18 
112 ± 6 
272 ± 18 
251 ± 21 
Figures in parentheses show tbe concentration ranges of radioligands used. 
'Control' represents binding in the absence of NaCl & GppNHp. 
280 ± 84 
513 ± 58 
1017 ± 27 
1639 ± 124 
"' " Specific 
Bound 
62 ± 1 
82 ± 1 
79 ± 1 
87 ± 1 
n 
6 
9 
9 
9 
Non-specific binding for ['H]naloxone was· defined using 1)lM unlabelled MR2266, and for ['H]diprenorphine using 10)lM 
unlabelled naloxone. 
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DISCUSSION 
Mouse 'spinal cord studies 
The total number of sites labelled in mouse spinal cord are in line 
with those seen in the rat but higher than seen in the guinea-pig 
(Chapter 6; Table 6.6l. Of these sites approximately 29~D were of the 
p-type, a level similar to that seen previously in the rat [192] and 
guinea-pig [152, 154] cords. When 6-sites were labelled using, 
['H][D-Ala 2 ,D-Leu S]enkephalin the presence of p-suppression the 
selective 6-antagonist ICI 174864 [237] ,displaced the bound radioligand 
with an affinity in the typical range for interaction with 6-sites 
[238, 239]. The labelled sites represented 14% of the total sites in 
line with previous reports for 6-binding in the spinal cords :of rat 
[152, 192], guinea-pig [152, 154], frog, pigeon and in man [152]. 
This work thus supports reports from in vivo work Which have postulated 
both spinal and supraspinal activity for p- and 6-selective compounds 
[223, 225, 236] in the mouse. In particular, supraspinal p-receptors 
appear to modulate thermally-induced pain [223, 225]. Spinal 
6-receptors have also been proposed to modulate thermal stimuli 
[224, 225, 235], but may also modulate visceral-chemical stimuli [225, 
228] and gastrointestinal transit [224, 226, 236]. Although some of 
these results are based on studies using the relatively unselective 
6-ligand [D-Ala 2 ,D-Leu S]enkephalin [223], supporting evidence has also 
been derived using the bis-penicillamine enkephalin analogues [224, 225], 
compounds which are known to be agonists with high selectivity for 
the 6-receptor [192, 238, 239]. 
When ['H]diprenorphine binding was studied in the presence of p-
and 6-suppression, results which were inconsistent with a k-population 
were afforded. Both U-50488H and (-l-bremazocine displaced this 
binding with lower affinities than reported previously for other 
tissues [96, 97, 108, 109]. A ,low Hill slope for U-50488H was 
indicative of interaction with an heterogeneous population of sites 
although no visually biphasic nature was apparent. These non p-
or 6-sites represented 22~D of the total labelled sites. 
It can be seen that in ,Swiss-Webster outbred mice, the total 
number of sites labelled by ['H]diprenorphine is greater than the 
sum total of the sites discussed so far. This anomaly is difficult 
to explain. One possibility is that over-suppression occurred, 
that is 100nM each of [D-Ala 2 ,D-Leu']enkephalin and [D-Ala 2 ,MePhe', 
Gly-ol']enkephalin removed some of the putative k-component. 
Since these conditions have been shown previously to remove only 
the ~- and 6-sites [97], this lends further evidence to the non-
~- or 6-sites in mouse spinal cord being different to k-sites seen 
in other tissues. 
An extensive literature covers k-opioid-mediated analgesia in the 
mouse. k-Selective agents have been shown to be especially 
effective against visceral-chemical pain after intrathecal 
. , 
administration [225, 235] but inactive after intracerebroventricular 
injection [223, 225, 229]. The k-selective peptides dynorphin 
A-(1-9) [226], dynorphin A-(1-13) and dynorphin A-(1-17) [235] have 
also been shown to have antinociceptive activity against cutaneous-
thermal pain. Some of the dynorphin A-(1-17) activity against 
. ' 
cutaneous-thermal pain was shown to be produced by a des-tyrosyl 
fragment and hence, was non-opioid in nature, but the same 
des-tyrosyl fragement was inactive against visceral-chemical pain 
[235]. Therefore, in this latter lower-threshold pain, k-agonists 
appear to operate via opioid receptors. Intrathecally-administered 
k-agents do not produce the depression of gastrointestinal transit 
in mice, seen with ~- and 6-selective opioids [224, 236]. 
The results of the displacement studies shown in Figure 8.5 suggest 
that if the i::. - k- binding site exists in mouse spinal cord 
it is present only as a very low percentage of the total residual 
population remaining after ~- and 6-suppression of ['H]diprenorphine 
binding. Therefore, the in vivo effects of spinally administered 
opioids may be via this small population of k-receptors or 
alternatively may be mediated in the mouse via a -- --
k-receptorlsubtype. 'I 
, , 
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It would be interesting to study the displacement profile of 
dynorphin A-(1-17) at these sites to determine whether the 
heterogeneity of binding seen in other tissues such as human 
brain [199] were present. 
This study has only been able to partially characterize the 
non- p- or 5-component, mainly due to the scarcity of tissue. 
Further work is necessary in which the ability of naloxone to 
displace the specifically bound [SH]diprenorphine and the 
stereoselectivity of the sites should be analysed in addition to' 
displacement studies using a range ,of opioid compounds with known 
binding profiles. 
Mice have shown strain differences in both their pharmacological 
response to opioids [74, 240] and binding characteristics of brain 
opioid binding sites [74,157] •. The results obtained in this 
current work may therefore, be unique to the Swiss-Webster strain 
of mice • 
. In conclusion, the spinal cord from Swiss-Webster outbred mice 
contains p-sites (29~i) and 5-sites (14~.). There is no evidence from 
these studies of a true k-site in the cord although it is possible 
that such sites are present in very small numbers, based on 
evidence from in vivo work. Further characterization of all the 
sites is necessary. 
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Xorphanol Studies 
The results obtained from binding studies in mouse spinal cord 
and guinea-pig CNS tissues suggest that xorphanol is a non-
selective opioid I· at.: \1- and k-sites. ~:~ _ .... __ ._;'_~:_. _______ . 
The small shift to lower potency when ['H]naloxone was displaced 
in guinea-pig brain by xorphanol in the presence of sodium ions 
and GppNHp lends evidence to xorphanol being an antagonist __ . ___ ' 
. ___ '; at the II-site, supporting in vitro results from the 
isolated rat vas deferens preparation.[229]; 
Displacement studies in the guinea-pig cerebellum show that 
xorphanolhas antagonist properties at the k-site, in agreement 
with observations made. using the field-stimulated guinea-pig ileum 
preparation where xorphanol displayed a low maximum 'agonist 
activity typical of a partial agonist [229]. B-Funaltrexamine, a 
selective II-receptor antagonist [243] had no effect on the xorphanol 
agonist activity, but s-chlornaltrexamine, an irreversible 
antagonist [244], in the presence of II-protection produced a shift 
to lower potency for xorphanol. These results indicate that the 
observed xorphanol agonism is mediated via k-receptors. 
However, in the rabbit vas deferens, a tissue containing only 
functional k-receptors [6B] xorphanol is an antagonist [229].· 
Reports in the literature on xorphanol interactions at 6-receptors 
are scarce. Hayes and co-workers [250] have demonstrated that 
xorphanol displays better 6-antagonist properties than lCI 174864 
against [D-Ala', D-Leu 5 ] enkephalin in the hamster vas de ferens, a 
tissue known to contain only functional o-receptors [251]. 
Xorphanol in vivo has been shown to produce potent antinociceptive 
activity in the mouse abdominal constriction and guinea~pig paw 
pressure test but is inRctive in the mouse hotplate and rat paw 
pressure test. [228]. This spectrum of activity is characteristic 
of a low efficacy k-agonist [229]. 
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Xorphanol is also known to produce 
no apparent physical-aependence in animal tests [232, 233] 
I 
I 
I 
which makes the compound a potentially useful analgesic clinically. 
These proposals are supported by preliminary clinical trials 
[230, 231}. , 
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C H APT E R 9 
GENERAL CONCLUSIONS 
The demonstration of k-sitesin the spinal cord lends further 
evidence for k-mediated, spinal analgesia [190, 203]. Previously, 
'immunohistochemical [134, 186] and autoradiographical [115, 116, 
119, 145] work has demonstrated a high concentration of opioid 
pepUdes and binding sites in the dorsal horn, most notably in 
laminae I and lI. However, autoradiographical work has been unable 
to demonstrate any significant binding in the ventral horn [115, 
116, 119]. The present work has confirmed the high dorsal levels 
of opioid binding sites but also proposes that significant levels 
occur in the ventral horn, in agreement with a previous study 
which'also used ligand binding techniques, [152]. 
One explanation of the apparent discrepency between methodologies 
would be that ventral sites are distributed in a diffuse manner, 
without the definite patterns found in the dorsal horn, and are not 
therefore visible to autoradiography. Although the function of' 
ventral horn opioid receptors has not been clearly established, such, 
receptors have been proposed to exist on sensory fibres entering 
the cord via this route [153] or to be involved in the modulation 
of motor activity [169, 181]. 
The location of opioid receptors in the dorsal· horn was initially 
proposed to be pre-synaptic [124, 271]. However, following the 
demonstration by immunohistochemical techniques that enkephalinergic 
fibres synapsed with spinothalamic-projecting neurones [127], a 
post-synaptic location was additionally proposed. Attempts were 'made 
• in the present work to study the location of k-sites using 
I ,-
capsaicin (Figure 9.1) a compound known to'destroy ! primary afferents 
i ! 
[114, 115, 120, 272]. Unfortunately the low'levels of capsaicin 
used did not affect opioid binding. Analysis of opioid binding after 
higher doses of capsaicin would indicate the levels to which dorsal 
horn binding is reduced and may also indicate whether particular 
site-types are selectively'destroyed i, 
, . ' 
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Figure 9.1 Capsaicin 
MeO 
The relatively uniform distribution of ~-, 5- and k-sites along 
the rostro-caudal axis demonstrated by the current studies 'both 
supports [146, 155] and,refutes [152] previous findings, and 
does not appear to correlate with reported distributions of 
endogenous opioid peptides [149-51, 173]. 
The apparently large population of opioid sites remaining after 
~- and 5-suppression in rat lumbo-sacral spinal cord is 
heterogeneous. Displacement of, this binding by [D~Ala2,D-LeuS] 
enkephalin affords hi~h and low affinity binding components. 
When the portion of binding "sensitive" to displacement by lower, 
concentrations of [D-Ala2,D-Leus ]enkephalin is suppressed, only a 
small residual population of sites with the binding characteristics 
of "classical k" ,sites remains. Therefore, the levels of k-binding 
in spinal cord may be lower than previously reported [160, 195]. 
Preliminary work in this thesis suggests that an heterogeneity of 
k-sites may also occur in the spinal cord of the guinea-pig, 
mouse and farmyard pig, which is supported by other workers who 
have identified apparent k-site heterogeneity in the spinal cords 
from different species [163, 196]. A similar heterogeneity has also 
been postulated in guinea-pig [200] and hUman brain [199]. 
Indeed, this current work has been able to demonstrate heterogeneity 
in brain tissues from the rat and guinea-pig where, after careful 
choice of conditions for the selective suppression of p-, 6- and 
k-sites, an additional population of opioid sites remained.' It is 
unlikely that these extra sites were on myelin since [SH]opioid 
binding followed closely the distribution of the external membrane 
marker-enzyme Na+,K+-activated ATPase when brain tissue from the 
rat was fractioned. They may however, represent a physiologically 
distinct class of sites or a 
studies in the 
low affinity state of another class of 
guinea-pig cerebellum [246] have shown opioid site. 
that U-50488H retains a shallow displacement profile under 
conditions which promote the agonist or antagonist state of the 
opioid receptor. This is evidence that the extra sites may represent 
a distinct class of opioid site, a factor supported by the 
insensitivity of the sites in brain to displacement by the k-opioids 
U-50488H and dynorphin A-(1-17). 
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Additionally autoradiographical studies [263, 264] have shown 
that the distribution of sites labelled by ['H](-)-bremazocine in 
the presence of p- and 6-suppression.was distinct from that of 
p- or 6-sites. Therefore, since under these conditions 
['H]( - )-bremazocine may also be labelling the additional sites, 
the apparent correlation with k-, but not p- or 6-sites lends 
evidence to the extra sites being k-subtypes. Alternatively, they 
may represent. a component which is only identified by binding. 
assay techniques and therefore, the use of a physiological correlate 
is necessary to identify the corresponding receptor in vivo. In 
this context Wood and colleagues [206] have claimed physiological 
evidence for the existence of k-subtypes from studies where the 
influence of proposed k-agonists on plasma TSH and corticosterone 
levels was determined. However, not all of the compounds used to 
evaluate k-activity were specific. For example,*MR 2034, tifluadom 
and ethy1ketocyclazocine possess 6-antagonist activity in the isolated 
hamster vas deferens preparation [250] and ethylketocyclazocine 
displays p-receptor antagonist properties in the isolated rat vas 
deferens preparation [273]. Therefore, the in vivo activity profiles 
of such compounds may well represent a combination of interactions 
at different opioid receptors. 
Using a different approach Herz and colleagues [274] have claimed 
the existence of possible k-subtypes in peripheral tissues. This 
work studied cross-tolerance in the isolated mouse vas deferens 
preparation. For example, vasa·deferentia.rendered tolerant to 
MR 2034, were tolerant to MR 2034 and to ethylketocyclazocine but 
vasa deferentia rendered tolerant to ethylketocyclazocine were 
highly tolerant to the infused benzomorphan, but displayed only a 
minor-degree of cross-tolerance to MR 2034. However, the possible 
cross-reactivity at other receptor types makes interpretation of the 
results difficult. 
Obviously, further work employing more selective agonists such as 
6-selective [D-Pen',D-Pens]enkephalin, \I-selective [D-Ala',MePhe", 
Gly-olS]enkepha1in or k-selective U-50488H and antagonists such as 
6-selective IeI 174864 is necessary to resolve these problems. In 
particular the resolution of the k-subtype problem has awaited the 
development of a k-selective antagonist. 
* See p.242 
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Recent work by Portoghese and colleagues [275] has produced 
bimorphinan compounds with claimed k-selective antagonist 
properties, which may help to resolve some of the uncertainty 
surrounding proposed k-heterogeneity. 
It will be of interest to see what physiological relevance, if 
any the extra opioid site possesses and whether this site 
corresponds to a receptor which is involved in analgesia 
particularly at the spinal level. 
* MR 2034 is: 5,9-dimethyl-2'-hydroxy-2-tetrahydrofurfuryl-
6,7-benzomorphan. 
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APPENDIX. 
A reviaed definition of the k-opioid binding site arising from. the 
work contained in chapters 6 and 7 of this thesis. 
At the commencement of this thesis the k-opioid binding site was 
universally recognized as the site to which an unselective ['H]opioid 
binds, after binding to ~- and ~-sites has been suppressed using 
selective ligands. 
However, the work presented in chapters 6 and 7 of this thesis shows 
that under the above conditions an heterogeneous population of binding 
sites is labelled. Work with more selective ligands has allowed the 
refinement of this definition to the following:_ 
The k-opioid binding site is the site recognized by the 
compounds trans-3,4-dichloro-N-methYl_N_[Z_(pyrrolidinYl) 
cyclohexyl]-benzeneacetamide (U-50488H) and (5a, 7a, 8S)-
(+)-N-methYl-N-(7-<1-pyrrOlidinYl)_1_oxasPiro [4,5].dec-8_yl) 
benzeneacetamide (U-69593), and by dynorphin A-(1-9) and 
dynorphin A-(1-17) with high affinity • 
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